<SEC-DOCUMENT>0001615774-18-008289.txt : 20180817
<SEC-HEADER>0001615774-18-008289.hdr.sgml : 20180817
<ACCEPTANCE-DATETIME>20180817154836
ACCESSION NUMBER:		0001615774-18-008289
CONFORMED SUBMISSION TYPE:	1-A/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20180817
DATE AS OF CHANGE:		20180817

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADiTx Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001726711
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823204328
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		1-A/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	024-10825
		FILM NUMBER:		181025732

	BUSINESS ADDRESS:	
		STREET 1:		11161 ANDERSON STREET
		STREET 2:		SUITE 105-10014
		CITY:			LOMA LINDA
		STATE:			CA
		ZIP:			92354
		BUSINESS PHONE:		909-488-0844

	MAIL ADDRESS:	
		STREET 1:		11161 ANDERSON STREET
		STREET 2:		SUITE 105-10014
		CITY:			LOMA LINDA
		STATE:			CA
		ZIP:			92354
</SEC-HEADER>
<DOCUMENT>
<TYPE>1-A/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/rega/oneafiler" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>1-A/A</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0001726711</cik>
          <ccc>XXXXXXXX</ccc>
        </issuerCredentials>
        <offeringFileNumber>024-10825</offeringFileNumber>
      </filer>
      <flags>
        <returnCopyFlag>false</returnCopyFlag>
        <overrideInternetFlag>false</overrideInternetFlag>
        <sinceLastFiling>false</sinceLastFiling>
      </flags>
    </filerInfo>
  </headerData>
  <formData>
    <employeesInfo>
      <issuerName>ADiTx Therapeutics, Inc.</issuerName>
      <jurisdictionOrganization>DE</jurisdictionOrganization>
      <yearIncorporation>2017</yearIncorporation>
      <cik>0001726711</cik>
      <sicCode>2834</sicCode>
      <irsNum>82-3204328</irsNum>
      <fullTimeEmployees>1</fullTimeEmployees>
      <partTimeEmployees>1</partTimeEmployees>
    </employeesInfo>
    <issuerInfo>
      <street1>11161 Anderson Street</street1>
      <street2>Suite 105-10014</street2>
      <city>Loma Linda</city>
      <stateOrCountry>CA</stateOrCountry>
      <zipCode>92354</zipCode>
      <phoneNumber>909-488-0844</phoneNumber>
      <connectionName>Richard A. Friedman, Esq.</connectionName>
      <industryGroup>Other</industryGroup>
      <cashEquivalents>25000.00</cashEquivalents>
      <investmentSecurities>0.00</investmentSecurities>
      <accountsReceivable>0.00</accountsReceivable>
      <propertyPlantEquipment>0.00</propertyPlantEquipment>
      <totalAssets>25000.00</totalAssets>
      <accountsPayable>8566.00</accountsPayable>
      <longTermDebt>0.00</longTermDebt>
      <totalLiabilities>84900.00</totalLiabilities>
      <totalStockholderEquity>-59900.00</totalStockholderEquity>
      <totalLiabilitiesAndEquity>25000.00</totalLiabilitiesAndEquity>
      <totalRevenues>0.00</totalRevenues>
      <costAndExpensesApplToRevenues>-212986.00</costAndExpensesApplToRevenues>
      <depreciationAndAmortization>0.00</depreciationAndAmortization>
      <netIncome>-212896.00</netIncome>
      <earningsPerShareBasic>0.03</earningsPerShareBasic>
      <earningsPerShareDiluted>0.03</earningsPerShareDiluted>
      <nameAuditor>dbbmckennon</nameAuditor>
    </issuerInfo>
    <commonEquity>
      <commonEquityClassName>Common Stock</commonEquityClassName>
      <outstandingCommonEquity>7284250</outstandingCommonEquity>
      <commonCusipEquity>000000000</commonCusipEquity>
      <publiclyTradedCommonEquity>None</publiclyTradedCommonEquity>
    </commonEquity>
    <preferredEquity>
      <preferredEquityClassName>None</preferredEquityClassName>
      <outstandingPreferredEquity>0</outstandingPreferredEquity>
      <preferredCusipEquity>000000000</preferredCusipEquity>
      <publiclyTradedPreferredEquity>None</publiclyTradedPreferredEquity>
    </preferredEquity>
    <debtSecurities>
      <debtSecuritiesClassName>None</debtSecuritiesClassName>
      <outstandingDebtSecurities>0</outstandingDebtSecurities>
      <cusipDebtSecurities>000000000</cusipDebtSecurities>
      <publiclyTradedDebtSecurities>None</publiclyTradedDebtSecurities>
    </debtSecurities>
    <issuerEligibility>
      <certifyIfTrue>true</certifyIfTrue>
    </issuerEligibility>
    <applicationRule262>
      <certifyIfNotDisqualified>true</certifyIfNotDisqualified>
      <certifyIfBadActor>true</certifyIfBadActor>
    </applicationRule262>
    <summaryInfo>
      <indicateTier1Tier2Offering>Tier2</indicateTier1Tier2Offering>
      <financialStatementAuditStatus>Audited</financialStatementAuditStatus>
      <securitiesOfferedTypes>Equity (common or preferred stock)</securitiesOfferedTypes>
      <securitiesOfferedTypes>Option, warrant or other right to acquire another security</securitiesOfferedTypes>
      <offerDelayedContinuousFlag>Y</offerDelayedContinuousFlag>
      <offeringYearFlag>N</offeringYearFlag>
      <offeringAfterQualifFlag>N</offeringAfterQualifFlag>
      <offeringBestEffortsFlag>Y</offeringBestEffortsFlag>
      <solicitationProposedOfferingFlag>Y</solicitationProposedOfferingFlag>
      <resaleSecuritiesAffiliatesFlag>N</resaleSecuritiesAffiliatesFlag>
      <securitiesOffered>1666666</securitiesOffered>
      <outstandingSecurities>7284250</outstandingSecurities>
      <pricePerSecurity>6.0000</pricePerSecurity>
      <issuerAggregateOffering>10000000.00</issuerAggregateOffering>
      <securityHolderAggegate>0.00</securityHolderAggegate>
      <qualificationOfferingAggregate>0.00</qualificationOfferingAggregate>
      <concurrentOfferingAggregate>0.00</concurrentOfferingAggregate>
      <totalAggregateOffering>10000000.00</totalAggregateOffering>
      <salesCommissionsServiceProviderName>Network 1 Financial Securities, Inc.</salesCommissionsServiceProviderName>
      <salesCommissionsServiceProviderFees>700000.00</salesCommissionsServiceProviderFees>
      <blueSkyServiceProviderName>0</blueSkyServiceProviderName>
      <blueSkyFees>0.00</blueSkyFees>
      <brokerDealerCrdNumber>13577</brokerDealerCrdNumber>
      <estimatedNetAmount>9300000.00</estimatedNetAmount>
    </summaryInfo>
    <juridictionSecuritiesOffered>
      <jurisdictionsOfSecOfferedNone>false</jurisdictionsOfSecOfferedNone>
      <jurisdictionsOfSecOfferedSame>true</jurisdictionsOfSecOfferedSame>
      <issueJuridicationSecuritiesOffering>AL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AZ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>FL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>GA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>HI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ID</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>LA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ME</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NJ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NM</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ND</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>RI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TX</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>UT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WY</issueJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AZ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>FL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>GA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>HI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ID</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>LA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ME</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NJ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NM</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ND</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>RI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TX</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>UT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WY</dealersJuridicationSecuritiesOffering>
    </juridictionSecuritiesOffered>
    <unregisteredSecurities>
      <ifUnregsiteredNone>false</ifUnregsiteredNone>
    </unregisteredSecurities>
    <securitiesIssued>
      <securitiesIssuerName>ADiTx Therapeutics, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Founders Shares, Shares of Common Stock</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>7284250</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>Founders shares issued at $0.001 per share at $7,100 in the aggregate; 131,250 shares of Common Stock issued for gross proceeds of $262,500.</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <unregisteredSecuritiesAct>
      <securitiesActExcemption>Private Placement under Rule 506(b) and/or Section 4(a)(2) of the Securities Act.</securitiesActExcemption>
    </unregisteredSecuritiesAct>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PART II AND III
<SEQUENCE>2
<FILENAME>s112118_partiiandiii.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 0; margin-bottom: 0"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
OFFERING CIRCULAR&nbsp;DATED AUGUST 17, 2018, SUBJECT TO COMPLETION</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>An
offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo; or the &ldquo;Commission&rdquo;).&nbsp;Information contained in this Preliminary offering circular is subject
to completion or amendment.&nbsp;These securities may not be sold nor may offers to buy be accepted before the offering statement
filed with the Commission is qualified.&nbsp;This Preliminary offering circular shall not constitute an offer to sell or the solicitation
of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would
be unlawful before registration or qualification under the laws of any such state.&nbsp;We may elect to satisfy our obligation
to deliver a Final offering circular by sending you a notice within two business days after the completion of our sale to you
that contains the URL where the Final offering circular or the offering statement in which such Final offering circular was filed
may be obtained.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="img001_v1.jpg" ALT="(ASITX LOGO)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ADiTx
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>$7,320,000
Minimum Offering Amount (1,220,000 Units)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>$10,000,000
Maximum Offering Amount (1,666,666 Units)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>$6.00
per Unit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11161
Anderson Street,&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
105-10014&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loma
Linda, California 92354&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(909)
488-0844&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.aditxt.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> ADiTx Therapeutics, Inc., a
Delaware corporation (the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; or &ldquo;our&rdquo;) is offering a minimum of $7,320,000
of Units (the &ldquo;Minimum Offering Amount&rdquo;) and a maximum of $10,000,000 of Units (the &ldquo;Maximum Offering
Amount&rdquo;) at a fixed price of $6.00 per Unit in a &ldquo;Tier 2 Offering&rdquo; under Regulation A of the Securities Act
of 1933, as amended (the &ldquo;Offering&rdquo;). The Units are being offered on a &ldquo;best efforts&rdquo; basis. Each
Unit shall consist of (a) one share (the &ldquo;Shares&rdquo;) of our Common Stock, par value $0.001 per share
(&ldquo;Common Stock&rdquo;), and (b) one warrant (the &ldquo;Warrants&rdquo;) to purchase one share of Common Stock at an
exercise price equal to $7.50 from the date that is six-months from the date of issuance until the 3<SUP>rd</SUP> anniversary
of the date of issuance (the &ldquo;Issuance Date&rdquo;). The Common Stock and Warrants will be separately transferable
immediately upon issuance. The minimum investment is for $600 (100 Units). See &ldquo;<I>Securities Being Offered</I>&rdquo;
beginning on page 46 for a discussion of certain items required by Item 14 of Part II of Form 1-A. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged Network 1 Financial Securities, Inc. as the Lead Underwriter (the &ldquo;Underwriter&rdquo;) to offer the Units to
prospective investors on a &ldquo;best efforts&rdquo; basis, and the Underwriter will have the right to engage such other broker-dealers
or agents as it determines to assist in the Offering. Neither the Underwriter nor any affiliate of the Company has the right to
purchase Units in the primary offering of such securities in order to meet the Minimum Offering Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Offering will terminate on the earlier of: (i) a date mutually acceptable to us and the Underwriter after the date at which the
Minimum Offering Amount is sold, (ii) such time as the Maximum Offering Amount is sold, or (iii) the date that is one (1) year
after this Offering is qualified by the SEC (the &ldquo;Termination Date&rdquo;). Funds for the Units will be deposited into an
escrow account with MVB Bank, Inc. In the event there are any funds remaining in escrow when we terminate the Offering, all escrowed
funds will be promptly returned to investors without interest or deduction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this Offering, there has been no public market for our Units, Common Stock, or Warrants. We have only applied to list our Common
Stock on the Nasdaq Capital Market (&ldquo;NASDAQ&rdquo;), and upon approval, we expect to list our Common Stock under the symbol
&ldquo;ADTX.&rdquo; If our Common Stock is not approved for listing on the NASDAQ, we will not consummate this Offering. Our Common
Stock will not commence trading on NASDAQ until a number of conditions are met, including that we have raised the Minimum Offering
Amount.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="margin: 0pt 0; text-align: justify"> We will not apply to list our Units, or the Warrants that form a part of the
Units, on NASDAQ. It is not anticipated that a public market for the Units or the Warrants will develop in the future. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this Offering to pay a licensing fee to Loma Linda University, for research and development
expenses, for repayment of debt and for offering expenses, for working capital and general corporate purposes and for other uses
as more specifically set forth in the &ldquo;<I>Use of Proceeds</I>&rdquo; section of this offering circular (&ldquo;Offering
Circular&rdquo;). We expect to commence the sale of the Units as of the date on which the offering statement, of which this Offering
Circular is a part (the &ldquo;Offering Statement&rdquo;), is qualified by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. These are speculative securities. You should purchase these securities only
if you can afford a complete loss of your investment. See &ldquo;<I>Risk Factors</I>&rdquo; starting on page 11 for a discussion
of certain risks that you should consider in connection with an investment in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SEC DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT
PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED
PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION
THAT THE SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price&nbsp;to&nbsp;Public</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commissions<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proceeds
                                         to&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>the</B>&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company<SUP>(2)</SUP></B>&nbsp;</FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Per Unit</I></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.42</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.58</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Minimum Offering</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">7,320,000</P> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">512,400</P> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">6,807,600</P> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Maximum Offering</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">700,000</P> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">9,300,000</P> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will enter into
    an Underwriting Agreement with the Underwriter to conduct this offering on a &ldquo;best efforts&rdquo; basis. We have agreed
    to pay the Underwriter (i) a cash fee equal to 7% of the aggregate gross proceeds received by the Company from the sale of
    the Units, and (ii) a non-accountable expense allowance equal to 1% of the aggregate gross proceeds received by the Company
    from the sale of Units in this offering. We have also agreed to issue the Underwriter warrants to purchase an amount of shares
    of Common Stock equal to 10% of the Shares sold in this offering, at an exercise price of $7.50 (125% of the Unit offering
    price) per share, exercisable for the period commencing on the date that is six-months from the date of issuance of the warrant
    through the fifth anniversary of the qualification date of this Offering Statement in compliance with FINRA Rule 5110(f)(2)(G)(i).
    See &ldquo;<I>Plan of Distribution</I>&rdquo; for more information on this Offering and the Underwriter arrangements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include
    expenses of the Offering, including without limitation, fees and expenses for administrative, accounting, audit and legal
    services and fees for EDGAR document conversion and filing, estimated to be as much as $400,000 to $500,000.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENERALLY,
NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN TEN PERCENT (10%) OF THE GREATER
OF YOUR ANNUAL INCOME OR YOUR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING
ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C)
OF REGULATION A+. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
Offering Circular contains all of the representations by us concerning this Offering, and no person shall make different or broader
statements than those contained herein. Investors are cautioned not to rely upon any information not expressly set forth in this
Offering Circular.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
securities underlying this Offering Circular may not be sold until qualified by the Securities and Exchange Commission. This Offering
Circular is not an offer to sell, nor soliciting an offer to buy, any shares of our Common Stock in any state or other jurisdiction
in which such sale is prohibited.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
of the Units will commence as of the date on which this Offering Statement on Form 1-A is qualified by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Offering Circular follows the disclosure format of Part I of Form S-1 pursuant to the general instructions of Part II(a)(1)(ii)
of Form 1-A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>The date of this Preliminary Offering
Circular is August 17, 2018</B> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 0; margin-bottom: 0"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center; border-bottom: Black 1pt solid"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a001_v1">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a002_v1">SUMMARY</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a003_v1">THE OFFERING</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a004_v1">SUMMARY FINANCIAL DATA</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a005_v1">RISK FACTORS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a006_v1">USE OF PROCEEDS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a007_v1">DILUTION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a008_v1">MANAGEMENT&rsquo;S DISCUSSION &amp; ANALYSIS OF FINANCIAL CONDITION &amp; RESULTS OF OPERATIONS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a009_v1">OUR BUSINESS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a010_v1">DIRECTORS, EXECUTIVE OFFICERS &amp; CORPORATE GOVERNANCE</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a011_v1">EXECUTIVE COMPENSATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a012_v1">INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a013_v1">SECURITY OWNERSHIP OF MANAGEMENT &amp; CERTAIN SECURITYHOLDERS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a014_v1">SECURITIES BEING OFFERED</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a015_v1">DIVIDEND POLICY</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a016_v1">PLAN OF DISTRIBUTION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a017_v1">ADDITIONAL INFORMATION ABOUT THE OFFERING</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a018_v1">LEGAL MATTERS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a019_v1">EXPERTS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a020_v1">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>INDEX TO FINANCIAL STATEMENTS</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-1</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering to sell, and seeking offers to buy, our securities only in jurisdictions where such offers and sales are permitted.
You should rely only on the information contained in this Offering Circular. We have not authorized anyone to provide you with
any information other than the information contained in this Offering Circular. The information contained in this Offering Circular
is accurate only as of its date, regardless of the time of its delivery or of any sale or delivery of our securities. Neither
the delivery of this Offering Circular nor any sale or delivery of our securities shall, under any circumstances, imply that there
has been no change in our affairs since the date of this Offering Circular. This Offering Circular will be updated and made available
for delivery to the extent required by the federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, data contained in this Offering Circular concerning the business of the Company are based on information
from various public sources. Although we believe that these data are generally reliable, such information is inherently imprecise,
and our estimates and expectations based on these data involve a number of assumptions and limitations. As a result, you are cautioned
not to give undue weight to such data, estimates or expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Offering Circular, unless the context indicates otherwise, references to the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo;
and &ldquo;us&rdquo; refer to the activities of and the assets and liabilities of the business and operations of ADiTx Therapeutics,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a001_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements under &ldquo;<B><I>Summary</I></B>,&rdquo; &ldquo;<B><I>Risk Factors</I></B>,&rdquo; &ldquo;<B><I>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</I></B>,&rdquo; &ldquo;<B><I>Our Business</I></B>&rdquo;
and elsewhere in this Offering Circular constitute forward-looking statements. Forward-looking statements relate to expectations,
beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts.
In some cases, you can identify forward-looking statements by terms such as &ldquo;<I>anticipate</I>,&rdquo; &ldquo;<I>believe</I>,&rdquo;
&ldquo;<I>could</I>,&rdquo; &ldquo;<I>estimate</I>,&rdquo; &ldquo;<I>expect</I>,&rdquo; &ldquo;<I>intend</I>,&rdquo; &ldquo;<I>may</I>,&rdquo;
&ldquo;<I>plan</I>,&rdquo; &ldquo;<I>potential,</I>&rdquo; &ldquo;<I>should</I>,&rdquo; &ldquo;<I>will</I>&rdquo; and &ldquo;<I>would</I>&rdquo;
or the negatives of these terms or other comparable terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not place undue reliance on forward looking statements. The cautionary statements set forth in this Offering Circular,
including in &ldquo;<B><I>Risk Factors</I></B>&rdquo; and elsewhere, identify important factors which you should consider in evaluating
our forward-looking statements. These factors include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to implement
    a sound business plan;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to comply
    with the provisions of our license agreement with Loma Linda University;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The success of our
    product candidates will require significant capital resources and years of clinical development efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of clinical
    testing and trial activities of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to obtain
    regulatory approval and market acceptance of, and reimbursement for our products;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to protect
    our intellectual property and to develop, maintain and enhance a strong brand;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to compete
    and succeed in a highly competitive and evolving industry;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lack of operating
    history on which to judge our business prospects and management;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to raise
    capital and the availability of future financing;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to manage
    our research, development, expansion, growth and operating expenses; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on
    third parties to conduct our research, preclinical studies and expected clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the forward-looking statements in this Offering Circular are based on our beliefs, assumptions and expectations, taking into account
all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes.
No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained,
or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law,
to re-issue this Offering Circular or otherwise make public statements updating our forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a002_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights selected information contained elsewhere in this Offering Circular. This summary is not complete and does not
contain all the information that you should consider before deciding whether to invest in our Common Stock. You should carefully
read the entire Offering Circular, including the risks associated with an investment in the company discussed in the &ldquo;Risk
Factors&rdquo; section of this Offering Circular, before making an investment decision. Some of the statements in this Offering
Circular are forward-looking statements. See the section entitled &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a Delaware corporation, incorporated on September 28, 2017 and is located in Loma Linda, CA. The Company is a preclinical
stage, life sciences company with the goal of developing nucleic acid (DNA)-based technologies to minimize rejection of transplanted
organs by human recipients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mailing address is ADiTx Therapeutics, Inc., 11161 Anderson Street, Suite 105-10014 Loma Linda, California 92354 and our telephone
number is (909) 488-0844. We are qualified to do business in the state of California. Our website address is <I>www.aditxt.com</I>.
The information contained therein or accessible thereby shall not be deemed to be incorporated into this Offering Circular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Business </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a pre-clinical stage, life
sciences company with a mission to prolong life and enhance life quality of transplanted patients. The discovery of immunosuppressive
(anti-rejection) drugs has made possible life-saving organ transplantation procedures. While these drugs prevent or delay organ
rejection, transplanted organs often ultimately fail, and about 40% survive no more than 5 years. Furthermore, immune suppression
leads to significant undesirable side effects such as increased susceptibility to life-threatening infections and cancers because
it is not specifically targeted towards the transplanted organs; rather, it indiscriminately and broadly suppresses immune function
throughout the body.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opportunity to extend the life of a transplanted organ, even by a few years, may have substantial benefits to organ recipients.
We have an exclusive worldwide license for commercializing a nucleic acid-based technology named Apoptotic DNA Immunotherapy (ADi)
which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues. While immune suppression
requires continuous administration to prevent rejection of a transplanted organ, induction of tolerance has the potential to retrain
the immune system to accept the organ for longer periods of time. Thus, ADi may allow patients to live with transplanted organs
with significantly reduced immune suppression. ADi is a technology platform which we believe can be engineered for application
to a wide variety of indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to develop ADi products for organ transplantation, skin grafting, and wound healing with the initial focus being on skin
allografts and other organ and/or tissue allografts, as we believe these indications will be most efficient in providing safety
and efficacy data in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with Loma Linda University</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with Sekris Biomedical, Inc. (&ldquo;Sekris&rdquo;).
Sekris was a party to a License Agreement with Loma Linda University (&ldquo;LLU&rdquo;), entered into and made effective on May
25, 2011, and amended on June 24, 2011, July 16, 2012 and December 27, 2012 (the &ldquo;Original Agreement,&rdquo; and together
with the Assignment Agreement, the &ldquo;Sekris Agreements&rdquo;). Pursuant to the Assignment Agreement, Sekris transferred
and assigned all of its rights and obligations in and to and liabilities under the Original Agreement, of whatever kind or nature,
to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 1,000,000 shares of our Common Stock (the
&ldquo;Sekris Warrant&rdquo;). The warrant will be exercisable for the period commencing on the date that is six-months from the
date of issuance of the warrant and the exercise price is $2.00 per share. The expiration date of the warrant is March 8, 2023.
On March 15, 2018, we entered into a Patent &amp; Technology License Agreement directly with LLU (the &ldquo;New License Agreement&rdquo;),
which amends and restates the Sekris Agreements.</FONT> </P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the New License Agreement, we obtained the <FONT STYLE="color: #1A1A1A">exclusive royalty-bearing worldwide license in and
to all intellectual property, including patents, technical information, trade secrets, proprietary rights, technology, know-how,
data, formulas, drawings, and specifications, owned or controlled by LLU and/or any of its affiliates (the &ldquo;LLU Patent and
Technology Rights&rdquo;) and related to therapy for immune-mediated inflammatory diseases (the ADi technology). </FONT>We refer
you to the section titled &ldquo;Our Business&mdash;Intellectual Property&mdash;Patent Rights&rdquo; for a summary of the patents
and patent applications that we licensed from LLU pursuant to the New License Agreement. In consideration for the New License
Agreement, we issued 50,000 shares of Common Stock to LLU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the New License Agreement, we are required to pay an annual license fee to LLU. Also, upon completion of this Offering, we
will be required to pay $200,000 to LLU as a milestone payment&nbsp;within thirty (30) days of July 31, 2018. We are also required
to pay to LLU milestone payments in connection with certain development milestones. Additionally, as consideration for prior expenses
incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we are obligated to make the following
payments to LLU: $70,000 due at the end of September 2018, $70,000 due at the end of December 2018, and a final payment of $60,000
due at the end of March 2019. We are required to defend the LLU Patent and Technology Rights during the term of the New License
Agreement. Additionally, we will owe royalty payments of (i) 1.5% of Net Product Sales and Net Service Sales on any Licensed Products
(defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture
or supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services not covered
by a valid patent claim for technology rights and know-how for a three (3) year period beyond the expiration of all valid patent
claims. We also are required to produce a written progress report to LLU, discussing our development and commercialization efforts,
within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and Technology Rights shall
remain with LLU (other than improvements developed by or on our behalf).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New License Agreement shall terminate on the last day that a patent granted in to us by LLU is valid and enforceable or the day
that the last patent application licensed to us is abandoned. The New License Agreement may be terminated by mutual agreement
or by us upon 90 days written notice to LLU. LLU may terminate the New License Agreement in the event of (i) non-payments or late
payments of royalty, milestone and license maintenance fees not cured within 90 days, (ii) a breach of any non-payment provision
(including the provision that requires us to meet certain deadlines for milestone events (each, a &ldquo;Milestone Deadline&rdquo;))
not cured within 90 days and (iii) three or more actual breaches of the New License Agreement by us in any 12-month period. The
next such Milestone Deadline is the requirement to complete a financing round by July 31, 2018. Additional Milestone Deadlines
include: (i) the requirement to have regulatory approval of an IND application to initiate a first-in-human clinical trials on
or before March 31, 2020, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2022, (iii) the completion
of Phase III clinical trials by March 31, 2024 and (iv) biologic licensing approval by the FDA by March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern Analysis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated on September 28, 2017 and has not generated revenues to date. As of December 31, 2017, the Company had
a net loss of $212,986 and will require significant additional capital in order to operate in the normal course of business and
fund clinical studies. As a result, these conditions have raised substantial doubt regarding our ability to continue as a going
concern beyond one year. While the Company believes in the viability of management&rsquo;s strategy to generate sufficient revenue,
control costs and the ability to raise additional funds if necessary, there can be no assurances to that effect. The Company&rsquo;s
ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement the business plan,
generate sufficient revenues and to control operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue
to face, competition in the development and marketing of our product candidates from biotechnology and pharmaceutical companies,
research institutions, government agencies and academic institutions. Competition may also arise from, among other things, other
drug development technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors enjoy several competitive advantages over us, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater financial,
    human and other resources for product research and development, sales and marketing;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly greater
    name recognition;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">established relationships
    with healthcare providers;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">large and established
    sales and marketing and distribution networks;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">products supported
    by long-term clinical data;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater experience
    in obtaining and maintaining regulatory clearances or approvals for products and product enhancements;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">more expansive portfolios
    of intellectual property rights; and</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater ability
    to cross-sell their products.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and our ability to execute our business strategy are subject to a number of risks as more fully described in the section
titled &ldquo;<B><I>Risk Factors</I></B>&rdquo; beginning on page 11. These risks include, among others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         success of our product candidates will require significant capital resources and years
                                         of clinical development efforts;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to comply with the provisions of our license agreement with Loma Linda University;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         results of clinical testing and trial activities of our products;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to obtain regulatory approval and market acceptance of, and reimbursement for
                                         our products;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to protect our intellectual property and to develop, maintain and enhance a strong
                                         brand;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to compete and succeed in a highly competitive and evolving industry;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         lack of operating history on which to judge our business prospects and management;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to raise capital and the availability of future financing;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         ability to manage our research, development, expansion, growth and operating expenses;
                                         and</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         reliance on third parties to conduct our research, preclinical studies and expected clinical
                                         trials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. Our future viability is largely dependent upon our ability
to raise additional capital to finance our operations. Our management expects that future sources of funding may include sales
of equity, obtaining loans, or other strategic transactions. Although our management continues to pursue these plans, there is
no assurance that we will be successful with this Offering or in obtaining sufficient financing on terms acceptable to us to continue
to finance our operations, if at all. These circumstances raise substantial doubt on our ability to continue as a going concern,
and our financial statements do not include any adjustments that might result from the outcome of these uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>REGULATION
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering our Common Stock pursuant to recently adopted rules under Regulation A by the Securities and Exchange Commission
mandated under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). These offering rules are often referred to as &ldquo;<I>Regulation
A+</I>.&rdquo; We are relying upon &ldquo;<I>Tier 2</I>&rdquo; of Regulation A+, which allows us to offer of up to $50 million
in a 12-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a003_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer:</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 64%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADiTx
    Therapeutics, Inc., a Delaware corporation.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities Offered:</B></FONT> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0"> A minimum of 1,220,000 Units and a maximum of 1,666,666 Units.
                                    Each Unit shall consist of (a) one share (the &ldquo;Shares&rdquo;) of our Common Stock, par
                                    value $0.001 per share (&ldquo;Common Stock&rdquo;), and (b) one warrant (the &ldquo;Warrants&rdquo;)
                                    to purchase one share of Common Stock at an exercise price equal to $7.50 from the date that
                                    is six-months from the date of issuance until the third anniversary of the date of issuance. </P>


<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum Number of Units Offered by Us</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000 of Units
    (the &ldquo;Maximum Offering Amount&rdquo;)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minimum
        Number of Units Offered by Us&nbsp;</B></FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$7,320,000
        of Units (the &ldquo;Minimum Offering Amount&rdquo;)&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of shares
    of Common Stock Outstanding before the Offering <SUP>(1)</SUP>:</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,284,250
    shares of Common Stock</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 34%"><FONT STYLE="font-size: 10pt"><B>Number of shares of Common Stock
    to be Outstanding after the Offering <SUP>(1)(2)</SUP>:</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 64%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8,950,916
                                         shares of Common Stock, or 11,525,833 shares on a fully-diluted basis if the Maximum
                                         Offering is sold.</P>

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin: 0">8,504,250 shares of Common Stock, or 11,079,167 shares on a fully-diluted basis if the Minimum Offering is
sold.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price per Unit:</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6.00
    per Unit</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 34%"><FONT STYLE="font-size: 10pt"><B>Minimum Investment </B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 64%"><FONT STYLE="font-size: 10pt">$600 (100 Units)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
                           of Proceeds:</B></FONT></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0"><SUP>(3)</SUP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 64%"><P STYLE="margin: 0">If we sell the Maximum Amount of Units being offered, our
                                         net proceeds (after estimated fees payable to the Underwriter) will be approximately
                                         $9,300,000. We will use these net proceeds to pay a licensing fee to Loma Linda University,
                                         for research and development expenses, for the repayment of debt and for offering expenses,
                                         working capital and general corporate purposes, and such other purposes described in
                                         the &ldquo;<I>Use of Proceeds&rdquo; </I>section of this Offering Circular.</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Best Efforts</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriter
    is selling shares of our Common Stock offered in this offering circular on a &ldquo;best efforts&rdquo; basis and is not required
    to sell any specific number or dollar amount of the shares offered by this prospectus, but will use its best efforts to sell
    such shares. However, if our Common Stock is not approved for listing on NASDAQ, we will not consummate this Offering. In
    order to list, NASDAQ requires that, among other criteria, at least 1,000,000 publicly-held shares of our Common Stock be
    outstanding, the shares be held in the aggregate by at least 300 round lot holders, the market value of the publicly-held
    shares of our Common Stock be at least $15.0 million, our stockholders&rsquo; equity after giving effect to the sale of our
    shares in this offering be at least $5.0 million, the bid price per share of our Common Stock be $4.00 or more, and there
    be at least three registered and active market makers for our Common Stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination of Offering; Escrow:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Offering will
    terminate on the earlier of: (i) a date mutually acceptable to us and the Underwriter after the date at which the Minimum
    Offering Amount is sold; (ii) such time as the Maximum Offering Amount is sold; or (iii) the date that is one (1) year after
    this Offering is qualified by the SEC (the &ldquo;Termination Date&rdquo;). Funds for the Units will be deposited into a non-interest
    bearing escrow account with MVB Bank, Inc. In the event we do not sell the Minimum Offering Amount the Termination Date, escrowed
    funds will be promptly returned to investors without interest or deduction.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain U.S. Federal Income Tax Considerations</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The acquisition
    of a Unit should be treated for U.S. federal income tax purposes as the acquisition of one share of Common Stock and one Warrant
    to acquire one share of Common Stock. Shares of Common Stock will be treated as stock of the Company for U.S. federal income
    tax purposes. Please see &ldquo;<I>Certain U.S. Federal Income Tax Considerations</I>.&rdquo; Before deciding whether to invest
    in the Company&rsquo;s securities, you should consult your tax advisor regarding possible tax consequences.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Units and
    the Common Stock and Warrants of which the Units consist are speculative securities. Investing in them involves significant
    risks. You should invest in them only if you can afford a complete loss of your investment. See &ldquo;<I>Risk Factors</I>&rdquo;
    starting on page 11 for a discussion of factors you should carefully consider before deciding whether to invest.</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 64%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Ticker Symbol:</B></FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt">We have applied
                                    to list our Common Stock on the NASDAQ Capital Market (&ldquo;NASDAQ&rdquo;) under the symbol
                                    &ldquo;ADTX.&rdquo;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<P STYLE="margin: 0pt 0"> We will not apply to list our Units, or the Warrants that form a part of the Units, on NASDAQ.&nbsp;It
is not anticipated that a public market for the Units or the Warrants will develop in the future. </P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">This figure does not include (a) 1,200,000
    shares of Common Stock reserved for issuance under our 2017 Plan of which 1,025,000 shares of Common Stock are issuable upon
    exercise of outstanding options having a weighted average exercise price of $2.00 per share, (b) 1,000,000 shares of Common
    Stock reserved for issuance under the Sekris Warrant, (c)&nbsp;131,250 shares of Common Stock reserved for issuance under
    the Private Placement Warrants, (d) 420,000 shares of Common Stock reserved for issuance under warrants issued to &nbsp;consultants
    of the Company, and (e) 18,667 shares of Common Stock reserved for issuance under the July Private Placement Warrants.</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assumes no exercise of the Warrants offered hereby.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include expenses of the Offering, including without
    limitation, fees and expenses for administrative, accounting, audit and legal services and fees for EDGAR document conversion
    and filing, estimated to be as much as $400,000 to $500,000.</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a004_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
present below our summary historical financial and operating data. The historical financial data as of December&nbsp;31, 2017
and for the for the period from September 28, 2017 (Inception) through December 31, 2017 has been derived from our audited consolidated
financial statements and the related notes thereto, which are included elsewhere in this Offering Circular and which have been
prepared in accordance with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical results are not necessarily indicative of the financial results to be expected in any future periods. You should read
this information in conjunction with our consolidated financial statements and related notes included elsewhere in this Offering
Circular, as well as the sections entitled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
    31,</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ASSETS</U></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT ASSETS</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 87%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL CURRENT ASSETS</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TOTAL ASSETS</U></B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>LIABILITIES
    AND STOCKHOLDERS&rsquo; DEFICIT</U></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT LIABILITIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,566</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation
    to related party</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,334</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL CURRENT LIABILITIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,900</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit on private
    placement</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL LIABILITIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,900</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITMENTS AND CONTINGENCIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; DEFICIT</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock,
    $0.001 par value, 3,000,000 shares authorized, 0 shares issued and outstanding</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $0.001
    par value, 27,000,000 shares authorized, 7,100,000 shares issued and outstanding</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in
    capital</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">145,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL STOCKHOLDERS&rsquo;
    DEFICIT</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(59,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL LIABILITIES
    AND STOCKHOLDERS&rsquo; DEFICIT</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENT
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Period From</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 28, 2017</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Inception) Through</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December 31, 2017</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REVENUE</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPERATING EXPENSES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation
    and services contributed by founders</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,086</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
    expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Operating Expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET LOSS FROM OPERATIONS</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER EXPENSES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Other Expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss before provision for income taxes</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision for income
    taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET LOSS</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share
    - basic and diluted</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.03</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average
    number of shares outstanding during the period - basic and diluted</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a005_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our Common Stock involves a high degree of risk. You should carefully consider the risks described below, together
with all of the other information included in this Offering Circular, before making an investment decision. If any of the following
risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the price of our
shares of Common Stock could decline and you may lose all or part of your investment. See &ldquo;<FONT STYLE="font-weight: normal">Cautionary
Statement Regarding Forward Looking Statements</FONT>&rdquo; above for a discussion of forward-looking statements and the significance
of such statements in the context of this Offering Circular.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Company and our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Company, having only recently commenced operations, is a development stage business and subject to the many risks associated with
new businesses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
formed the company in September 2017 and commenced operations in October 2017.&nbsp;&nbsp;Accordingly, we have only a limited
history by which you can assess our Company and our prospects. We are, and expect for the foreseeable future to be, subject to
all the same risks and uncertainties inherent in a new business enterprise and in the further development of our technology.&nbsp;&nbsp;No
assurances can be given as to the ability of the Company to operate profitably.&nbsp;&nbsp;If we do not generate positive cash
flow in the future and hence become profitable, we may not be able to remain in business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
only recently commenced operations, our ability to operate successfully is materially uncertain and our operations and prospects
are subject to all risks inherent in a developing business enterprise. In investing in this Offering, potential Investors should
be aware of the difficulties normally encountered by early-revenue, development stage companies and the high rate of failure of
such enterprises. The likelihood of our viability and potential for revenue and profit generation must be considered in light
of the significant problems, expenses, difficulties, complications and delays that may be encountered.&nbsp;&nbsp;These potential
problems and uncertainties include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may have difficulty implementing a sound business plan;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to successfully commercialize and demonstrate the safety and efficacy of our
                                         technology;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to secure regulatory approvals;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         future products may never be developed, manufactured, launched, or work as planned;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customers
                                         may not adopt our products quickly, or at all;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                         costs may exceed our expectations;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not be able to adequately protect our intellectual property, trademarks, and trade
                                         secrets;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be exposed to product liability and remediation claims;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to generate significant sales;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to attract and retain high quality personnel for management, executive, and board
                                         positions;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                         of more established and better capitalized companies;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to raise capital when needed to advance our business plans; and</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be exposed to economic downturns, political and economic events and technological
                                         developments.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that we can successfully address these and other challenges with which we may be confronted, if we are unsuccessful,
the Company and its business, financial condition and operating results could be materially and adversely affected, in which case
the value of the Company could be negatively impacted and you could lose all or a part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
financial situation creates doubt whether we will continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated on September 28, 2017 and through the date of this Offering Circular has generated no revenues. As of
December 31, 2017, the Company had a net loss of $212,986. There can be no assurances that we will be able to achieve a level
of revenues adequate to generate sufficient cash flow from operations or obtain funding from this Offering or additional financing
through private placements, public offerings and/or bank financing necessary to support our working capital requirements. To the
extent that funds generated from any private placements, public offerings and/or bank financing are insufficient, we will have
to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will
be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern. If adequate
working capital is not available we may be forced to discontinue operations, which would cause investors to lose their entire
investment. Our auditors have indicated that these conditions raise substantial doubt about the Company&rsquo;s ability to continue
as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
technology is subject to a license from LLU, which is revocable in certain circumstances, including in the event we do not achieve
certain Milestone Deadlines. Without this license, we cannot continue to develop our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New License Agreement may be terminated by LLU in the event of a breach by us of any non-payment provision (including the provision
that requires us to meet certain deadlines for milestone events (each, a &ldquo;Milestone Deadline&rdquo;)) not cured within 90
days. The next such Milestone Deadline is the requirement to complete a financing round by July 31, 2018. Additional Milestone
Deadlines include: (i) the requirement to have regulatory approval of an IND application to initiate a first-in-human clinical
trials on or before March 31, 2020, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2022, (iii)
the completion of Phase III clinical trials by March 31, 2024 and (iv) biologic licensing approval by the FDA by March 31, 2025.
If New License Agreement were to be terminated by LLU, we would lose our significant asset and would no longer be able to develop
our product candidates, which would have a material adverse effect on our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to satisfy certain contractual milestone obligations</I></B><I>. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the New License Agreement,
we are contractually obligated to pay LLU, within thirty (30) days &nbsp;of July 31, 2018, a milestone fee of $200,000 (the &ldquo;Milestone
Fee&rdquo;) upon the completion of a financing round. The Company intends for this Offering to qualify as a financing round pursuant
to the terms of the License Agreement and to pay the Milestone Fee from the proceeds of this Offering. There can be no assurance
that the Company will raise sufficient capital to pay the Milestone Fee, or complete the Offering at all, thus potentially causing
a material adverse effect to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not generated any revenue and may not generate revenue in the manner or within the timeframe we anticipate. We do not have
positive operating cash flow. We expect to incur losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenue to date, our technology is still in development. Because of the various risks and uncertainties
associated with developing, obtaining regulatory approvals for and marketing new products, we are unable to predict with any certainty
the extent of any future revenues, cash flows, profits or losses or when we will generate positive operating cash flow or become
profitable, if at all. We expect to derive future revenues principally from the sale and licensing of our products, but we cannot
guarantee the magnitude of any sales or licensing revenues. We expect to continue to require substantial resources to expand our
development activities, seek regulatory approvals, secure manufacturing capabilities, undertake sales and marketing activities,
and take other actions necessary to develop and grow our business. We expect that we will continue to incur operating losses for
the foreseeable future, and we may never be profitable. Continuing losses will, among other things, have an adverse effect on
our stockholders&rsquo; equity and working capital. Failure to generate revenue or achieve profitability would materially adversely
affect the value of our Company and our ability to grow our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to raise substantial additional investment capital, which may be unavailable to us or, if raised, will cause dilution
of our existing investors and could place significant restrictions on our ability to operate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
in the event that all of the Units offered in the Offering are sold, the company will still need to raise substantial additional
equity or debt financing to provide sufficient capital required to fully execute its business plan and expand its operations.&nbsp;&nbsp;We
do not currently have any arrangements or credit facilities in place as a source of funds, and there can be no assurance that
we will be able to raise sufficient capital in this offering or additional capital on acceptable terms, if at all. If such financing
is not available on satisfactory terms, or is not available, we may be required to delay, scale back or eliminate the development
of business opportunities and our operations and financial condition may be materially adversely affected. If we raise additional
capital by issuing equity securities, the percentage ownership of our existing stockholders will be reduced, and these stockholders
may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior
to those of our common stock. Debt financing, if obtained, may involve agreements that include liens on our assets and covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, would increase our expenses and
could require that our assets be provided as security for such debt. Debt financing would also be required to be repaid regardless
of our operating results. There are no assurances that the Company will have sufficient funds to pay the debt off, or that the
Company will not default on its debt.&nbsp;&nbsp;If we raise additional funds through collaborations and licensing arrangements,
we may be required to relinquish some rights to our technologies or product candidates, or to grant licenses on terms that are
not favorable to us. Funding from any source may be unavailable to us on acceptable terms, if at all. If we do not have sufficient
capital to fund our operations and expenses, this could lead to the failure of our business and the loss of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we cannot develop our technology and launch products we may not achieve profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success will depend in part on our ability to develop, market and sell multiple products. Currently, we a pre-clinical
company that does not have&nbsp;&nbsp; A failure by us to do so could make it difficult to grow our business.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as products and processes being developed at universities and other research
institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with
our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical
community and any new treatments that may enter the market. We believe that a significant number of products are currently available,
under development, and may become commercially available in the future, for the treatment of indications for which we may try
to develop product candidates.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
established companies may have a competitive advantage over us due to their greater size, cash flows and institutional experience.
Compared to us, many of our competitors may have significantly greater financial, technical and human resources. As a result of
these factors, our competitors may have an advantage in marketing their approved products and may obtain regulatory approval of
their product candidates before we are able to, which may limit our ability to develop or commercialize our product candidates.
Our competitors may also develop drugs that are safer, more effective, more widely used and less expensive than ours, and may
also be more successful than us in manufacturing and marketing their products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among
a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining
qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
in-licensing of technologies and the successful testing and early development of technologies in the laboratory may not be indicative
of future results and may not result in commercially viable technologies or products. Further, our future products may have to
be modified from their originally conceived versions in order to reach or be successful in the market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
results from laboratory testing and early developmental successes, may not be predictive of future successful development, commercialization
and sales results and should not be relied upon as evidence that products developed from our technologies will become commercially
viable and successful. Further, the products we plan to develop in the future may have to be significantly modified from their
originally conceived versions in order for us to control costs, compete with similar products, receive market acceptance, meet
specific development and commercialization timeframes, avoid potential infringement of the proprietary rights of others, or otherwise
succeed in developing our business and earning ongoing revenues. This can be a costly and resource draining activity. What appear
to be promising technologies when we license them may not lead to viable technologies or products, or to commercial success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conflicts
of Interest </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to various potential conflicts of interest because of the fact that some of its officers and directors
may be engaged in a range of business activities. Dr. Shabahang, our CTO, is the CEO of Sekris. In addition, the Company&rsquo;s
executive officers and directors may devote time to their outside business interests, so long as such activities do not materially
or adversely interfere with their duties to the Company. In some cases, the Company&rsquo;s executive officers and directors may
have fiduciary obligations associated with these business interests that interfere with their ability to devote time to the Company&rsquo;s
business and affairs and that could adversely affect the Company&rsquo;s operations. These business interests could require significant
time and attention of the Company&rsquo;s executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
technologies and products under development, and our business, may fail if we are not able to successfully commercialize them
and ultimately generate significant revenues as a result.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of technologies and our product candidates will require significant additional investment, including costs associated
with additional development, completing trials and obtaining regulatory approval, as well as the ability to manufacture or have
others manufacture our products in sufficient quantities at acceptable costs while also preserving product quality. Difficulties
often encountered in scaling up production include problems involving production yields, quality control and assurance, shortage
of qualified personnel, production costs and process controls. In addition, we are subject to inherent risks associated with new
technologies and products. These risks include the possibility that any of our technologies or future products may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be found unsafe;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be ineffective or less effective than anticipated;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
fail to receive necessary regulatory approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be difficult to competitively price relative to alternative solutions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be harmful to consumers or the environment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be difficult or impossible to manufacture on an economically viable scale;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be subject to supply chain constraints for raw materials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
fail to be developed and accepted by the market prior to the successful marketing of alternative products by competitors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be difficult or impossible to market because of infringement on the proprietary rights of third parties; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be too expensive for commercial use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we may be faced with lengthy market partner or distributor evaluation and approval processes. Consequently, we may incur substantial
expenses and devote significant management effort in order to customize products for market partner or distributor acceptance,
though there can be no assurance of such acceptance. As a result, we cannot accurately predict the volume or timing of any future
sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Customers
may not adopt our products quickly, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers
in the sector in which we operate can be generally cautious in their adoption of new products and technologies. In addition, given
the relative novelty of our future planned products, customers of those products may require education regarding their utility
and use, which may delay their adoption. There can be no assurance that customers will adopt our products quickly, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
significant level of competition in the markets for our products developed in the future may result in pricing pressure, reduced
margins or the inability of our future product to achieve market acceptance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
markets for our future products are intensely competitive and rapidly changing. We may be unable to compete successfully, which
may result in price reductions, reduced margins and the inability to achieve market acceptance for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may have longer operating histories, significantly greater resources, greater brand recognition than we do and large
customer bases. As a result, they may be able to devote greater resources to the manufacture, promotion or sale of their products,
receive greater resources and support from market partners and independent distributors, initiate or withstand substantial price
competition or more readily take advantage of acquisition or other opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our future pre-clinical development and future Clinical Phase I/II Studies are unsuccessful, we may be unable to obtain regulatory
approval of, or commercialize, our product candidates on a timely basis or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful completion of pre-clinical development and multiple clinical trials is critical to the success of our future products.
If the pre-clinical development and clinical trials are unsuccessful or produce inconsistent results or unanticipated adverse
side effects, or if we are unable to collect reliable data, regulatory approval of our products could be delayed or not given
and as a result we may be unable to commercialize our products. Generally, we expect to engage third parties such as consultants,
universities or other collaboration partners to conduct clinical trials on our behalf. Incompatible practices or misapplication
of our products by these third parties could impair the success of our clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to complete required clinical trials, or we experience significant delays in completing such clinical trials, we
could experience significant delays our targeted product launch timeframe and impair our viability and business plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of any clinical trials that we may be required to undertake could be delayed, suspended or terminated for several reasons,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         failure or inability to conduct the clinical trial in accordance with regulatory requirements;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sites
                                         participating in the trial may drop out of the trial, which may require us to engage
                                         new sites for an expansion of the number of sites that are permitted to be involved in
                                         the trial;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                         may not enroll in, remain in or complete, the clinical trial at the rates we expect;
                                         and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                         investigators may not perform our clinical trial on our anticipated schedule or consistent
                                         with the clinical trial protocol and good clinical practices.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our clinical trials are delayed it will take us longer to ultimately commercialize our products and generate revenues. Moreover,
our development costs will increase if we have material delays in our clinical trials or if we need to perform more or larger
clinical trials than planned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
results of operations will be affected by the level of royalty and milestone payments that we are required to pay to third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to the New License Agreement which require us to remit royalty payments and meet certain performance milestones related
to in-licensed intellectual property. Any failure on our part to pay royalties owed or meet milestones could lead to us losing
rights under our licenses and could thereby adversely affect our business. As our product sales increase, we may, from time-to-time,
disagree with our third-party collaborators as to the appropriate royalties owed and the resolution of such disputes may be costly
and may consume management&rsquo;s time. Furthermore, we may enter into additional license agreements in the future, which may
also include royalty payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will likely rely on third parties for the production of our future products.&nbsp;&nbsp;If these parties do not produce our products
at a satisfactory quality, in a timely manner, in sufficient quantities or at an acceptable cost, our sales and development efforts
could be delayed or otherwise negatively affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will likely rely on third parties for the manufacture of our future products. Our reliance on third parties to manufacture our
future products may present significant risks to us, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control
    over delivery schedules, yields and product reliability;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing deviations
    from internal and regulatory specifications;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of a
    key manufacturer to perform as we require for technical, market or other reasons;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in
    establishing additional manufacturer relationships if we are presented with the need to transfer our manufacturing process
    technologies to them;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation
    of our intellectual property; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.12in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks in potentially
    meeting our product development schedule or satisfying the requirements of our market partners, distributors, direct customers
    and end users.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we need to enter into agreements for the manufacturing of our future products, there can be no assurance we will be able to do
so on favorable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish successful relations with third-party market partners or distributors, or these market partners or
distributors do not focus adequate resources on selling our products or are otherwise unsuccessful in selling them, sales of our
products may not develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate relying on independent market partners and distributors to distribute and assist us with the marketing and sale of
our products. Our future revenue generation and growth will depend in large part on our success in establishing and maintaining
this sales and distribution channel. If our market partners and distributors are unable to sell our products, or receive negative
feedback from end users, they may not continue to purchase or market our products. In addition, there can be no assurance that
our market partners and distributors will focus adequate resources on selling our products to end users or will be successful
in selling them. Many of our potential market partners and distributors are in the business of distributing and sometimes manufacturing
other, possibly competing, products.&nbsp;&nbsp;As a result, these market partners and distributors may perceive our products
as a threat to various product lines currently being distributed or manufactured by them. In addition, these market partners and
distributors may earn higher margins by selling competing products or combinations of competing products. If we are unable to
establish successful relationships with independent market partners and distributors, we will need to further develop our own
sales and distribution capabilities, which would be expensive and time-consuming and might not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to attract and retain highly skilled employees and contractors, we may not be able to implement our business model
successfully.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will rely upon employees and third-party consultant/contractors to effectively establish, manage and grow our business. Consequently,
we believe that our future viability will depend largely on our ability to attract and retain highly skilled personnel.&nbsp;&nbsp;In
order to do so, we may need to pay higher compensation, fees, and/or other incentives to our employees or consultants than we
currently expect and such higher compensation payments would have a negative effect on our operating results. Competition for
experienced, high-quality employees, consultants and contractors is intense and we cannot assure that we will be able to recruit
and retain such personnel. We may not be able to hire or retain the necessary personnel to implement our business strategy. Our
failure to hire and retain such personnel could impair our ability to develop new products and manage our business effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
loss of our management team or other key personnel would have an adverse impact on our future development and impair our ability
to succeed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the early stages of development, our business will be significantly dependent on the company&rsquo;s management team and other
key personnel. Our success will be particularly dependent upon Mr. Amro Albanna, Dr. Leonard Bailey, and Dr. Shahrokh Shabahang.
The loss of any one of these individuals or any other future key personnel could have a material adverse effect on the Company
and our ability to further execute our intended business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supply
problems could harm our business</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we may commit to purchase component parts and substances from suppliers based on sales forecasts of our future
products. If we cannot change or be released from these purchase commitments, and if orders for our future products do not materialize,
we could incur significant costs related to the purchase of excess parts and substances. Additionally, a delay in production of
the parts or substances or inaccuracies in our sales forecasts could materially adversely affect our results or reputation if
we are unable to timely ship ordered products or provide replacements under warranty or maintenance contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
use of our products may be limited by regulations, and we may be exposed to product liability and remediation claims.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of our planned products may be regulated by various local, state, federal and foreign regulators.&nbsp;&nbsp;Even if we are
able to comply with all such regulations and obtain all necessary registrations, we cannot provide assurance that our future products
will not cause injury to the environment, people, or animals and/or otherwise have unintended adverse consequences, under all
circumstances. For example, our products may be improperly combined with other chemicals or, even when properly combined, our
products may be blamed for damage caused by those other chemicals. The costs of remediation or products liability could materially
adversely affect our results, financial condition and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be held liable for, or incur costs to settle, liability and remediation claims if any products we develop, or any products
that use or incorporate any of our technologies, cause injury or are found unsuitable during product testing, manufacturing, marketing,
sale or use. These risks exist even with respect to products that have received, or may in the future receive, regulatory approval,
registration or clearance for commercial use. We cannot guarantee that we will be able to avoid product liability exposure.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
at the stage customary to do so, we expect to maintain product liability insurance at levels we believe are sufficient and consistent
with industry standards for like companies and products. However, we cannot guarantee that our product liability insurance will
be sufficient to help us avoid product liability-related losses. In the future, it is possible that meaningful insurance coverage
may not be available on commercially reasonable terms or at all. In addition, a product liability claim could result in liability
to us greater than our assets or insurance coverage. Moreover, even if we have adequate insurance coverage, product liability
claims or recalls could result in negative publicity or force us to devote significant time and attention to these matters, which
could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
inability to obtain regulatory approvals, or to comply with ongoing and changing regulatory requirements, could delay or prevent
sales of the products we are developing.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing, manufacture, sale and use of some of our planned future products will be regulated by government agencies in the U.S.
and abroad. These regulations substantially increase the time and cost associated with bringing future products to market. If
we do not receive the necessary governmental approvals to test, manufacture and market our products, or if regulatory authorities
revoke our approvals, do not grant approvals in a timely manner or grant approvals subject to restrictions on their use, we may
be unable to sell our products in the United States or other jurisdictions, which could adversely affect our results and operations.
As we introduce new technologies and applications for our planned products, we will need to seek new regulatory approvals prior
to commercial sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will be able to obtain regulatory approval for marketing technologies, products, and applications
we may develop. Because many of the products that may be sold by us must be registered with one or more government agencies, the
registration process can be time consuming and expensive, and there is no guarantee that the product will obtain all needed registrations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain all necessary regulatory approvals to market and sell our products, they will be subject to continuing review and
extensive regulatory requirements, including periodic re-registrations. Regulatory authorities could withdraw a previously approved
product from the market upon receipt of newly discovered information, including an inability to comply with regulatory requirements
or the occurrence of unanticipated problems with our products, or for other reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization
of our future product candidates, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing, manufacturing, labeling, approval, selling, marketing and distribution of health- and life science-related products are
subject to extensive regulation, which regulations differ from country to country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategic plan is to demonstrate clinical proof-of-concept of our product candidates in early (phase I/II) clinical trials and
to secure strategic partners who will acquire or enter into co-development agreements to complete later stage clinical trials
and to obtain regulatory approval for product distribution.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we elect to develop any product candidates in late stage development and/or marketing and distribution and for product candidates
that qualify under biopharmaceuticals, we will not be permitted to market them in the United States or other regions until we
receive approval to do so by the appropriate regulatory agencies for the regions we plan to market our product(s). We have not
submitted an application or premarket notification for or received marketing clearance or approval for any of our product candidates.
Obtaining approval of any premarket approval can be a lengthy, expensive and uncertain process. There is no guarantee that our
products will receive Investigational New Drug (IND) approval to initiate human trials and after completion of the necessary clinical
testing, there is no guarantee that our products will receive regulatory approval for marketing and distribution. If the FDA or
other relevant regulatory agencies do not approve our applications for marketing our biopharmaceutical product(s), then we cannot
market the product(s). The regulatory agencies may seek additional information or additional data, which would further delay our
ability to market the product. In addition, if we modify our regulatory approved product(s), we may need to seek additional clearance
or approvals, which, if not granted, would prevent us from selling our modified products. Furthermore, failure to comply with
FDA, non-U.S. regulatory authorities or other applicable U.S. and non-U.S. regulatory requirements may, either before or after
product clearance or approval, if any, subject us to administrative or judicially imposed sanctions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
restrictions on the products, manufacturers or manufacturing process;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
adverse inspectional observations (Form 483), warning letters or non-warning letters incorporating inspectional observations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
civil and criminal penalties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
injunctions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension or withdrawal of regulatory clearances or approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product seizures, detentions or import bans;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
voluntary or mandatory product recalls and publicity requirements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
total or partial suspension of production;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
imposition of restrictions on operations, including costly new manufacturing requirements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusal to clear or approve pending applications or premarket notifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and/or other regulatory agencies can delay, limit or deny clearance or approval of a biopharmaceutical product candidate for
many reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a biopharmaceutical product may not be deemed safe or effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
regulatory officials may not find the data from pre-clinical studies and clinical trials sufficient;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the regulatory agency might not approve our third-party manufacturer&rsquo;s processes or facilities; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the regulatory may change its clearance or approval policies or adopt new regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes of the FDA, the EMA and other comparable foreign regulatory authorities are lengthy, time</I></B>-<B><I>consuming
and inherently unpredictable, and if we are ultimately unable to obtain timely regulatory approval for our product candidates,
our business will be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not be permitted to market our product candidates in the United States or the EU until we receive approval of an NDA from
the FDA or an MAA from the EMA, or in any foreign countries until we receive the requisite approval from such countries. Prior
to submitting an NDA to the FDA or an MAA to the EMA for approval of our product candidates we will need to complete our preclinical
studies and initiate and complete clinical trials. Successfully completing our clinical program and obtaining approval of an NDA
or MAA is a complex, lengthy, expensive and uncertain process, and the FDA or EMA may delay, limit or deny approval of our product
candidates for many reasons, including, among others, because:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able
    to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction of the FDA or EMA;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our
    clinical trials may not meet the level of statistical or clinical significance required by the FDA or EMA for marketing approval;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or EMA may
    disagree with the number, design, size, conduct or implementation of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or EMA may
    require that we conduct additional clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or EMA or
    other applicable foreign regulatory authorities may not approve the formulation, labeling or specifications of our product
    candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the contract research
    organizations (CROs) and other contractors that we may retain to conduct our clinical trials may take actions outside of our
    control that materially adversely impact our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or EMA may
    find the data from preclinical studies and clinical trials insufficient to demonstrate that EHP-101 or EHP-102 are safe and
    effective for their proposed indications;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or EMA may
    disagree with our interpretation of data from our preclinical studies and clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or EMA may
    not accept data generated at our clinical trial sites or may disagree with us over whether to accept efficacy results from
    clinical trial sites outside the United States or outside the EU, as applicable, where the standard of care is potentially
    different from that in the United States or in the EU, as applicable;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if and when our
    NDAs or MAAs are submitted to the FDA or EMA, as applicable, the regulatory authorities may have difficulties scheduling the
    necessary review meetings in a timely manner, may recommend against approval of our application or may recommend or require,
    as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution
    and use restrictions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may require
    development of a Risk Evaluation and Mitigation Strategy (REMS), which would use risk minimization strategies to ensure that
    the benefits of certain prescription drugs outweigh their risks, as a condition of approval or post-approval, and the EMA
    may grant only conditional marketing authorization or impose specific obligations as a condition for marketing authorization,
    or may require us to conduct post-authorization safety studies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, DEA, EMA
    or other applicable foreign regulatory agencies may not approve the manufacturing processes or facilities of third-party manufacturers
    with which we contract or DEA or other applicable foreign regulatory agency quotas may limit the quantities of controlled
    substances available to our manufacturers; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, EMA or
    other applicable foreign regulatory agencies may change their approval policies or adopt new regulations.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors, many of which are beyond our control, could increase development costs, jeopardize our ability to obtain regulatory
approval for and successfully market our product candidates and generate product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
failure to obtain or maintain patents, licensing agreements and other intellectual property could materially impact our ability
to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for our business to be viable and to compete effectively, we need to develop and maintain, and we will heavily rely on,
a proprietary position with respect to our technologies and intellectual property. However, there are significant risks associated
with our actual or proposed intellectual property. The risks and uncertainties that we face with respect to our rights principally
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending
                                         patent applications we have filed or will file may not result in issued patents or may
                                         take longer than we expect to result in issued patents;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to interference proceedings;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to reexamination proceedings;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to post grant review proceedings;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to <I>inter partes </I>review proceedings;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to derivation proceedings;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may be subject to opposition proceedings in the U.S. or in foreign countries;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         patents that are issued to us may not provide meaningful protection;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         may not be able to develop additional proprietary technologies that are patentable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         companies may challenge patents licensed or issued to us;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         companies may have independently developed and patented (or may in the future independently
                                         develop and patent) similar or alternative technologies, or duplicate our technologies;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         companies may design around technologies we have licensed or developed;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
                                         of patents is complex, uncertain and very expensive and we may not be able to secure,&nbsp;&nbsp;enforce
                                         and defend our patents; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.12in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                         the event that we were to ever seek to enforce our patents in ligation, there is some
                                         risk that they could be deemed invalid, not infringed, or unenforceable.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that any patents will be issued as a result of any pending or future applications, or that any patents, once
issued, will provide us with adequate protection from competing products. For example, issued patents may be circumvented or challenged,
declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in scientific or patent
literature often lags behind actual discoveries, we cannot be certain that we or our licensors were the first to invent or to
file patent applications covering them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that others may have or may obtain issued patents that could prevent us from commercializing our products or
require us to obtain licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business.
There is no guarantee that such licenses will be available based on commercially reasonable terms. As to those patents that we
have licensed, our rights depend on maintaining our obligations to the licensor under the applicable license agreement, and we
may be unable to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain patent protection for our products, or if the scope of the patent protection obtained is
not sufficiently broad, competitors could develop and commercialize products similar or identical to ours, and our ability to
successfully commercialize our products could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable
patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to
identify patentable aspects of our development output before it is too late to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of life science companies generally is highly uncertain, involves complex legal and factual questions and has
in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to
the same extent as the laws of the United States and we may fail to seek or obtain patent protection in all major markets. For
example, unlike the U.S., European patent law restricts the patentability of methods of treatment of the human body. Our pending
and future patent applications may not result in patents being issued which protect our technology or products, in whole or in
part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow
the scope of our patent protection, even post-grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
patent reform legislation has increased the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith
Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include
provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark
Office, or USPTO, recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many
of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions,
only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the
operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding
the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material
adverse effect on our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation,
reexamination, <I>inter partes </I>review, post-grant review or interference proceedings challenging our patent rights (whether
licensed or otherwise held) or the patent rights of others. An adverse determination in any such submission, proceeding or litigation
could reduce the scope of, or invalidate, our patent rights (whether licensed or otherwise held), allow third parties to commercialize
our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize
products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents
and patent applications (whether licensed or otherwise held) is threatened, it could dissuade companies from collaborating with
us to license, develop or commercialize current or future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our patent applications (whether licensed or otherwise held) result in the issuance of patents, they may not issue in a form
that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any
competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative
technologies or products in a non-infringing manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our licensed or owned patents
may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity
or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent
protection of our products. Given the amount of time required for the development, testing and regulatory review of new life science
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our intellectual property rights portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming
and ultimately unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their intellectual property or that our intellectual property is invalid or
unenforceable. In addition, in a patent infringement proceeding, a court may decide that a licensed or owned patent of ours is
invalid or unenforceable, in whole or in part, construe the patent&rsquo;s claims narrowly or refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover that technology. Moreover, lawsuits to protect or enforce
our intellectual property rights could be expensive, time-consuming and ultimately unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which
would be uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability to develop, manufacture, market and sell our product candidates without infringing
the proprietary rights of third parties. There is considerable intellectual property litigation in the life sciences industry.
We cannot guarantee that our product candidates will not infringe third-party patents or other proprietary rights. We may become
party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect
to our products and technology, including <I>inter partes </I>review, interference, or derivation proceedings before the USPTO
and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual
property rights and intellectual property rights that may be granted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&rsquo;s intellectual property rights, we could be required to obtain a license from such
third party to continue developing and marketing our products. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors
access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing
technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&rsquo;
fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our
product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that
we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our own patent protection could be reduced or eliminated for noncompliance
with these requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees and annuities on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages
over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse
of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time
limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might
be able to enter our markets, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property,
or claiming ownership of what we regard as our own intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our employees and contractors were previously employed at universities or other companies, including potential competitors.
Although we try to ensure that our employees and contractors do not use the proprietary information or know-how of others in their
work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade
secrets or other proprietary information, of any such employee&rsquo;s former employer. Litigation may be necessary to defend
against these claims, and any such litigation could have an unfavorable outcome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may
not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may
bring against us, to determine the ownership of what we regard as our intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result
in substantial costs and adverse results, and be a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
substantial portion of our in-licensed intellectual property will be subject to the provisions of the Bayh-Dole Act, if the underlying
inventions were achieved using federal government funding. Such innovations are subject to &ldquo;march-in&rdquo; rights and other
provisions under that Act.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
we fail to take &ldquo;effective steps to achieve practical application of&rdquo; inventions we have licensed or fail to satisfy
&ldquo;health and safety needs&rdquo; of consumers, then, under the federal Bayh-Dole Act, a federal government agency that has
funded the discovery of the invention may &ldquo;march in&rdquo; and, despite our intellectual property rights in the invention,
compel the granting of a license, or grant the license itself, to the invention to third-party petitioners who are &ldquo;reasonable
applicants&rdquo;. There is also nothing prohibiting such government agency in exercising its &ldquo;march-in&rdquo; rights by
granting such licenses to any of our competitors. Any such &ldquo;march-in&rdquo; under this Act could disrupt our operations
and business plans with respect to the invention at issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition,
there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities
analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.
Such litigation or proceedings could increase our operating losses and reduce the resources available for development activities
or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings
more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may spend considerable resources developing and maintaining patents, licensing agreements and other intellectual property that
may later be abandoned or may otherwise never result in products brought to market. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
all technologies and candidate products that initially show potential as the basis for future products end up meeting the rigors
of our development process and as a result may be abandoned and/or never otherwise result in products brought to market.&nbsp;&nbsp;In
some cases prior to abandonment we may be required to incur significant cost developing and maintaining intellectual property
and/or maintaining license agreements and our business could be harmed by such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on information technology, and if we are unable to protect against service interruptions, data corruption, cyber-based attacks
or network security breaches, our operations could be disrupted and our business could be negatively affected. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology networks and systems to process, transmit and store electronic and financial information; to coordinate
our business; and to communicate within our Company and with customers, suppliers, partners and other third-parties. These information
technology systems may be susceptible to damage, disruptions or shutdowns, hardware or software failures, power outages, computer
viruses, cyber-attacks, telecommunication failures, user errors or catastrophic events. If our information technology systems
suffer severe damage, disruption or shutdown, and our business continuity plans do not effectively resolve the issues in a timely
manner, our operations could be disrupted and our business could be negatively affected. In addition, cyber-attacks could lead
to potential unauthorized access and disclosure of confidential information, and data loss and corruption. There is no assurance
that we will not experience these service interruptions or cyber-attacks in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Information
about our Company, technologies and product concepts that can be found on social media, websites, blogs, and/or other forms of
electronic media must not be relied upon as it may be out-of-date, inaccurate, incomplete, and/or fabricated by others.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about our company, technologies, product concepts, plans and past activities can be found on social media, websites, blogs, and/or
other forms of electronic media.&nbsp;&nbsp;Such information should not be relied upon as part of your evaluation of our Company
and the Offering as such information may be found to be out-of-date, inaccurate, and/or incomplete. Further, such information
may have been created by others, fabricated by others, or our original material may have been edited by others without our approval
and such information must not be relied upon as having been authorized by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no assurance that an active and liquid trading market in our Common Stock will develop.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> This Offering will close only if our
Common Stock is accepted to be listed on the NASDAQ Capital Market. There can be no assurance any broker will be interested in
trading our Common Stock. Therefore, it may be difficult to sell any securities you purchase in this offering if you desire or
need to sell them. Neither we nor the underwriters can provide any assurance that an active and liquid trading market in our common
stock will develop or, if developed, that the market will continue. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the
Warrants being offered, and we do not anticipate such a market ever developing in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for the Warrants and we do not intend to have the Warrants listed on a national securities exchange or any other recognized
trading system in the future. Without an active market, the liquidity of the Warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Warrants may not have value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Warrants being offered by us in
this Offering are exercisable for the period commencing on the date that is six-months from the date of issuance of the warrant,
have an exercise price of $7.50 per share, and expire three (3) years from the date of issuance. In the event that our Common
Stock does not exceed the exercise price of the Warrants during the period when the Warrants are exercisable, the Warrants may
not have any value.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of our Warrants will have
no rights as shareholders until they acquire shares of our common stock, if ever.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you acquire Warrants to purchase shares
of our common stock in this offering, you will have no rights with respect to our Common Stock until you acquire shares of such
Common Stock upon exercise of your Warrants. Upon exercise of your Warrants, you will be entitled to exercise the rights of a
holder of Common Stock only as to matters for which the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud
may materially harm our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect that internal control over financial accounting and disclosure, even if timely and well established, will prevent
all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute,
assurance that the control system&rsquo;s objectives will be met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances
of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely affect
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not expect to pay dividends in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to declare dividends for the foreseeable future, as we anticipate that we will reinvest any and all future earnings
in the development and growth of our business. Therefore, investors will not receive any funds unless they sell their securities,
and holders may be unable to sell their securities on favorable terms or at all. We cannot assure you of a positive return on
your investment or that you will not lose the entire amount of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Upon
dissolution of our Company, you may not recoup all or any portion of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, dissolution or winding-up of our Company, whether voluntary or involuntary, our assets would be used
to pay all of our debts and liabilities, and only thereafter would any remaining assets be distributed to our stockholders, subject
to rights of the holders of the Preferred Stock, if any, on a <I>pro rata </I>basis. There can be no assurance that we will have
assets available from which to pay any amounts to our stockholders upon such a liquidation, dissolution or winding-up. In such
an event, you would lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitation
of Liability and Indemnification of Management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Delaware Corporation Law and the Company&rsquo;s Amended and Restated Certificate of Incorporation provides for the limitation
of the liability of directors for monetary damages. Such provisions may discourage shareholders from bringing a lawsuit against
directors for breaches of fiduciary duty and may also have the effect of reducing the likelihood of derivative litigation against
directors and officers even though such action, if successful, might otherwise be a benefit to the Company&rsquo;s shareholders.&nbsp;&nbsp;In
addition, a shareholder&rsquo;s investment in the Company may be adversely affected to the extent that costs of settlement and
damage awards against the Company&rsquo;s officers or directors are paid by the Company pursuant to such provisions. Additionally,
In accordance with Delaware Corporation Law and the Company&rsquo;s Amended and Restated Certificate of Incorporation, the Company
shall indemnify, hold harmless and provide advancement of expenses, to the fullest extent permitted by applicable law, directors,
officers, employees, and agents that are made a party or threatened to be made a party to legal proceedings by reason of the fact
that such parties were working at the request of the Company.&nbsp;&nbsp;We direct you to the Company&rsquo;s Amended and Restated
Certificate of Incorporation for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions under Delaware law could discourage, delay or prevent a change in control of our Company and could affect the trading
price of our securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent
a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three
years after the person becomes an interested stockholder, even if a change in control would be beneficial to our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need but may be unable to obtain additional funding on satisfactory terms, which could dilute our stockholders or impose
burdensome financial restrictions on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon our majority stockholder to finance our operations to date, and in the future, we hope to rely on revenues generated
from operations to fund all of the cash requirements of our activities. However, there can be no assurance that our majority stockholder
will continue to finance our operations or that we will be able to generate any significant cash from our operating activities
in the future. Our majority stockholder has financed our operations through unsecured promissory notes. Future financings may
not be available on a timely basis, in sufficient amounts or on terms acceptable to us, if at all. Any debt financing or other
financing of securities senior to the Common Stock will likely include financial and other covenants that will restrict our flexibility.
Any failure to comply with these covenants would have a material adverse effect on our business, prospects, financial condition
and results of operations because we could lose our existing sources of funding and impair our ability to secure new sources of
funding. However, there can be no assurance that the Company will be able to generate any investor interest in its securities.
If we do not obtain additional financing, our business will never commence, in which case you would likely lose the entirety of
your investment in us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Upon
qualification of the Offering Statement of which this Offering Circular is a part, we will incur increased costs as a result of
our public reporting obligations, and our management team will be required to devote substantial time to new compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
qualification of this Form 1-A, particularly after we are no longer an &ldquo;<I>emerging growth company</I>,&rdquo; we will incur
significant legal, accounting and other expenses that we did not incur as a private company. Our management and other personnel
would need to devote a substantial amount of time to comply with our reporting obligations. Moreover, these reporting obligations
will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to develop our internal controls over financial reporting as we grow could have an adverse impact on us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our Company matures we will need to develop our current internal control systems and procedures to manage our growth. We are required
to establish and maintain appropriate internal controls over financial reporting. Failure to establish appropriate controls, or
any failure of those controls once established, could adversely impact our public disclosures regarding our business, financial
condition or results of operations. In addition, management&rsquo;s assessment of internal controls over financial reporting may
identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters
that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal
control over financial reporting, disclosure of management&rsquo;s assessment of our internal controls over financial reporting
or disclosure of our public accounting firm&rsquo;s attestation to or report on management&rsquo;s assessment of our internal
controls over financial reporting may have an adverse impact on the price of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Need for Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we raise the Maximum Offering, we will need to raise additional funding, which may not be available on acceptable terms, or
at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development
efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we raise the Maximum Offering amount, we expect that the net proceeds will be sufficient to fund our current operations
for at least the next 36 months. However, our operating plan may change as a result of many factors currently unknown to us, and
we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other
third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements
or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and
to commercialize, our product candidates. Raising funds in the current economic environment may present additional challenges.
Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability
to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available
in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings
or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility
of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities
may dilute our existing stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we
may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely
impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners
or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our
technologies or product candidate or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect
on our business, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more
of our research or development programs or the commercialization of any product candidate or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase our Units in this Offering, you will incur immediate and substantial dilution in the book value of your Shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will suffer immediate and substantial dilution in the net tangible book value of the Common Stock you purchase in this Offering.
Assuming an offering price of $6.00&nbsp;per share and the maximum number of Units are sold for gross proceeds of $10,000,000,
purchasers in this Offering will experience immediate dilution of $5.09&nbsp;per share of Common Stock in net tangible book value
of the Common Stock. See &ldquo;<FONT STYLE="font-weight: normal"><I>Dilution</I></FONT>&rdquo; on page 27 for a more detailed
description of the dilution to new investors in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
executive officers, directors, major stockholder and their respective affiliates will continue to exercise significant control
over our Company after this Offering, which will limit your ability to influence corporate matters and could delay or prevent
a change in corporate control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the completion of this Offering, and disregarding any shares of Common Stock that they purchase in this Offering, if
any, the existing holdings of our executive officers, directors, major stockholders and their affiliates, will represent beneficial
ownership, in the aggregate, of approximately 76.53% of our outstanding Common Stock, assuming we issue the number of shares of
Common Stock as set forth on the cover page of this Offering Circular. Please see &ldquo;<FONT STYLE="font-weight: normal"><I>Security
Ownership of Management &amp; Certain Security Holders</I></FONT>&rdquo; on page 45 for more information. As a result, these stockholders
will be able to influence our management and affairs and control the outcome of matters submitted to our stockholders for approval,
including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These
stockholders acquired their shares of Common Stock for substantially less than the price of the shares of Common Stock being acquired
in this Offering, and these stockholders may have interests, with respect to their Common Stock, that are different from those
of investors in this Offering and the concentration of voting power among one or more of these stockholders may have an adverse
effect on the price of our Common Stock. In addition, this concentration of ownership might adversely affect the market price
of our Common Stock by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying, deferring
    or preventing a change of control of the Company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impeding a merger,
    consolidation, takeover or other business combination involving the Company; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging a potential
    acquirer from making a tender offer or otherwise attempting to obtain control of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have broad discretion in how we use the proceeds of this Offering and may not use these proceeds effectively, which could affect
our results of operations and cause our Common Stock and Warrant price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have considerable discretion in the application of the net proceeds of this Offering. We intend to use the net proceeds from
this Offering to fund our business strategy, including without limitation, new and ongoing research and development expenses,
offering expenses, working capital and other general corporate purposes, which may include funding for the hiring of additional
personnel. As a result, investors will be relying upon management&rsquo;s judgment with only limited information about our specific
intentions for the use of the balance of the net proceeds of this Offering. We may use the net proceeds for purposes that do not
yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds
from this Offering in a manner that does not produce income or that loses value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our stock price fluctuates after the Offering, you could lose a significant part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Common Stock could be subject to wide fluctuations in response to, among other things, the risk factors described
in this section of this Offering Circular, and other factors beyond our control, such as fluctuations in the valuation of companies
perceived by investors to be comparable to us. Furthermore, the stock markets have experienced price and volume fluctuations that
have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been
unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as
well as general economic, political, and market conditions, such as recessions, interest rate changes or international currency
fluctuations, may negatively affect the market price of our Common Stock. In the past, many companies that have experienced volatility
in the market price of their stock have been subject to securities class action litigation. We may be the target of this type
of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&rsquo;s
attention from other business concerns, which could seriously harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>After
the completion of this Offering, we may be at an increased risk of securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
securities class action litigation has often been brought against a company following a decline in the market price of its securities.
This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock
price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&rsquo;s
attention and resources, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying any cash dividends on our common stock in the foreseeable future and, as such, capital appreciation,
if any, of our common stock will be your sole source of gain for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock
in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and
growth of our business. In addition, and any future loan arrangements we enter into may contain, terms prohibiting or limiting
the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common
stock will be your sole source of gain for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could issue &ldquo;blank check&rdquo;&nbsp;preferred stock&nbsp;without stockholder approval with the effect of diluting interests
of then-current stockholders and impairing their voting rights, and provisions in our charter documents and under Delaware law
could discourage a takeover that stockholders may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation provides for the authorization to issue up to 3,000,000 shares of &ldquo;blank check&rdquo;&nbsp;preferred
stock&nbsp;with designations, rights and preferences as may be determined from time to time by our board of directors. Our board
of directors is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation,
conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common stockholders.
The issuance of a series of preferred stock could be used as a method of discouraging, delaying or preventing a change in control.
For example, it would be possible for our board of directors to issue preferred stock with voting or other rights or preferences
that could impede the success of any attempt to change control of our company. In addition, advanced notice is required prior
to stockholder proposals, which might further delay a change of control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Our
Amended and Restated Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the sole
and exclusive forum&nbsp;for substantially all disputes between the Company and its stockholders, which could limit stockholders&rsquo;
ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Amended and Restated Certificate of Incorporation provides that unless the Company consents in writing to the selection of an
alternative forum, the State of Delaware is the&nbsp;sole and exclusive forum for: (i) any derivative action or proceeding brought
on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other
employee of the Company to the Company or the Company&rsquo;s stockholders, (iii) any action asserting a claim against the Company,
its directors, officers or employees arising pursuant to any provision of the DGCL or our Amended and Restated Certificate of
Incorporation or the Company&rsquo;s Bylaws, or (iv) any action asserting a claim against the Company, its directors, officers,
employees or agents governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as
to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of
Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following
such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for
which the Court of Chancery does not have subject matter jurisdiction. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with the Company or its directors, officers or other employees, which may discourage such lawsuits against the Company
and its directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained
in our Amended and Restated Certificate of Incorporation to be inapplicable or unenforceable in an action, the Company may incur
additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations,
and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a006_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
the sale by us of the Maximum Offering of $10,000,000 and assuming Offering related expenses, including without limitation, the
Underwriter&rsquo;s commissions, professional fees and marketing expenses, estimated to be as much as $1,300,000, we estimate
that our net proceeds will be $8,700,000 which we currently intend to use as set forth below. We expect from time to time to evaluate
the acquisition of businesses, intellectual property, products and technologies for which a portion of the net proceeds may be
used, although we currently are not planning or negotiating any such transactions. The following table represents management&rsquo;s
best estimate of the uses of the net proceeds received from the sale of Common Stock assuming the sale of, respectively, $10,000,000
(the Maximum Offering Amount) and $7,320,000 (the Minimum Offering Amount) of Units offered for sale in this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
of Offering Sold</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>10,000,000</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>7,320,000</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Clinical Studies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Preclinical Studies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,000,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Repayment of Existing Debt <SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Research and Development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,582,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,582,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Milestone License Fee &ndash; Loma Linda University</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">200,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">General and Administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,893,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,427,400</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Offering Related Expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,300,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,085,600</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">7,320,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends
    to repay two promissory notes that have a total of $25,000 in principal outstanding. Each note bears interest at four percent
    (4%). The fist note has $15,000 in principal outstanding and is due on August 12, 2018. The second note has $10,000 in principal
    outstanding and is due on September 2, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use
    the net proceeds from this Offering to pay a Milestone licensing fee to Loma Linda University. We have attached a copy of
    the License Agreement as an exhibit to this Offering Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a007_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this Offering Circular,
an aggregate of 7,284,250 shares of our Common Stock are issued and outstanding. This figure does not include: (a) 1,200,000 shares
of Common Stock reserved for issuance under our 2017 Plan of which 1,025,000 shares of Common Stock are issuable upon exercise
of outstanding options having a weighted average exercise price of $2.00 per share, (b) 1,000,000 shares of Common Stock reserved
for issuance under the Sekris Warrant, (c) 131,250 shares of Common Stock reserved for issuance under the Private Placement Warrant,
and (d) 420,000 shares of Common Stock reserved for issuance under warrants issued to consultants of the Company; and (e) 18,667
shares of Common Stock reserved for issuance under the July Private Placement Warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase Units (and therefore Shares) in this Offering, your ownership interest in our Common Stock will be diluted immediately,
to the extent of the difference between the price to the public charged for each share in this Offering and the net tangible book
value per share of our Common Stock after this Offering. We have allocated a purchase price per Unit of $3.00&nbsp;per Share and
$3.00&nbsp;per Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net tangible book value as of December
31, 2017 was -$59,900 or $0 per share based on 7,284,250&nbsp;outstanding shares of Common Stock as at the date of this Offering
Circular. Net tangible book value per share equals the amount of our total tangible assets less total liabilities, divided by
the total number of shares of our Common Stock outstanding, all as of the date specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Maximum Offering, at an offering price
of $6.00 &nbsp;per share, is sold in this Offering, after deducting approximately $1,300,000 in offering expenses payable by us,
our pro forma as adjusted net tangible book value at December 31, 2017 would be approximately $8,140,100 ($0.91 per share). This
amount represents an immediate increase in pro forma net tangible book value of $0.91 per share to our existing stockholders at
the date of this Offering Circular, and an immediate dilution in pro forma net tangible book value of approximately $5.09 per
share to new investors purchasing shares of Common Stock in this Offering at a price of $6.00 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates the per share dilution to new investors discussed above, assuming the sale of, respectively, $10,000,000
(the Maximum Offering Amount) and $7,320,000 (the Minimum Offering Amount) of the shares offered for sale in this offering (after
our estimated offering expenses of $500,000):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Funding
    Level</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,320,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    Price</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma net tangible book value per Common Stock share before the Offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    per common share attributable to investors in this Offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.91</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.66</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma net tangible book value per Common Stock share after the Offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.91</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    to investors after the Offering<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.09</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.34</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    per common share attributable to investors in this Offering after Conversion</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.77</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.59</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma net tangible book value per Common Stock share after the Offering and Conversion</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.77</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.59</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    to investors after the Offering and Conversion<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.41</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><SUP>(1)
</SUP></FONT>Does not include any exercise of (i) outstanding awards under the 2017 Plan or the exercise of any outstanding warrants;
(ii) outstanding, but not yet vested, warrants to purchase up to 420,000 shares of Common Stock issued to consultants of the Company;
or (iii) 18,667 shares of Common Stock reserved for issuance under the July Private Placement Warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables set forth, assuming the
sale of, respectively, $10,000,000 (the Maximum Offering Amount), and $7,320,000 (the Minimum Offering Amount) of the shares offered
for sale in this offering the total number of shares previously sold to existing stockholders as of December 31, 2017, the total
consideration paid for the foregoing and the respective percentages applicable to such purchased shares and consideration paid
based on an average price of $0.01 per share paid by our existing stockholders and $6.00 per share paid by investors in this Offering.
The tables do not include the effect of (i) the exercise of outstanding awards under the 2017 Plan; (ii) the exercise of any outstanding
warrants; (iii) outstanding, but not yet vested, warrants to purchase up to 420,000 shares of Common Stock issued to consultants
of the Company; or (iii) 18,667 shares of Common Stock reserved for issuance under the July Private Placement Warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares
    Purchased</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total Consideration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Assuming $10,000,000 of Units Sold:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Existing stockholders</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">7,284,250</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">81</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">262,500</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">New Investors</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,666,666</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">97</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">8,950,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">10,262,500</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    Purchased</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Consideration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assuming $7,320,000 of
    Units Sold:</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Stockholders</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,284,250</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">262,500</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Investors</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,220,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,320,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,504,250</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,582,500</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 28; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a008_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT&rsquo;S
DISCUSSION &amp; ANALYSIS OF FINANCIAL CONDITION &amp; RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read the following discussion and analysis of our financial condition and results of our operations together with our financial
statements and the notes thereto appearing elsewhere in this Offering Circular. This discussion contains forward-looking statements
reflecting our current expectations, whose actual outcomes involve risks and uncertainties. Actual results and the timing of events
may differ materially from those stated in or implied by these forward-looking statements due to a number of factors, including
those discussed in the sections entitled &ldquo;<FONT STYLE="font-weight: normal">Risk Factors</FONT>&rdquo; starting on page
11, &ldquo;<FONT STYLE="font-weight: normal">Cautionary Statement Regarding Forward-Looking Statements</FONT>&rdquo; starting
on page 4, and elsewhere in this Offering Circular. Please see the notes to our Financial Statements for information about our
Significant Accounting Policies.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history. Therefore, there is limited historical financial information upon which to base an evaluation
of our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently
encountered by companies in their early stages of operations. Our financials as of December 31, 2017, show a net loss of $212,986.
We expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations.
The amount of future losses and when, if ever, we will achieve profitability are uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period September 28, 2017 (&ldquo;Inception&rdquo;) though ended December 31, 2017, we incurred a loss from operations of
$212,986. This is due to stock-based compensation expense and the fair value of services contributed by founders totaling $153,086
and general and administrative expenses of $59,900.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a startup and anticipate that we will incur operating losses for the foreseeable future. As of December 31, 2017, we had cash
of $25,000 and working capital deficit of $34,900.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
activities used no cash for the period from Inception though ended December 31, 2017 as our net loss of $212,986 was offset by
$153,086 in stock based compensation and fair value of services contributed by founders, and a $59,900 increase in accounts payable
and accrued expenses and accrued compensation to related parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
activities provided $25,000 in cash a deposit on a private placement investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no investing activities for the period from Inception though ended December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2018 the Company entered into an unsecured promissory note for $40,000 that accrues interest of 4% annually. The note
is due on the earlier of July 22, 2018 or in the event of default, as defined in the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 12, 2018 the Company entered into an unsecured promissory note for $50,000 that accrues interest of 4% annually. The
note is due on the earlier of August 12, 2018 or in the event of default, as defined in the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 2, 2018 the Company entered into an unsecured promissory note for $10,000 that accrues interest of 4% annually. The note
is due on the earlier of September 2, 2018 or in the event of default, as defined in the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first quarter of 2018, the Company received $262,500 in cash for shares of common stock under a private placement at $2.00
per share. Of this amount $25,000 was received in 2017 as noted above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
accounting policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs consist primarily of non-capitalized development and maintenance costs. We expense these costs
as incurred unless such costs qualify for capitalization under applicable guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation costs under the provisions of ASC 718, &ldquo;Compensation&mdash;Stock Compensation&rdquo;,
which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC 718 is also applied to awards modified, repurchased, or canceled during the periods reported.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation for Non-Employees</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants and options issued to non-employees under ASC 505-50, <I>Equity &ndash; Equity Based Payments to
Non-Employees, </I>using the Black-Scholes option-pricing model. The value of such non-employee awards unvested are re-measured
over the vesting terms at each reporting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not own any real estate. The Company does not currently lease any office space, but intends to sign an office lease
in Loma Linda, California prior to the commencement of this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a009_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OUR
BUSINESS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transplantation
can be a lifesaving treatment option, but the immune system continues to pose the greatest challenge to transplantation becoming
routine medical treatment. This is due to the rejection that occurs when the recipient&rsquo;s immune system recognizes the transplanted
tissue or organ as foreign.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discovery of immunosuppressants (anti-rejection
drugs), such as cyclosporine, has allowed survival of transplanted organs by preventing acute or early rejection.&nbsp;&nbsp;However,
immunosuppressants fail to prevent the chronic or long-term rejection that occurs years after the initial transplant. About 40%
of transplanted organs survive for no more than 5 years.&nbsp;&nbsp;Furthermore, immune suppression leads to significant undesirable
side effects such as increased susceptibility to life-threatening infections and cancers because it is not specifically targeted
towards the transplanted organs; rather, it indiscriminately and broadly suppresses immune function throughout the body.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New,
focused therapeutic approaches are needed that modulate only the small portion of immune cells that are involved in rejection
of the transplanted organ, as this will be safer for patients than indiscriminate immune suppression.&nbsp;&nbsp;These approaches
are referred to as immune tolerance.&nbsp;&nbsp;Therapeutically induced immune tolerance may not only be safer for patients, they
could also allow long-term survival of transplanted tissues and organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the late 1990s, academic research was being conducted at the Transplant Center in Loma Linda University, for a project that secured
initial funding through grants from the Department of Defense (DOD), which was funding projects with high probabilities of commercialization
and potential benefit to the DOD.&nbsp;&nbsp;The direct benefit in this case was for skin grafting for burn victims.&nbsp; Fifteen
years of research led to a series of discoveries that translated to a large patent portfolio that may be applied to the modulation
of the immune system to induce tolerance to self and transplanted organs - tolerogenic immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an exclusive worldwide license for commercializing this nucleic acid-based technology called Apoptotic DNA Immunotherapy
(ADi) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues. ADi is a technology
platform which we believe can be engineered for application to a wide variety of indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to develop ADi products for organ transplantation, skin grafting, and wound healing with the initial focus being on skin
allografts and other organ and/or tissue allografts, as we believe these indications will be most efficient in providing safety
and efficacy data in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
immune suppression requires continuous administration to prevent acute or early rejection of transplanted organs, induction of
tolerance has the potential to retrain the immune system to accept the organ for longer periods of time.&nbsp;&nbsp;Thus, ADi
may allow patients to live with transplanted organs with significantly reduced immune suppression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADi
Advantages</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi
is a nucleic acid-based technology (<I>e.g.</I>, plasmid DNA-based) which we believe selectively suppresses only those immune
cells involved in the rejection of tissue and organ transplants. It does so by tapping into the body&rsquo;s natural process of
cell death (apoptosis) to reprogram the immune system to stop unwanted attacks on self or transplanted tissues. In short, it retrains
the immune system to become accepting of the organ much like how natural apoptosis reminds our immune system to be tolerant to
our own &ldquo;self&rdquo; tissues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
efforts have been made by various groups to promote tolerance through cell therapies and ex vivo manipulation of patient cells
(takes place outside the body typically requiring hospitalization), to our knowledge, we will be unique in our approach of using
in-body induction of apoptosis to promote tolerance to specific tissues.&nbsp;&nbsp;In addition, ADi treatment itself does not
require hospitalization, only an injection in minute amounts directly into the skin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Reduce
Chronic Rejection</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
immunosuppressants control acute rejection during the early time-period after receiving an organ, chronic rejection of the organ
that occurs one or more years after the transplant procedure continues to pose a major challenge for organ recipients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
rejection has been likened to autoimmunity (a misdirected immune response that occurs when the immune system goes awry), where
specific tissues in the transplanted organ are attacked by the immune system.&nbsp;&nbsp;In other words, chronic rejection may
not be caused just by differences between the donor and the recipient, but rather by an immune response by the recipient to specific
tissues in the organ.&nbsp;&nbsp;With ADi&rsquo;s ability to tolerize to specific tissues in a transplanted organ, it has the
potential to reduce incidences of chronic rejection.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
preclinical studies have demonstrated that ADi treatment significantly and substantially prolongs graft survival, in addition
to successfully &ldquo;reversing&rdquo; other established immune-mediated inflammatory processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Reduce
immune suppression</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
in animal models have shown that conditioning/desensitizing the animals to receive the transplant, prolongs the survival of the
transplanted tissue or organ.&nbsp;&nbsp;These studies have used repeated exposure to low doses of protein components in specific
organs to reduce immunologic recognition and attack on the transplanted organ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on some of our data, we believe that with ADi treatment, recipients can be conditioned/desensitized ahead of transplantation,
thereby retraining the immune system to more readily accept the organ and also reduce the levels of immunosuppressive drugs needed
post-transplantation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Hypersensitivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
have shown that hypersensitivity increases the rate of organ rejection. Hypersensitivity can occur in previously-transplanted
patients, patients who have given birth, and patients who have previously received blood transfusions. With more than 116,000
patients on transplant waiting lists in the U.S. alone, hypersensitive patients have much lower chances at qualifying to receive
organs due to their increased risk of rejection &ndash; even with immune suppression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.55pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sadly,
transplanted patients have a probability of needing re-transplantation at some point due to eventual chronic rejection of their
transplanted organ, with the possible exception of some newborn recipients. With increased incidence of hypersensitivity, these
patients may never have the opportunity to receive another organ. Based on experimental data, we believe that ADi may have the
potential to address this hypersensitivity issue providing these individuals better opportunities at receiving an organ transplantation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.55pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADi
Key Differentiators</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Ease
of Delivery</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic
products are typically administered systemically (i.e., by mouth in pill form or injected intramuscularly/intravenously). This
requires repeated large doses to allow sufficient concentrations to reach the affected sites. ADi is a DNA-based product that
can be injected in minute amounts directly into the skin where the target cells of the immune system reside, thereby significantly
simplifying the delivery of the product and reducing the amount of product needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Better
Safety Profile</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA-based
products are generally considered safe. In fact, over the last twenty years, several DNA vaccines have been evaluated in clinical
trials for cancer and infectious diseases and no severe adverse events have been reported.&nbsp;&nbsp;In addition, DNA-based products
generally do not result in allergic responses, which lend themselves to repeat dosing as may be required by ADi products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Cost
of Goods Advantage</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi
products are DNA-based and easy to manufacture at a low cost. Furthermore, DNA-based products are very stable and do not require
adherence to cold chain (temperature-controlled) protocols for shipping. This also makes the product ideal for global distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Simplified
Therapy Delivery System</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tolerance
induction using ADi does not require hospitalization because it can be simply injected into the skin. This approach reduces treatment
costs and complexities in treatment delivery.&nbsp;&nbsp;The anticipated administration of ADi will include an initial priming
regimen that will require injections administered once a week for several weeks.&nbsp;&nbsp;Thereafter, booster or maintenance
doses will be provided on an individual basis as determined by immune and inflammation testing.&nbsp;&nbsp;ADi treatments will
be significantly more convenient and comfortable for patients because they do not require removal of patient cells for ex vivo
manipulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADi
Technology Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi
utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues.&nbsp;&nbsp;It is a technology
platform which we believe can be engineered for application to a wide variety of indications. ADi includes two DNA molecules which
are designed to deliver signals to induce tolerance.&nbsp;The first DNA molecule encodes a pro-apoptotic protein, which induces
&lsquo;programmed&rsquo; cell death.&nbsp;&nbsp;This is a core component of the technology because it is intended to greatly increase
the recruitment of dendritic cells which are implicated in regulating the immune system.&nbsp;&nbsp;The second DNA molecule encodes
the protein of interest (guiding antigen), which is modified to promote a path of tolerance.&nbsp;&nbsp;The guiding antigen is
intended to result in tolerance induction specific to the tissue where the protein is found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img002_v1.jpg" ALT="(GRAPHIC)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi
has been successfully tested in several preclinical models and its efficacy can be attributed to multiple factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi does not rely
    on a single mechanistic approach.&nbsp;&nbsp;It has multiple components that affect different arms of the immune system &ndash;
    antigen-specific, apoptotic, plasmid DNA which can be manipulated.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi activates key
    immune cells known to maintain tolerance in test animals and humans.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi has been successfully
    applied to a stringent transplantation model.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi is designed
    to be safely and can be repeatedly administered to achieve its full potential therapeutic effect, thereby increasing its potency.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proof
of Concept: Skin Grafting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Results
shown are 5 weeks post-transplantation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proof of concept experiment performed was a skin allograft transplantation procedure in which the donor skin was obtained from
white BALB/c mice and transplanted to black C57BL/6 mice.&nbsp;&nbsp;The experiment was designed to address a more challenging
scenario where the donor tissue was obtained from a donor which is genetically mismatched with the recipient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><IMG SRC="img003_v1.jpg" ALT="(GRAPHIC)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><IMG SRC="img004_v1.jpg" ALT="(GRAPHIC)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with Loma Linda University</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with Sekris Biomedical, Inc. (&ldquo;Sekris&rdquo;).
Sekris was a party to a License Agreement with Loma Linda University (&ldquo;LLU&rdquo;), entered into and made effective on May
25, 2011, and amended on June 24, 2011, July 16, 2012 and December 27, 2012 (the &ldquo;Original Agreement,&rdquo; and together
with the Assignment Agreement, the &ldquo;Sekris Agreements&rdquo;). Pursuant to the Assignment Agreement, Sekris transferred
and assigned all of its rights and obligations in and to and liabilities under the Original Agreement, of whatever kind or nature,
to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 1,000,000 shares of our Common Stock (the
&ldquo;Sekris Warrant&rdquo;). The warrant is immediately exercisable and the exercise price is $2.00 per share. The expiration
date of the warrant is March 8, 2023. On March 15, 2018, we entered into a Patent &amp; Technology License Agreement directly
with LLU (the &ldquo;New License Agreement&rdquo;), which amends and restates the Sekris Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the New License Agreement, we obtained the <FONT STYLE="color: #1A1A1A">exclusive royalty-bearing worldwide license in and
to all intellectual property, including patents, technical information, trade secrets, proprietary rights, technology, know-how,
data, formulas, drawings, and specifications, owned or controlled by LLU (the &ldquo;LLU Patent and Technology Rights&rdquo;)
and/or any of its affiliates and related to therapy for immune-mediated inflammatory diseases (the ADi technology). </FONT>We
refer you to the section titled &ldquo;<I>Our Business&mdash;Intellectual Property&mdash;Patent Rights</I>&rdquo; for a summary
of the patents and patent applications that we licensed from LLU pursuant to the New License Agreement. In consideration for the
New License Agreement, we issued 50,000 shares of Common Stock to LLU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the New License Agreement, we are required to pay an annual license fee to LLU. Additionally, upon completion of this Offering,
we will be required to pay $200,000 to LLU as a milestone payment&nbsp;within thirty (30) days of July 31, 2018. We are also required
to pay to LLU milestone payments in connection with certain development milestones. Additionally, as consideration for prior expenses
incurred by LLU to prosecute, maintain and defend <FONT STYLE="color: #1A1A1A">the LLU Patent and Technology Rights, we are obligated
to make</FONT> the following payments to LLU: $70,000 due at the end of September 2018, $70,000 due at the end of December 2018,
and a final payment of $60,000 due at the end of March 2019. We are required to defend the LLU Patent and Technology Rights during
the term of the New License Agreement. Additionally, we will owe low single-digit royalty payments on any Licensed Products (defined
as any finished pharmaceutical product which utilizes the <FONT STYLE="color: #1A1A1A">LLU Patent and Technology Rights </FONT>in
its development, manufacture or supply). We also are required to produce a written progress report to LLU, discussing our development
and commercialization efforts, within 45 days following the end of each year. <FONT STYLE="color: #1F1F1F">All intellectual property
rights in and to LLU Patent and Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New License Agreement shall terminate on the last day that a patent granted in to us by LLU is valid and enforceable or the day
that the last patent application licensed to us is abandoned. The New License Agreement may be terminated by mutual agreement
or by us upon 90 days written notice to LLU. LLU may terminate the New License Agreement in the event of (i) non-payments or late
payments of royalty, milestone and license maintenance fees not cured within 90 days, (ii) a breach of any non-payment provision
(including the provision that requires us to meet certain deadlines for milestone events (each, a &ldquo;Milestone Deadline&rdquo;))
not cured within 90 days and (iii) three or more actual breaches of the New License Agreement by us in any 12-month period. The
next such Milestone Deadline is the requirement to complete a financing round by July 31, 2018. Additional Milestone Deadlines
include: (i) the requirement to have regulatory approval of an IND application to initiate a first-in-human clinical trials on
or before March 31, 2020, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2022, (iii) the completion
of Phase III clinical trials by March 31, 2024 and (iv) biologic licensing approval by the FDA by March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are successful in raising the maximum offering amount of $10 million, we believe that the Company will have sufficient cash
resources to fund its plan of operations for the next 36 months. The first 18 months will be focused on IND-enabling Preclinical
Development and the next 18 months will be focused on Phase I/II Clinical Trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alternatively,
if we raise the minimum offering amount of $7.32 million, we believe that the Company will only have sufficient cash resources
to fund its plan of operations for the next 18 months. This period will be focused on IND-enabling Preclinical Development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Months
1 to 18: IND-Enabling Preclinical Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-level
Objectives:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP manufacturing
    of clinical grade material for clinical trials</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety/Toxicology
    (TOX) studies by an independent GLP facility in preparation for clinical trials</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigational
    New Drug (IND) submission to the Food and Drug Administration (FDA) and/or other applicable regulatory agencies in the U.S.
    and abroad to initiate First-In-Human(&ldquo;FIH&rdquo;) Phase I/II clinical trials</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the first 12 months, our focus will be on preclinical studies in skin allografts and other organ and/or tissue allografts in preparation
for selection of lead product candidate(s) and completion of IND-enabling studies required to initiate clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the initiation of the studies, we will be optimizing the dose formulation and administration intervals of our product candidate(s)
to determine the most effective ratio of the plasmid DNA components and optimum administration regimen before, during, and after
transplantation procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
studies will be conducted using the appropriate large animal model (<I>e.g.</I> pig) that is commonly utilized for testing of
new drugs and protocols for skin allografts. The product candidate(s) will be produced in clinical grade under GMP conditions
and subjected to IND-directed safety/toxicology studies to prepare a dossier for submission of an IND application to the Food
and Drug Administration (FDA) and/or other applicable regulatory agencies in the U.S. and abroad. In parallel, additional preclinical
studies will be conducted to obtain new proof-of-concept and proof-of-mechanism data in other organ and/or tissue transplantation
models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Months
19 to 36: Phase I/II Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-level
Objectives:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose optimization
    to determine optimum dose/ratio of product candidate in human patients requiring skin and other organ and/or tissue allografts
    </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Phase I/II
    FIH Study to demonstrate safety and clinical proof-of-concept in patients requiring skin allografts</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
FIH clinical studies will combine Phase I (designed to test clinical safety) and Phase II (designed to obtain proof of effectiveness
in human patients), in patients requiring skin and other organ and/or tissue allografts. We have selected this indication for
several reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing preclinical
    data has shown effectiveness of ADi in prolonging skin allografts;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The relative ease
    of visualization of the graft without the need for biopsies; and</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The need for therapies
    that allow reduction of levels of immune suppression that are currently used for skin allografts to prevent rejection of skin,
    which is highly antigenic.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have already identified a clinical trial center with adequate patients, which will simplify and reduce the time required for patient
recruitment. Upon approval by the FDA and/or the applicable regulatory agency, and once the exact protocol has been determined
in the preclinical studies, clinical trials will be initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Drug
Approval Process </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="img005_v1.jpg" ALT="(GRAPHIC)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Food
and Drug Administration (&ldquo;FDA&rdquo;) approval is required before any new drugs can be introduced to the market.&nbsp;&nbsp;We
are currently in the drug discovery phase.&nbsp;&nbsp;While selecting the product candidate for our first-in-human studies, we
will be preparing to initiate GMP (Good Manufacturing Process). As of the date of this Offering Statement, we have not submitted
any application to the FDA for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently working with a contract manufacturer who has the know-how, product ingredients including plasmid DNA molecules,
and our patent-pending bacterial strain.&nbsp;&nbsp;Several batch runs have been successfully completed to demonstrate our ability
to produce the plasmid DNA components of what would be our final product candidates in a GMP facility and based on validation
studies, we are reasonably confident in our ability to produce clinical grade product candidates at larger scales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the product has been produced in clinical grade, it must be subjected to safety/toxicology studies by an independent GLP (Good
Laboratory Practice) laboratory to demonstrate its suitability for clinical testing in human patients.&nbsp;&nbsp;Upon completion
of manufacturing and safety/toxicology testing, an Investigation New Drug (IND) application will be prepared for submission to
the regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
receipt of approval to initiate clinical testing, the ADi product can be tested in human patients.&nbsp;&nbsp;Our product will
be tested in patients who require skin allograft/VCA in a transplant setting. Therefore, our first-in-human studies will be a
combined Phase I/Phase II study in which safety and efficacy data will be obtained.&nbsp;&nbsp;We plan to start with patients
with superficial grafts in order to provide an opportunity to evaluate safety, as well as monitor the survival of the graft more
easily than internal solid organs.&nbsp;&nbsp;In parallel, we will continue to develop additional product formulations for other
indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Target
market </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S. alone, there are over 30,000 patients who receive organ transplantations each year, with more than 116,000 on transplant
waiting lists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
field of organ transplantation has been made possible and continues to rely on broad-acting immunosuppressive drugs, high levels
of which can result in a compromised immune system that renders organ recipients susceptible to cancer and potentially life-threatening
infections including re-activation of latent viruses.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, immunosuppressants control acute rejection during the early time-period after receiving an organ but chronic rejection
of the organ remains an unmet challenge for surgeons and transplant recipients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
efforts have been made by various groups to promote tolerance through cell therapies and ex vivo manipulation of patient cells,
these procedures take place outside the body and typically require hospitalization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
transplanted patients will need re-transplantation at some point, with the possible exception of some newborn recipients.&nbsp;&nbsp;With
increased incidence of hypersensitivity, these patients may never have the opportunity to receive another organ.&nbsp;&nbsp;Hypersensitivity
can occur in previously-transplanted patients, patients who have given birth, and patients who have previously received blood
transfusions.&nbsp;&nbsp;These patients have much lower chances at qualifying to receive organs due to their increased risk of
rejection &ndash; even with immune suppression.&nbsp;&nbsp;The potential to reduce hypersensitivity in these patients will provide
better opportunities for them to receive their first, second, third, or even fourth organ replacements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are gaps between current approaches and what the market needs.&nbsp;&nbsp;ADi addresses these gaps.&nbsp;&nbsp;ADi is easy to
administer (does not require <I>ex-vivo </I>treatment of patient cells), it does not suppress the immune system, it may allow
patients to live with transplanted organs with significantly reduced immune suppression, provides for long-term survival of transplanted
tissues and organs, may be more effective because it does not rely on a single immune pathway/mechanism, and potentially provides
hypersensitive patients better chances at qualifying to receive organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operational
Advantages </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Management</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
team of experts come from a variety of different scientific fields and commercial backgrounds, with a collective experience that
range from founding startup biotech companies, to developing and marketing biopharmaceutical products, to designing clinical trials,
and management of private and public companies.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Location</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to sign a lease in Southern California prior to the commencement of this Offering. Assuming we do, we will then be located
to nearby resources including Loma Linda University.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Strategic
Partners</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
plan is to work with strategic partners to leverage common resources to accomplish milestones over the next 3 years. We hope that
this strategy will reduce costs by obviating the need to duplicate resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property (IP)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our
business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.
Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States
and in jurisdictions outside of the United States directed to our proprietary technology, inventions, improvements and product
candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how
relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop,
strengthen and maintain our proprietary position in the field of immuno-oncology. We also plan to rely on data exclusivity, market
exclusivity, and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and
maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality
of our trade secrets; to obtain and maintain licenses to use intellectual property owned by third parties; to defend and enforce
our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and
enforceable patents and other proprietary rights of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ADi technology and its various components are protected by multiple families of patents and patent applications, including several
U.S. and non-U.S. issued patents. As of March 27, 2018, our patent portfolio licensed from LLU includes six U.S. patents, three
U.S. pending patent applications, fifty-seven foreign patents, and twelve foreign pending patent applications directed to ADi
and related technologies. We also possess and/or in-license substantial know-how and trade secrets relating to the development
and commercialization of our product candidates, including related manufacturing processes and technology. We plan to continue
expanding and strengthening our IP portfolio with additional patent applications in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2017 the Company issued 7,100,000 shares of its common stock, including: (a) 3,500,000 shares to Sekris, (b) 1,000,000
shares to Dr. Shahrokh Shabahang, our co-founder and Chief Technology Officer (c) 1,000,000 shares to Dr. Leonard Bailey, the
Chairman of our Board of Directors and (d) 800,000 shares to Amro Albanna, our co-founder and Chief Executive Officer. Dr. Shabahang
is the Chief Executive Officer of Sekris, and is deemed to have beneficial ownership of the shares held by Sekris.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we issued the Sekris Warrant to Sekris. The exercise price of the Sekris Warrant is subject to adjustment in the
event of stock splits, stock dividends or similar events. Beginning in January 2018, we issued an aggregate principal amount of
$100,000 of unsecured promissory notes to Sekris, which accrue interest at 4% and are due and payable six months from their respective
issuance dates or immediately upon an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2018 and March 23, 2018,
we entered into private placement transactions with accredited investors pursuant to which we sold 125,000 shares and 6,250 shares
of Common Stock, respectively, and warrants to purchase, in the aggregate, 131,250 shares of Common Stock for aggregate gross
proceeds of $262,500 (warrants to purchase 125,000 shares of Common Stock were issued on March 17, 2018 and warrants to purchase
6,250 shares of Common Stock were issued on March 23, 2018). All such warrants have an exercise price of $2.00 and expire three
years from their respective date of issuance (the &ldquo;Private Placement Warrants&rdquo;). Such securities were issued in reliance
on an exemption from such registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and/or Rule 506 of Regulation D promulgated thereunder.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2017, we granted stock options to Rod Turner, an advisor, to purchase 60,000 shares of Common Stock at an exercise
price of $2.00 per share, with a five year expiration date. Mr. Turner&rsquo;s service was terminated in January 2018, and only
20,000 shares of Common Stock underlying such option vested. Such options were issued under our 2017 Equity Incentive Plan (our
&ldquo;2017 Plan&rdquo;). On November 1, 2017, we granted stock options to Gordon Winston, an advisor&nbsp;and David Briones,
our interim chief financial officer, to purchase an aggregate of 180,000 shares of Common Stock at an exercise price of $2.00
per share. Such options vest monthly over the term of one year and have a five year expiration date. Such options were issued
under our 2017 Plan. On February 9, 2018, we granted stock options to Rowena Albanna, a contractor, to purchase 100,000 shares
of Common Stock at an exercise price of $2.00 per share. Such options were fully vested and immediately exercisable as of the
grant date. On March 6, 2018, we granted stock options to David Alleva, an advisor, to purchase 300,000 shares of Common Stock
at an exercise price of $2.00 per share. Such options vest one-third on each of September 30, 2018, September 30, 2019 and September
30, 2020 and have a five year expiration date. Additionally, on March 6, 2018, we granted stock options to Amro Albanna, our CEO&nbsp;and
Adrian Luchian, an advisor, to purchase an aggregate of 435,000 shares of Common Stock at an exercise price of $2.00 per share.
Such options were fully vested and immediately exercisable as of the grant date and have a five year expiration date. All such
options were issued under our 2017 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2018, we issued warrants to purchase up to 420,000 shares of Common Stock to two (2) consultants of the Company. These warrants
are subject to vesting requirements that begin in 2019.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2018, we entered into private placement
transactions with accredited investors pursuant to which we sold (i) promissory notes which have principal amounts, in the aggregate
of $145,600, and (ii) warrants to purchase, in the aggregate, 18,667 shares of Common Stock (the &ldquo;July Private Placement
Warrants&rdquo;) for aggregate gross proceeds to the Company of $112,000. All such warrants have an exercise price of $6.00 per
share and expire three (3) years from their respective date of issuance. Such securities were issued in reliance on an exemption
from such registration pursuant to Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have one (1) full-time employee and one (1) part-time employee. We engage consultants on an as needed basis from time to time.
Currently, we have engaged nine (9) consultants. We believe our relations with employees to be good.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a010_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DIRECTORS,
EXECUTIVE OFFICERS &amp; CORPORATE GOVERNANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 16%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 27%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 5%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    of Office</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 29%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
    hours per week</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>for part-time employees</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive Officers:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    2017</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shahrokh
    Shabahang</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technology
    Officer and Director</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    2017</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
    hours</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Briones</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard L. Bailey</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no arrangement or understanding between the persons described above and any other person pursuant to which the person was selected
to his or her office or position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers, Directors and Significant Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amro
Albanna&nbsp;&ndash; <I>President, Chief Executive Officer, and Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Albanna has been our President, Chief Executive Officer and a Director since our inception. In 2008, Mr. Albanna co-founded the
Innovation Economy Initiative, a public-private initiative to encourage the development of innovation-focused businesses in the
Riverside, CA area. The initiative led to the creation of Innovation Economy Corporation (&ldquo;IEC&rdquo;), formed to license
or acquire untapped innovations and create a group of life and health subsidiaries diversified across various business development
stages and product, service and technology markets. From 2010 until May 2017, Mr. Albanna was Chief Executive Officer and a Director
of IEC. During that same time, he was the Chief Executive Officer and Director of Olfactor Laboratories, Inc., a majority-owned
subsidiary of IEC. From 2010 to August 2016, he was the Chief Executive Officer and a Director of Nano Engineered Applications,
Inc., a majority-owned subsidiary of IEC. In 2003, Mr. Albanna founded Qmotions, Inc. (subsequently renamed Deal A Day Group Corp.).
He served as its Chief Executive Officer and a Director until 2011. Qmotions designed and developed a new generation of video
game controllers that incorporated body motion. In 1997, he founded Timely Technology Corporation (&ldquo;TTC&rdquo;), which designed
and developed internet-based software systems for organizations and industries seeking to transact online. In 2002, TTC was acquired
by Digital Angel Corporation. Mr. Albanna graduated from California State University San Bernardino in 1991 with a B.S. in Business
Administration and Computer Information Systems. The Board believes that Mr. Albanna&rsquo;s broad expertise leading technology
companies across various sectors, leading private and public financing, and in positioning companies for mergers and acquisitions,
qualifies him to serve as a director of our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shahrokh
Shabahang &ndash; <I>Chief Technology Officer, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Shabahang<I>&nbsp;</I>has been our Chief Technology Officer and Director since our inception. In 2009, Dr. Shabahang co-founded
Sekris Biomedical Inc. to incubate technologies for immune modulation. He serves as its Chief Executive Officer and is also a
member of its board of directors. In 2005, Dr. Shabahang co-founded Genelux Corporation. In his capacity as Board Secretary and
Director of Clinical Operations, he helped the company raise substantial capital and to obtain regulatory approval to initiate
First-In-Human clinical studies in Europe with patients who had not responded to chemotherapy to fight cancer. Dr. Shabahang attended
the University of California Santa Barbara from 1982 to 1984 and later received his DDS in Dentistry from the University of Pacific
in 1987 and his MS and PhD from Loma Linda University (&ldquo;LLU&rdquo;) in 1997 and 2001, respectively. Following completion
of his PhD in Microbiology and Molecular Genetics at LLU, Dr. Shabahang established a laboratory at LLU to focus his academic
research on infectious diseases and the host immune responses during disease progression. Between 2001 to 2005, Dr. Shabahang
divided his academic research time between basic research in microbiology/immunology and applied research for development of novel
therapeutics. He has also been practicing as an endodontist since 2010. The Board believes that Dr. Shabahang&rsquo;s experience
leading biotech startups and his expertise in immunology and immune tolerance qualifies him to serve as a director of our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
Briones &ndash; <I>Interim Chief Financial Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Briones has been
our interim Chief Financial Officer since January 2018. Mr. Briones is the founder and managing member of Brio Financial Group
since its inception in October 2010, with over nineteen years of public accounting and executive level experience. He consults
with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting.
Mr. Briones has also been the Chief Financial Officer for Petro River Oil Corp., an independent energy company focused on the
exploration and development of conventional oil and gas assets, since August 2013. From October 2017 to May 2018 Mr. Briones was
the Chief Financial Officer of Bitzumi, Inc., a Bitcoin exchange and marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leonard
L. Bailey &ndash; <I>Director </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Bailey<I>&nbsp;</I>has served as a Director since our inception. Since 2005, Dr. Bailey has been a Distinguished Professor at
Loma Linda University (Surgery and Pediatrics). In 1978, Dr. Bailey was appointed the Director of the Cardiothoracic Surgical
Research Laboratory at Loma Linda University Medical Center and, in 2007 was appointed the Surgeon-in-Chief of Loma Linda University
Children&rsquo;s Hospital. He has also served on the board of directors of Sekris Biomedical Inc. since 2011. Dr. Bailey received
his medical degree from Loma Linda University School of Medicine in 1969. Dr. Bailey has performed over 200 experimental transplantations
in infant research animals at Loma Linda University School of Medicine to determine the feasibility of transplantation in the
very young before his first human transplantation in October 1984 when he transplanted a baboon heart into an infant known as
Baby Fae. This pioneering work led to the first successful human to human heart transplantation in a newborn baby performed in
November 1985. Dr. Bailey is an internationally recognized authority on congenital cardiac surgery and infant heart transplantation.
He has also lectured and operated throughout the world, and is a thought leader in the field of organ transplantation. The Board
believes that Dr. Bailey&rsquo;s pioneering work in infant heart transplantation along with his entire body of work qualifies
him to serve as a director of our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Leadership Structure and Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board oversees our business and considers the risks associated with our business strategy and decisions. The Board currently implements
its risk oversight function as a whole. Each of the Board committees, when established, will also provide risk oversight in respect
of its areas of concentration and reports material risks to the Board for further consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
of Office</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
hold office until his or her successor is elected and qualified. Directors are appointed to serve for one year until the meeting
of the Board following the annual meeting of stockholders and until their successors have been elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use the definition of &ldquo;<I>independence</I>&rdquo; of The NASDAQ Stock Market to make this determination. NASDAQ Listing
Rule 5605(a)(2) provides that an &ldquo;<I>independent director</I>&rdquo; is a person other than an officer or employee of the
company or any other individual having a relationship which, in the opinion of the Company&rsquo;s Board, would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that
a director cannot be considered independent if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director is,
    or at any time during the past three years was, an employee of the company;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director or
    a family member of the director accepted any compensation from the company in excess of $120,000 during any period of twelve
    consecutive months within the three years preceding the independence determination (subject to certain exemptions, including,
    among other things, compensation for board or board committee service);</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director or
    a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which
    the company made, or from which the company received, payments in the current or any of the past three fiscal years that exceed
    5% of the recipient&rsquo;s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain
    exemptions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director or
    a family member of the director is employed as an executive officer of an entity where, at any time during the past three
    years, any of the executive officers of the company served on the compensation committee of such other entity; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director or
    a family member of the director is a current partner of the company&rsquo;s outside auditor, or at any time during the past
    three years was a partner or employee of the company&rsquo;s outside auditor, and who worked on the company&rsquo;s audit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
such definitions, we believe that we have one independent director, Mr. Bailey. However, our Common Stock is not currently quoted
or listed on any national exchange or interdealer quotation system with a requirement that a majority of our Board be independent
and, therefore, the Company is not subject to any director independence requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Delaware General Corporation Law and the Company&rsquo;s Amended and Restated Certificate of Incorporation,
the Company will indemnify, hold harmless and provide advancement of expenses, to the fullest extent permitted by applicable law,
directors, officers, employees, and agents that are made a party or threatened to be made a party to legal proceedings by reason
of the fact that such parties were working at the request of the Company. For more information see the section of this Offering
Statement titled &ldquo;<I>Risk Factors</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers
or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of
1933, as amended, and is therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Shabahang, our co-founder and CTO, is the Chief Executive Officer of Sekris, and is deemed to have beneficial ownership of the
shares held by Sekris.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Involvement
in Certain Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, none of our current directors or executive officers has, during the past ten years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been convicted in a criminal proceeding or been
    subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">had any bankruptcy
    petition filed by or against the business or property of the person, or of any partnership, corporation or business association
    of which he or she was a general partner or executive officer, either at the time of the bankruptcy filing or within two years
    prior to that time;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been subject to
    any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or
    federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement
    in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities,
    or to be associated with persons engaged in any such activity;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been found by a
    court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated
    a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject
    of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed,
    suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged
    violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial
    institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement
    or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or
    any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject
    of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
    (as defined in Section 3(a)(26) of the Securities Exchange Act of 1934, as amended (the Exchange Act)), any registered entity
    (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization
    that has disciplinary authority over its members or persons associated with a member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above and in our discussion below in &ldquo;<FONT STYLE="font-weight: normal"><I>Certain Relationships and Related
Transactions</I></FONT>,&rdquo; none of our directors or executive officers has been involved in any transactions with us or any
of our directors, executive officers, affiliates or associates which are required to be disclosed pursuant to the rules and regulations
of the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently a party to any legal proceedings, the adverse outcome of which, individually or in the aggregate, we believe
will have a material adverse effect on our business, financial condition or operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, our CEO, Mr. Amro Albanna, is a party to a litigation matter unrelated to the Company or any of its properties.
Such litigation, relates to Innovation Economy Corporation (IEC), a company in which Mr. Albanna served as the CEO and a Director
from 2010 until 2017, and its wholly-owned subsidiary (Innovation Economy Corporation d/b/a ieCrowd v. Kim, et. al, Superior Court,
Los Angeles County). The litigation was originally commenced by IEC and its subsidiary after Mr. Albanna was no longer affiliated
with IEC, against certain third party defendants based upon claims related to their misconduct and mismanagement. Such defendants
subsequently brought a countersuit against IEC and its subsidiary, in which they named Mr. Albanna and others as defendants, alleging
that they were misled to invest in IEC and its subsidiary based upon misrepresentations by, among others, Mr. Albanna. The cases
have now been consolidated. Mr. Albanna believes that the counteraction commenced by the third parties against him is without
merit and intends to vigorously defend himself in this action.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
Consulting Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 1, 2018, we entered into a Consulting Agreement for project management services with Canyon Ridge Development LLC d/b/a
Mission Critical Solutions International (&ldquo;Mission Critical&rdquo;). Pursuant to the agreement, and in consideration of
advisory and consulting services rendered by Mission Critical, we have agreed to pay Mission Critical a monthly fee of $13,000.
The term of the agreement expires on May 31, 2018. A copy of the agreement is attached as an exhibit to this Offering Statement.
The Company subsequently entered into a new Consulting Agreement with Mission Critical on substantially the same terms as the
previous agreement (the &ldquo;New Consulting Agreement&rdquo;). The New Consulting Agreement became effective as of June 1, 2018
and expires on August 31, 2018.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 1, 2018, we entered into
a Consulting Agreement with ICR, LLC (&ldquo;ICR&rdquo;) for integrated communication and marketing services. Pursuant to the
agreement, and in consideration for services rendered to the Company, we have agreed to pay ICR&nbsp;$40,000 (payable in three
monthly installments) for up to three months of services prior to our listing on NASDAQ. If we do not list on NASDAQ before July
24, 2018, the agreement will automatically terminate and the Company will not be obligated to pay the third installment payment.
Upon listing on NASDAQ we have agreed to pay ICR a monthly fee of $16,000 per month. A copy of the agreement is attached as an
exhibit to this Offering Statement.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a011_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents information regarding the total compensation for the executive officers of the Company as of December
31, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name and
    Principal Position</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
    </B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
    </B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    </B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro
    Albanna, Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,000</FONT></TD>
    <TD STYLE="width: 1%"></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">800</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,800</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Briones</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,484</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,484</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0">$800 represents 800,000 founder shares issued to Amro Albanna.</P>


</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0">$36,484 represents the option expense for 20,000 vested options as of
                                    December 31, 2017. A total of 120,000 options were granted on 11/1/2017 with a vesting period
                                    of 12 months, an exercise price of $2.00, expiration date of 11/1/2022, and 100,000 unvested
                                    options as of December 31, 2017.</P>


</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not compensated our directors for their services in such positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have employment agreements with any of our officers or employees but intend to enter into employment agreements
prior to the commencement of this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a012_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>INterest
of Management and others in CERTAIN TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
with Related Persons</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below and except for employment arrangements which are described under &ldquo;executive compensation,&rdquo; since
Inception, there has not been, nor is there currently proposed, any transaction in which we are or were a participant, the amount
involved exceeds the lesser of $120,000 or 1% of the total assets at September 30, 2017, and any of our directors, executive officers,
holders of more than 5% of our common stock or any immediate family member of any of the foregoing had or will have a direct or
indirect material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with (&ldquo;Sekris&rdquo;). See
&ldquo;Summary&mdash;Overview&mdash;License Agreement with Loma Linda University.&rdquo; Dr. Shabahang is the Chief Executive
Officer or Sekris, and is deemed to have beneficial ownership of the shares held by Sekris. On March 8, 2018, we issued the Sekris
Warrant to Sekris. On March 2, 2018, we issued a 4% unsecured promissory note to Sekris in the principal amount of $10,000. Principal
and interest is due on September 2, 2018 or immediately upon an event of default. On February 12 2018, we issued a 4% unsecured
promissory note to Sekris in the principal amount of $50,000. Principal and interest is due on August 12, 2018 or immediately
upon an event of default. On January 22, 2018, we issued a 4% unsecured promissory note to Sekris in the principal amount of $40,000.
Principal and interest is due on July 22, 2018 or immediately upon an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2017 the Company issued 7,100,000 shares of its common stock to its founders, including: (a) 3,500,000 shares to Sekris,
(b) 1,000,000 shares to Dr. Shabahang, our co-founder and Chief Technology Officer (c) 1,000,000 shares to Dr. Leonard Bailey,
the Chairman of our Board of Directors and (d) 800,000 shares to Amro Albanna, our co-founder and Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Review,
Approval and Ratification of Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or
ratification of transactions, such as those described above, with our executive officer(s), Director(s) and significant stockholders.
We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional
Directors, so that such transactions will be subject to the review, approval or ratification of our Board of Directors, or an
appropriate committee thereof. On a moving forward basis, our Directors will continue to approve any related party transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a013_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITY
OWNERSHIP OF MANAGEMENT &amp; CERTAIN SECURITYHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth certain information regarding beneficial ownership of our Common Stock as of the date of this Offering Circular by
(i) each person (or group of affiliated persons) who is known by us to own more than five percent (10%) of the outstanding shares
of our Common Stock, (ii) each director and executive officer, and (iii) all of our directors, executive officers and director
nominees as a group. As of the date of this Offering Circular, there were 7,284,250 shares of our Common Stock issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common
stock owned by them, except to the extent that power may be shared with a spouse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities.
For purposes of this table, a person or group of persons is deemed to have &ldquo;beneficial ownership&rdquo; of any shares of
common stock that such person currently owns or has the right to acquire within 60 days of the date of this Memorandum.&nbsp;With
respect to options and warrants, this would include options and warrants that are currently exercisable or exercisable within
60 days. With respect to convertible securities this would include convertible securities that are currently convertible or conversable
within 60 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Memorandum, none of the beneficial owners included in the table below hold any options or warrants that are
currently exercisable or exercisable within 60 days or convertible securities that are currently convertible or convertible within
60 days.&nbsp;&nbsp;Except as indicated in footnotes to this table, we believe that the stockholders named in this table have
sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them, based on information
provided to us by such stockholders. Unless otherwise indicated, the address for each director and executive officer listed is:
c/o ADiTx Therapeutics, Inc., 11161 Anderson Street, Suite 105-10014, Loma Linda, California 92354</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number
    of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>shares of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Common Stock</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Owned</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Before Offering</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Beneficially
    Owned</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>After Maximum</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt"><B><U>Directors and Officers:</U></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dr. Leonard Bailey, Chairman </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13.73</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Shahrokh Shabahang, Chief Technology Officer (1)(3)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,065,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">55.81</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">45.42</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Amro Albanna, Chief Executive Officer (2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">800,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.98</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.94</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">All directors and named executive officers as a group (3 persons)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,865,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">80.52</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65.53</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Greater than 10% Beneficial Owners:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Sekris Biomedical, Inc. (3)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,028,125</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">41.57</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33.83</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Held beneficially by Shabahang-Hatami Family
    Trust, Shahrokh Shabahang, Trustee.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Held beneficially by Albanna Family Trust, Amro
    Albanna, Trustee.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shahrokh Shabahang, as CEO of Sekris, has voting
    and dispositive power over shares owned by Sekris.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a014_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITIES
Being offered</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following is a summary of the rights of our capital stock as provided in our Certificate of Incorporation, and bylaws. For more
detailed information, please see our Certificate of Incorporation and bylaws which have been filed as exhibits to the Offering
Statement of which this Offering Circular is a part.</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total number of shares of stock which
the Company is authorized to issue is Thirty Million (30,000,000) shares of capital stock, consisting of Twenty Seven Million
(27,000,000) shares of Common Stock and Three Million shares of blank check preferred stock. As of the date of this Offering Circular,
the Company had (a)&nbsp;7,284,250 shares of Common Stock outstanding, (b) 1,200,000 shares of Common Stock reserved for issuance
under our 2017 Plan of which 1,025,000 shares of Common Stock are issuable upon exercise of outstanding options having a weighted
average exercise price of $2.00 per share, (c) 1,000,000 shares of Common Stock reserved for issuance under the Sekris Warrant,
and (d) 131,250 shares of Common Stock reserved for issuance under the Private Placement Warrants; (e) outstanding, but not yet
vested, warrants to purchase up to 420,000 shares of Common Stock issued to consultants of the Company; and (f) 18,667 shares
of Common Stock reserved for issuance under the July Private Placement Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Units Offered Hereby</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are offering a minimum of 1,220,000 Units
and a maximum of 1,666,666 Units at a fixed price of $6.00 per Unit. Each Unit shall consist of (a) one share of our Common Stock,
and (b) one Warrant to purchase one share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Warrants Offered Hereby</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> The Warrants entitle
the registered holder to purchase one share of our Common Stock at a price equal to $7.50 per share (125% of the price of the
Units sold in the Offering), subject to adjustment as discussed below, at any time commencing on the date that is six-months from
the consummation of this offering and terminating at 5:00 p.m., New York City time, on the third (3<SUP>rd</SUP>) anniversary
of the date of issuance (the &ldquo;Issuance Date&rdquo;). </P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Warrants will be issued in registered form under a warrant agent agreement (the &ldquo;Warrant Agent Agreement&rdquo;)
between us and our warrant agent, VStock Transfer, LLC (the &ldquo;Warrant Agent&rdquo;). The material provisions of the Warrants
are set forth herein and a copy of the Warrant Agent Agreement has been filed as an exhibit to the Offering Statement of which
this Offering Circular forms a part. The Company and the Warrant Agent may amend or supplement the Warrant Agent Agreement without
the consent of any holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision
contained therein or adding or changing any other provisions with respect to matters or questions arising under the Warrant Agent
Agreement as the parties thereto may deem necessary or desirable and that the parties determine, in good faith, shall not adversely
affect the interest of the holders. All other amendments and supplements shall require the vote or written consent of holders
of at least 50.1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The exercise price
and number of shares of Common Stock issuable upon exercise of the Warrants may be adjusted in certain circumstances, including
in the event of a stock dividend, extraordinary dividend on or recapitalization, reorganization, merger or consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Warrants
may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent,
with the exercise form attached to the warrant certificate completed and executed as indicated, accompanied by full payment of
the exercise price, by certified or official bank check payable to us, for the number of Warrants being exercised. The warrant
holders do not have the rights or privileges of holders of Common Stock and any voting rights until they exercise their warrants
and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the Warrants, each holder will
be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">No Warrants
will be exercisable unless at the time of the exercise a prospectus or offering circular relating to Common Stock issuable upon
exercise of the warrants is current and the Common Stock has been registered or qualified or deemed to be exempt under the securities
laws of the state of residence of the holder of the Warrants. Under the terms of the Warrant Agent Agreement, we have agreed to
use our best efforts to maintain a current offering circular or prospectus relating to common stock issuable upon exercise of
the Warrants until the expiration of the Warrants. If we are unable to maintain the qualification or effectiveness of such offering
statement or registration statement until the expiration of the Warrants, and therefore are unable to deliver registered shares
of Common Stock, the Warrants may become worthless. Such expiration would result in each holder paying the full Unit purchase
price solely for the shares of Common Stock underlying the Units. Additionally, the market for the warrants may be limited if
the offering circular or prospectus relating to the common stock issuable upon exercise of the Warrants is not current or if the
Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of such warrants reside.
In no event will the registered holders of a Warrant be entitled to receive a net-cash settlement, stock or other consideration
in lieu of physical settlement in shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">No fractional
shares of Common Stock will be issued upon exercise of the Warrants. If, upon exercise of the Warrants, a holder would be entitled
to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of shares
of Common Stock to be issued to the Warrant holder. If multiple Warrants are exercised by the holder at the same time, we will
aggregate the number of whole shares issuable upon exercise of all the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The price of
the Warrants has been arbitrarily established by us and the Underwriter after giving consideration to numerous factors, including
but not limited to, the pricing of the Units in this Offering. No particular weighting was given to any one aspect of those factors
considered. We have not performed any method of valuation of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares of Common Stock Offered Hereby</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock Voting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Common Stock are entitled to one vote for each share held on all matters to be voted on by the Company&rsquo;s
stockholders. There shall be no cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of shares of Common Stock are entitled to dividends when and as declared by the Board from funds legally available therefor
if, as and when determined by the Board of Directors of the Company in their sole discretion, subject to provisions of law, and
any provision of the Company&rsquo;s Certificate of Incorporation, as amended from time to time. There are no preemptive, conversion
or redemption privileges, nor sinking fund provisions with respect to the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our Common Stock
will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of or
provision for all of our debts and other liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fully
Paid and Non-assessable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding shares of Common Stock are, and the Common Stock to be outstanding upon completion of this Offering will be, duly
authorized, validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
in Authorized Number</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of authorized shares of Common Stock may be increased or decreased subject to the Company&rsquo;s legal commitments at
any time and from time to time to issue them, by the affirmative vote of the holders of a majority of the stock of the Company
entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Anti-Takeover Statute</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &ldquo;interested
stockholders&rdquo; from engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three
years following the date these persons become interested stockholders unless the business combination is, or the transaction in
which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies.
Generally, an &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three
years prior to the determination of interested stockholder status did own, 15% or more of a corporation&rsquo;s voting stock.
Generally, a &ldquo;business combination&rdquo; includes a merger, asset or stock sale, or other transaction resulting in a financial
benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions
not approved in advance by the Board of Directors. A Delaware corporation may &ldquo;opt out&rdquo; of these provisions with an
express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or
bylaws resulting from a stockholders&rsquo; amendment approved by at least a majority of the outstanding voting shares. We have
not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged
or prevented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue up to 3,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, the
terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The
terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters),
preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. No preferred stock is currently
outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock,
and therefore, reduce the value of our common stock and the Notes. In particular, specific rights granted to future holders of
preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve
control by the present management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exclusive Forum </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Our
Amended and Restated Certificate of Incorporation provides that unless the Company consents in writing to the selection of an
alternative forum, the State of Delaware is the&nbsp;sole and exclusive forum for: (i) any derivative action or proceeding brought
on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other
employee of the Company to the Company or the Company&rsquo;s stockholders, (iii) any action asserting a claim against the Company,
its directors, officers or employees arising pursuant to any provision of the DGCL or our Amended and Restated Certificate of
Incorporation or the Company&rsquo;s Bylaws, or (iv) any action asserting a claim against the Company, its directors, officers,
employees or agents governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as
to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of
Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following
such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for
which the Court of Chancery does not have subject matter jurisdiction. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2017
Equity Incentive Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;), was adopted by our board of directors and approved by our stockholders
in October 2017. Our 2017 Plan provides for the grant of incentive stock options (within the meaning of Section&nbsp;422 of the
Code), or ISOs to employees, and non-statutory stock options, or NSOs, restricted stock, restricted stock units and stock appreciation
rights, to our employees, directors, consultants and advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
Shares</I></B>. A total of 1,200,000 shares of our Common Stock have been reserved for issuance pursuant to the 2017 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Plan
Administration</I></B>. Currently, our board administers our 2017 Plan. Subject to the provisions of our 2017 Plan, the administrator
has the power to determine the terms of the awards, including the exercise price, the number of shares subject to each such award,
the exercisability of the awards, and the form of consideration, if any, payable upon exercise. The administrator also has the
authority to amend existing awards to reduce their exercise price, to allow participants the opportunity to transfer outstanding
awards to a financial institution or other person or entity selected by the administrator and to institute an exchange program
by which outstanding awards may be surrendered in exchange for awards with a higher or lower exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options</I></B>. The exercise price of options granted under our 2017 Plan must at least be equal to the fair market value of
our common stock on the date of grant. The term of an incentive stock option may not exceed ten years, except that with respect
to any participant who owns more than 10% of the voting power of all classes of our outstanding stock, the term must not exceed
five years and the exercise price must equal at least 110% of the fair market value on the grant date. Subject to the provisions
of our 2017 Plan, the administrator will determine the term of all other options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the termination of service of an employee, director or consultant, he or she may exercise his or her option or stock appreciation
right for the period of time stated in his or her award agreement. Generally, if termination is due to death or disability, the
option or stock appreciation right will remain exercisable for six months. In no event may an option be exercised later than the
expiration of its term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Appreciation Rights</I></B>. Stock appreciation rights may be granted under our 2017 Plan. Stock appreciation rights allow the
recipient to receive the appreciation in the fair market value of our common stock between the exercise date and the date of grant.
Subject to the provisions of our 2017 Plan, the administrator determines the terms of stock appreciation rights, including when
such rights become exercisable and whether to pay any increased appreciation in cash or with shares of our common stock, or a
combination thereof, except that the per share exercise price for the shares to be issued pursuant to the exercise of a stock
appreciation right will be no less than 100% of the fair market value per share on the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock</I></B>. Restricted stock may be granted under our 2017 Plan. Restricted stock awards are grants of shares of our common
stock that vest in accordance with terms and conditions established by the administrator. The administrator determines the number
of shares of restricted stock granted and may impose whatever conditions to vesting it determines to be appropriate (for example,
the administrator may set restrictions based on the achievement of specific performance goals or continued service to us). The
administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Shares of restricted
stock that do not vest are subject to our right of repurchase or forfeiture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Units</I></B>. Restricted stock units may be granted under our 2017 Plan. Restricted stock units represent an amount equal
to the fair market value of one share of our common stock. The administrator will determine the terms and conditions of restricted
stock units, including the number of units granted, the vesting criteria (which may include accomplishing specified performance
criteria or continued service to us), and the form and timing of payment. The administrator, in its sole discretion, may accelerate
the time at which any restrictions will lapse or be removed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
Adjustments</I></B>. In the event of certain changes in our capitalization, to prevent diminution or enlargement of the benefits
or potential benefits available under the 2017 Plan, the administrator will adjust the number and class of shares that may be
delivered under the 2017 Plan or the number, class and price of shares covered by each outstanding award, and the numerical share
limits set forth in the 2017 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Merger
or Change in Control</I></B>. Our 2017 Plan provides that in the event of a merger or change in control, as defined in the 2017
Plan, each outstanding award will be treated as the administrator determines, including that the successor corporation or its
parent or subsidiary will assume or substitute an equivalent award for each outstanding award. The administrator will not be required
to treat all awards similarly. If there is no assumption or substitution of outstanding awards, the awards will fully vest, all
restrictions will lapse and the awards will become fully exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Penny
Stock Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted regulations which generally define &ldquo;<I>penny stock</I>&rdquo; to be any equity security that has a market
price of less than $5.00 per share or an exercise price of less than $5.00 per share. Such securities are subject to rules that
impose additional sales practice requirements on broker-dealers who sell them. For transactions covered by these rules, the broker-dealer
must make a special suitability determination for the purchaser of such securities and have received the purchaser&rsquo;s written
consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the
rules require the delivery, prior to the transaction, of a disclosure schedule prepared by the SEC relating to the penny stock
market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative,
current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this
fact and the broker-dealer&rsquo;s presumed control over the market. Finally, among other requirements, monthly statements must
be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny
stocks. As our Common Stock immediately following this Offering may be subject to such penny stock rules, purchasers in this Offering
will in all likelihood find it more difficult to sell their Common Stock shares in the secondary market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a015_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to retain any earnings for the foreseeable future for our operations. We have never paid any dividends on our Common Stock
and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will
be at the sole discretion of our Board and will depend on our financial condition, operating results, capital requirements and
such other factors as our Board deems relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a016_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PLAN
OF DISTRIBUTION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We are offering a minimum of 1,220,000
Units (the &ldquo;Minimum Offering Amount&rdquo;), and maximum of 1,666,666 Units (the &ldquo;Maximum Offering Amount&rdquo;)
for $6.00 per Unit, each Unit consisting of one share of Common Stock and one Warrant exercisable for one share of Common Stock
at the exercise price of $7.50 per share, subject to adjustment in certain circumstances, from the date that is six-months from
the date of issuance until the 3<SUP>rd</SUP> anniversary date of the date of issuance. We have engaged Network 1 Financial Securities,
Inc. as the lead underwriter (the &ldquo;Underwriter&rdquo;) pursuant to an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;).
The Underwriter is not purchasing or selling any Units or underlying securities offered by this Offering Statement, nor is it
required to arrange for the purchase or sale of any specific number or dollar amount of Units; but, rather, the Underwriter has
agreed to use its commercially reasonable &ldquo;best efforts&rdquo; to arrange for the sale of all of Units offered hereby. The
Underwriter may engage selected dealers (&ldquo;Dealers&rdquo;) to assist in the placement of the Units for a cash compensation.
We will enter into subscription agreements directly with purchasers in connection with this Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement provides that the obligation of the Underwriter to arrange for the offer and sale of the Units, on a best
efforts basis, is subject to certain conditions precedent, including but not limited to (i) receipt of a listing approval letter
from the Nasdaq Capital Market, (ii) delivery of legal opinions, and (iii) delivery of auditor comfort letters. The Underwriter
is under no obligation to purchase any Units for its own account. As a &ldquo;best efforts&rdquo; offering, there can be no assurance
that the offering contemplated hereby will ultimately be consummated, or even if consummated that we will in fact obtain a listing
on the Nasdaq Capital Market. The Underwriter may, but is not obligated to, retain other selected dealers that are qualified to
offer and sell the Units and that are members of the Financial Industry Regulatory Authority, Inc., or FINRA. The Underwriter
proposes to offer the Units to investors at the public offering price, and will receive the underwriting commissions, set forth
on the cover of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering price of the Units and exercise price of the Warrants underlying the Units have has determined based upon arms&rsquo;
length negotiations between us and the Underwriter. The Offering price of the Units, concession and reallowance to dealers may
be changed by the Company and the Underwriter. No such change shall change the amount of proceeds to be received by us as set
forth on the cover page of this Offering Circular.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commissions
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the Underwriter an aggregate cash fee equal to seven percent (7%) of the gross proceeds of the Units sold in
this Offering. We have also agreed to pay a non-accountable expense allowance to the Underwriter equal to one percent (1%) of
the gross proceeds of the Units sold in this Offering at the closing of this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the public Offering price, commission, and proceeds before expenses to us. The information assumes either
no exercise of the Underwriter Warrants (as discussed below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commissions</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proceeds
    to the</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Before</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expenses <SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 61%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Unit</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.42</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.58</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum Offering
    Amount </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,320,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">512,400</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,807,600</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum Offering
    Amount </FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><P STYLE="margin: 0">700,000</P> </TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><P STYLE="margin: 0">9,300,000</P> </TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Consists
    of an underwriting commission of 7%. The Company has also agreed to pay the Underwriter a non-accountable expense allowance
    equal to 1% of the gross proceeds raised in this Offering.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the
    total expenses of this Offering that will be payable by us, excluding the Underwriter&rsquo;s fees, will be approximately
    $400,000 to 500,000, which includes legal and printing costs, various other fees and reimbursement of the Underwriter&rsquo;s
    expenses.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to reimburse the Underwriter for incurred expenses relating to the Offering, including all actual fees and expenses
incurred by them in connection with, among other things, due diligence costs, &ldquo;road show&rdquo; expenses, and the fees and
expenses of the Underwriter&rsquo;s counsel which, in the aggregate, shall not exceed $75,000 in the aggregate, $65,000 of which
has been paid in advance and will be returned to us to the extent that Offering expenses are not actually incurred in compliance
with FINRA Rule 5110(f)(2)(C).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Offering will start on or after such date
that this Offering Statement on Form 1-A is qualified by the SEC and will terminate on the Termination Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also agreed to issue to the Underwriter
at the closing common stock purchase warrants exercisable for an amount of shares of Common Stock equal to 10% of the Shares underlying
the Units sold in this Offering (the &ldquo;Underwriter&rsquo;s Warrants&rdquo;) for $7.50 per share (125% of the Offering price
of the Units). The Underwriter&rsquo;s Warrants may be exercised on a cashless basis and will be exercisable six months following
the closing date until the fifth anniversary of the qualification date of this Offering Circular in compliance with FINRA Rule
5110(f)(2)(G)(i). The Underwriter&rsquo;s Warrants are not redeemable by us and will provide for unlimited &ldquo;piggyback&rdquo;
registration rights at our expense with respect to the underlying shares of Common Stock during the five-year period commencing
on the qualification date of the Offering in compliance with FINRA Rule 5110(f)(2)(G)(v). The Underwriter&rsquo;s Warrants will
provide for adjustment in the number and exercise price of such warrants (and the shares of Common Stock underlying such warrants)
in the event of recapitalization, merger or other fundamental transaction. The Underwriter&rsquo;s Warrants and the shares of
Common Stock issuable upon the exercise of the Underwriter&rsquo;s Warrants have been deemed compensation by FINRA and are therefore
subject to FINRA Rule 5110(g)(1). In accordance with FINRA Rule 5110(g)(1), none of such securities may be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would
result in the effective economic disposition of such securities by any person for a period of 180 days immediately following the
qualification date of the Form 1-A of which this Offering Circular is a part or commencement of sales of the Offering pursuant
to which the Underwriter&rsquo;s Warrants are being issued, except the transfer of any security:&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by operation of law or by reason of our reorganization;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any FINRA member
    firm participating in this Offering and the officers or partners thereof, if all securities so transferred remain subject
    to the lock-up restriction described above for the remainder of the time period;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the aggregate
    amount of our securities held by either an underwriter or a related person does not exceed 1% of the securities being offered;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is beneficially
    owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise
    directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the
    fund; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise or
    conversion of any security, if all securities received remain subject to the lock-up restriction set forth above for the remainder
    of the time period.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in accordance with FINRA Rule 5110(f)(2)(G), the Underwriter&rsquo;s Warrants may not contain certain terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligation to issue and sell our securities to the purchasers is subject to the conditions set forth in the agreements with such
purchasers, which may be waived by us at our discretion. A purchaser&rsquo;s obligation to purchase securities is subject to the
conditions set forth in his or her subscription agreement as well, which may also be waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Escrow
Agent&nbsp;and Deposit of Offering Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the Underwriter have executed an Escrow Deposit Agreement with MVB Bank, Inc. (the &ldquo;Escrow Agreement&rdquo;) pursuant
to which MVB Bank, Inc. shall serve as the escrow agent (the &ldquo;Escrow Agent&rdquo;) in connection with this Offering. All
monies collected from prospective purchasers of Units will be held in a separate escrowed non-interest bearing bank account at
MVB Bank, Inc. (the &ldquo;Escrow Account&rdquo;). All checks delivered to the Escrow Agent shall be made payable to &ldquo;ADiTx
Therapeutics, Inc., MVB Bank, Inc., as Escrow Agent.&rdquo; The Underwriter and Dealers will instruct their customers to transfer
funds from their respective accounts directly to the Escrow Agent by wire transfer and will instruct other purchasers of the Units
to make checks payable to &ldquo;ADiTx Therapeutics, Inc., MVB Bank, Inc., as Escrow Agent.&rdquo; The Underwriter and Dealers
shall deliver to the Escrow Agent all funds in the form of checks or wire transfers which they receive from prospective purchasers
by noon of the next business day. Funds will not be released to the Company until the Minimum Amount is raised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with each deposit to the Escrow Account, the Underwriter and Dealers shall inform the Escrow Agent about the subscription information
for each prospective purchaser. Upon the Escrow Agent&rsquo;s receipt of such monies, they shall be credited to and deposited
into the Escrow Account. The Escrow Agent shall not be required to accept for credit to the Escrow Account or for deposit into
the Escrow Account checks which are not accompanied by the appropriate subscription information. Wire transfers representing payments
by prospective purchasers shall not be deemed deposited in the Escrow Account until the Escrow Agent has received in writing the
subscription information required with respect to such payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
deposited in escrow with the&nbsp;Escrow Agent&nbsp;may not be withdrawn by investors prior to the earlier of the closing of the
Offering or the date the Offering is terminated. If the Offering is withdrawn or canceled or terminated and proceeds therefrom
are not received by us on or prior to the date the Offering is terminated, all proceeds will be promptly returned by the&nbsp;Escrow
Agent&nbsp;without interest or deduction to the persons from which they are received (within one business day) in accordance with
applicable securities laws. All such proceeds will be placed in a non-interest-bearing account pending such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our acceptance of a subscription and receipt of full payment, and subject to the timing qualification set forth above, we will
countersign the subscription agreement along with a copy of the subscription agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the right to accept or reject subscriptions in whole or in part, for any reason or for no reason. All monies from rejected
subscriptions will be returned immediately by the Escrow Agent to the subscriber, without interest or deductions. Subscriptions
for securities will be accepted or rejected within three (3) business days after we receive them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Escrow Account is for (i) the deposit of all subscription monies (checks or wire transfers) which are received
by the Underwriter and Dealers from prospective purchasers of our offered Units and are delivered by the Underwriter and Dealers
to the&nbsp;Escrow Agent, (ii) the holding of amounts of subscription monies which are collected through the banking system, and
(iii) the disbursement of collected funds. The&nbsp;Escrow Agent&nbsp;will exercise signature control on the Escrow Account and
will act based on joint instructions from us and the Underwriter. On the closing date of the Offering and presuming that all conditions
to closing have been satisfied (such as the delivery of legal opinions, auditor comfort letters, other conditions described in
the Underwriting Agreement), proceeds in the Escrow Account will be delivered to us. The Escrow Account will be non-interest bearing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Release
of the funds to us is based upon the&nbsp;Escrow Agent&nbsp;reviewing the records of the depository institution holding the escrow
to verify that the funds received have cleared the banking system prior to releasing the funds to us. All subscription information
and subscription funds through checks or wire transfers should be delivered to the&nbsp;Escrow Agent. Failure to do so will result
in subscription funds being returned to the investor. In event that the Offering is canceled or terminated, all subscription funds
from the Escrow Account will be returned to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any dispute between us and the Underwriter, including whether and how funds are to be disbursed, the&nbsp;Escrow
Agent&nbsp;is entitled to petition a court of competent jurisdiction to resolve any such dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Prior to this Offering, there has been
no public market for our Units, Common Stock, or Warrants. We have only applied to list our Common Stock on the Nasdaq Capital
Market (&ldquo;NASDAQ&rdquo;), and upon approval, we expect to list our Common Stock under the symbol &ldquo;ADTX.&rdquo; If our
Common Stock is not approved for listing on the NASDAQ, we will not consummate this Offering. Our Common Stock will not commence
trading on NASDAQ until a number of conditions are met, including that we have raised the minimum amount of Offering proceeds
necessary for us to meet the initial listing requirements of NASDAQ under the Market Value of Listed Securities Standard. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
in order to list, NASDAQ requires that, among other criteria, at least 1,000,000 publicly-held shares of our common stock be outstanding,
the shares be held in the aggregate by at least 300 round lot holders, the market value of the publicly-held shares of our Common
Stock be at least $15.0 million, our stockholders&rsquo; equity after giving effect to the sale of our shares in this offering
be at least $5.0 million, the bid price per share of our Common Stock be $4.00 or more, and there be at least three registered
and active market makers for our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> There is presently no public market
for the Units or the Warrants, and it is not anticipated that a public market for the Units or the Warrants will develop in the
future. We will not apply to list the Units or the Warrants on NASDAQ.&nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Underwriter against liabilities under the Securities Act of 1933, as amended. We have also agreed
to contribute to payments the Underwriter may be required to make in respect of such liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our executive officers and directors, and holders of at 5% or more of our Common Stock have agreed to enter into lock-up agreements
in connection with this Offering. Under the lock-up agreements, subject to certain exceptions, we and each of these persons may
not, without the prior written approval of the Underwriter, offer, sell, contract to sell, pledge, or otherwise dispose of, directly
or indirectly, or hedge our Common Stock or securities convertible into or exchangeable or exercisable for our Common Stock. These
restrictions remain in effect and will generally terminate on 181<SUP>st</SUP> day after the closing date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Offering, we agreed that we will not: (i) offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer
or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable
for shares of our capital stock; (ii) file or cause to be filed any Offering statement with the SEC relating to the Offering of
any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock;
or (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of our capital stock, whether any such transaction described in clause (i), (ii) or (iii) above is to be settled
by delivery of shares of our capital stock or such other securities, in cash or otherwise, in each case without the prior consent
of the Underwriter for a period of 12 months after the date of the Underwriting Agreement, other than (A) the securities sold
in this Offering, (B) the issuance by us of shares of our Common Stock upon the exercise of the Warrants underlying the Units
sold in this Offering or a stock option or warrant or the conversion of a security outstanding on the date of this Offering, hereafter
issued pursuant to our currently existing or hereafter adopted equity compensation plans or employment or consulting agreements
or arrangements of which the Underwriter has been advised in writing or which have been filed with the SEC or (C) the issuance
by us of stock options or shares of our capital stock of our company under any currently existing or hereafter adopted equity
compensation plan or employment/consulting agreements or arrangements of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Offering Circular may be made available
in electronic format on websites or through other online services maintained by the underwriter, or by its affiliates. Other than
this Offering Circular in electronic format, the information on an Underwriter&rsquo;s website and any information contained in
any other website maintained by an Underwriter is not a part of this Offering Circular or the Offering statement of which this
Offering Circular forms a part, has not been approved and/or endorsed by us or the Underwriter, and should not be relied upon
by any purchaser of the securities offered pursuant to the Offering statement of which this Offering Circular forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing does not purport to be a
complete statement of the terms and conditions of the Underwriting Agreement and agreements with purchasers in this Offering.
A copy of the Underwriting Agreement and the form of agreement with the purchasers are included as exhibits to this Offering statement
of which this Offering Circular forms a part. See &ldquo;<I>Where You Can Find Additional Information</I>.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
M Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Underwriter is an &ldquo;underwriter&rdquo; within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the securities sold by it while acting as a principal may be deemed to
be underwriting discounts or commissions under the Securities Act. As an underwriter, each Underwriter would be required to comply
with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities
Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and
sales of our securities by the Underwriter acting as a principal. Under these rules and regulations, the Underwriter:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">must not engage
    in any stabilization activity in connection with our securities; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">must not bid for
    or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted
    under the Exchange Act, until it has completed its participation in the distribution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Offering, the Underwriter and any selling group members may engage in passive market making transactions
in our Common Stock on The&nbsp;NASDAQ Stock Market, or other exchange on which the Company&rsquo;s securities are traded, in
accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of
the securities and extending through the completion of the distribution. A passive market maker must display its bid at a price
not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Underwriter and
its affiliates have provided, and may in the future provide, various investment banking, financial advisory and other services
to us and our affiliates for which services they have received, and may in the future receive, customary fees. In the course of
their business, the Underwriter and its affiliates may actively trade our securities or loans for their own account or for the
accounts of customers, and, accordingly, the Underwriter and its affiliates may at any time hold long or short positions in such
securities or loans. Except for services provided in connection with this Offering, the Underwriter has not provided any investment
banking or other financial services during the 180-day period preceding the date of this Offering Circular and we do not expect
to retain the Underwriter to perform any investment banking or other financial services for at least 90 days after the date of
this Offering Circular.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a017_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ADDITIONAL
INFORMATION ABOUT THE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment
Limitations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
no sale may be made to you in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual
income or net worth (please see below on how to calculate your net worth). Different rules apply to accredited investors and non-natural
persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review
Rule 251(d)(2)(i)(C) of Regulation A+. For general information on investing, we encourage you to refer to <I>www.investor.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
this is a Tier 2, Regulation A+ offering, most investors must comply with the 10% limitation on investment in the Offering. The
only investor in this Offering exempt from this limitation is an &ldquo;<I>accredited investor</I>&rdquo; as defined under Rule
501 of Regulation D under the Securities Act. If you meet one of the following tests you should qualify as an accredited investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                         are a natural person who has had individual income in excess of $200,000 in each of the
                                         two most recent years, or joint income with your spouse in excess of $300,000 in each
                                         of these years, and have a reasonable expectation of reaching the same income level in
                                         the current year;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are a natural
    person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase Units
    (please see below on how to calculate your net worth);</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are an executive
    officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are an organization
    described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation, a Massachusetts
    or similar business trust or a partnership, not formed for the specific purpose of acquiring the Units, with total assets
    in excess of $5,000,000;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are a bank or
    a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant
    to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered
    under the Investment Company Act of 1940 (Investment Company Act), or a business development company as defined in that act,
    any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development
    company as defined in the Investment Advisers Act of 1940;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are an entity
    (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are a trust
    with total assets in excess of $5,000,000, your purchase of Units is directed by a person who either alone or with his purchaser
    representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial
    and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not
    formed for the specific purpose of investing in the Units; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">

    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You are a plan established
    and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions,
    for the benefit of its employees, if such plan has assets in excess of $5,000,000.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering
Period and Expiration Date</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Offering will start on the date on which the SEC initially qualifies this Offering Statement (the Qualification Date) and will
terminate on the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Procedures
for Subscribing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
purchase Units in this Offering, investors must complete and sign a subscription agreement. Investors will be required to pay
for their shares of Units by wire, ACH, or certified check for the full purchase price of the shares, payable to &ldquo;ADiTx
Therapeutics, Inc., MVB Bank, Inc., as Escrow Agent.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscriptions
will be effective only upon our acceptance of the subscriptions, and we reserve the right to reject any subscriptions in whole
or in part. In compliance with Rule 15c2-4 under the Exchange Act, we and the Underwriter will instruct investors to deliver all
monies in the form of checks, ACH or wire transfers to the Escrow Agent and the Underwriter shall deliver to the&nbsp;Escrow Agent&nbsp;all
funds in the form of checks or wire transfers which they receive from prospective purchasers by&nbsp;noon&nbsp;of the next business
day. Upon the Escrow Agent&rsquo;s receipt of such monies, they shall be credited to the Escrow Account. Pursuant to an escrow
agreement among us, the Underwriter and Escrow Agent, the funds received in payment for the Units purchased in this Offering will
be wired to a non-interest bearing escrow account at MVB Bank, Inc. and held until we and the Underwriter determine that we have
raised the minimum amount of Offering proceeds necessary for us to meet the initial listing requirements of NASDAQ under the Market
Value of Listed Securities Standard and have met the closing obligations set forth in the Underwriting Agreement. In the event
we do not meet NASDAQ&rsquo;s initial listing qualification requirements, all subscription funds from the Escrow Account will
be returned to investors. On the closing date, the Escrow Agent will release the funds in accordance with the written instructions
provided by us and the Underwriter, indicating the date on which the Units purchased in this Offering are to be delivered to the
investors and the date the net proceeds are to be delivered to us. Unless investors instruct us otherwise, The Depository Trust
Company will credit the shares of Common Stock to the respective accounts of the purchasers and we will mail the warrants to the
addresses set forth in the agreements with purchasers in this Offering.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the right to accept or reject subscriptions in whole or in part, for any reason or for no reason. All monies from rejected
subscriptions will be returned immediately by the Escrow Agent to the subscriber, without interest or deductions. Subscriptions
for securities will be accepted or rejected within three (3) business days after we receive them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Right
to Reject Subscriptions</I></B>. After we receive your complete, executed subscription agreement and the funds required under
the subscription agreement have been transferred to our designated account, we have the right to review and accept or reject your
subscription in whole or in part, for any reason or for no reason. We will return all monies from rejected subscriptions immediately
to you, without interest or deduction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acceptance
of Subscriptions</I></B>. Upon our acceptance of a subscription agreement, we will countersign the subscription agreement and
issue the shares subscribed at closing. Once you submit the subscription agreement, you may not revoke or change your subscription
or request your subscription funds. All submitted subscription agreements are irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Rule 251 of Regulation A+, non-accredited, non-natural investors are subject to the investment limitation and may only invest
funds which do not exceed 10% of the greater of the purchaser&rsquo;s revenue or net assets (as of the purchaser&rsquo;s most
recent fiscal year end). A non-accredited, natural person may only invest funds which do not exceed 10% of the greater of the
purchaser&rsquo;s annual income or net worth (please see below on how to calculate your net worth).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>NOTE</U></B>:
For the purposes of calculating your net worth, it is defined as the difference between total assets and total liabilities. This
calculation must exclude the value of your primary residence and may exclude any indebtedness secured by your primary residence
(up to an amount equal to the value of your primary residence). In the case of fiduciary accounts, net worth and/or income suitability
requirements may be satisfied by the beneficiary of the account or by the fiduciary, if the fiduciary directly or indirectly provides
funds for the purchase of the Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to purchase our Common Stock shares and prior to the acceptance of any funds from an investor, an investor will be required
to represent, to the Company&rsquo;s satisfaction, that such investor is either an accredited investor or is in compliance with
the 10% of net worth or annual income limitation on investment in this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a discussion of the material
U.S. federal income tax considerations relevant to the ownership and disposition of the Units and the Common Stock and Warrants
composing such Units, which the Company refers to collectively as its securities. This discussion is based upon provisions of
the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), Treasury regulations, rulings and judicial decisions as
of the date of this offering circular. These authorities may change, perhaps retroactively, which could result in U.S. federal
income tax consequences different from those summarized below. This discussion only applies to persons who hold the Company&rsquo;s
securities as capital assets within the meaning of Section 1221 of the Code (generally property held for investment). This discussion
does not address all aspects of U.S. federal income taxation (such as the alternative minimum tax or any Medicare contribution
tax imposed on certain unearned income) and does not describe any foreign, state, local or other tax considerations that may be
relevant to a purchaser or holder of the Company&rsquo;s securities in light of their particular circumstances. In addition, this
discussion does not describe the U.S. federal income tax consequences applicable to a purchaser or holder of the Company&rsquo;s
securities who is subject to special treatment under U.S. federal income tax laws (including, a corporation that accumulates earnings
to avoid U.S. federal income tax, a pass-through entity or an investor in a pass-through entity, a tax-exempt entity, a pension
or other employee benefit plan, a financial institution or broker-dealer, a regulated investment company, a real estate investment
trust, a foreign government or international organization, a U.S. Holder (as defined below) whose functional currency is not the
U.S. dollar, a person holding the Company&rsquo;s securities as part of a hedging or conversion transaction or straddle, a person
subject to the alternative minimum tax, an insurance company, a former U.S. citizen, or a former long-term U.S. resident). The
Company cannot assure you that a change in law will not significantly alter the tax considerations that the Company describes
in this discussion. The conclusions in this discussion are based on professional judgment and are not a guarantee of a result
and are not binding on the Internal Revenue Service or the courts. Accordingly, no assurance can be given that the conclusions
set forth herein will be sustained if challenged by the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds the Company&rsquo;s securities,
the U.S. federal income tax treatment of a partner of that partnership generally will depend upon the status of the partner and
the activities of the partnership. If you are a partnership or a partner of a partnership holding the Company&rsquo;s securities,
you should consult your tax advisor as to the particular U.S. federal income tax consequences of holding and disposing of the
Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IF
YOU ARE CONSIDERING THE PURCHASE OF THE COMPANY&rsquo;S SECURITIES, YOU SHOULD CONSULT YOUR OWN TAX ADVISOR CONCERNING THE U.S.
FEDERAL INCOME TAX CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF THE COMPANY&rsquo;S SECURITIES IN LIGHT OF YOUR PARTICULAR
CIRCUMSTANCES AND ANY CONSEQUENCES ARISING UNDER OTHER FEDERAL TAX LAW AND THE LAWS OF APPLICABLE STATE, LOCAL AND FOREIGN TAXING
JURISDICTIONS. YOU SHOULD ALSO CONSULT WITH YOUR TAX ADVISOR CONCERNING ANY POSSIBLE ENACTMENT OF LEGISLATION THAT WOULD AFFECT
YOUR INVESTMENT IN THE COMPANY&rsquo;S SECURITIES IN YOUR PARTICULAR CIRCUMSTANCES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S.
Holders:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are a &ldquo;U.S. Holder&rdquo; if you are a beneficial owner of the Company&rsquo;s securities and you are for U.S. federal income
tax purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual citizen
    or resident of the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or
    other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the
    United States, any state thereof or the District of Columbia;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income
    of which is subject to U.S. federal income taxation regardless of its source; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust if it (a)
    is subject to the primary supervision of a court within the United States and one or more United States persons have the authority
    to control all substantial decisions of the trust or (b) has a valid election in effect under applicable United States Treasury
    regulations to be treated as a United States person.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a &ldquo;Non-U.S. Holder&rdquo; is a beneficial owner of the Company&rsquo;s securities that is neither
a U.S. Holder nor an entity treated as a partnership for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Allocation
of Purchase Price and Characterization of a Unit</I>. There is no statutory, administrative or judicial authority directly addressing
the treatment, for U.S. federal income tax purposes, of securities with terms substantially the same as the Units, and, therefore,
that treatment is not entirely clear. The acquisition of a Unit should be treated for U.S. federal income tax purposes as the
acquisition of one share of Common Stock and one Warrant to acquire one share of Common Stock. Each holder of a Unit must allocate
the purchase price paid by such holder for such Unit among the share of Common Stock and the Warrant that comprise the Unit based
on their respective relative fair market values at the time of issuance. A holder&rsquo;s initial tax basis in the share of Common
Stock and Warrant included in each Unit should equal the portion of the purchase price of the Unit allocated thereto. Any disposition
of a Unit should be treated for U.S. federal income tax purposes as a disposition of the share of Common Stock and Warrant comprising
the Unit, and the amount realized on the disposition should be allocated between the share of Common Stock and the Warrant based
on their respective relative fair market values at the time of disposition. The separation of the share of Common Stock and the
Warrant comprising a Unit should not be a taxable event for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing treatment of the shares of Common Stock and Warrants and a holder&rsquo;s purchase price allocation are not binding
on the IRS or the courts. Because there are no authorities that directly address instruments that are similar to the Units, no
assurance can be given that the IRS or the courts will agree with the characterization described above or the discussion below.
Accordingly, each holder is advised to consult its own tax advisor regarding the risks associated with an investment in a Unit
(including alternative characterizations of a Unit) and regarding an allocation of the purchase price among the share of Common
Stock and Warrant that comprise a Unit. The balance of this discussion generally assumes that the characterization of the Units
described above is respected for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distributions
in General.</I>&nbsp;If distributions are made with respect to Common Stock, such distributions will be treated as taxable dividends
to the extent paid from the Company&rsquo;s current or accumulated earnings and profits as determined under the Code. Any portion
of a distribution that exceeds the Company&rsquo;s current and accumulated earnings and profits will first be applied to reduce
a U.S. Holder&rsquo;s tax basis in the Common Stock on a share-by-share basis, and the excess will be treated as gain from the
disposition of the Common Stock, the tax treatment of which is discussed below under &ldquo;<I>U.S. Holders: Sale or Other Disposition</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
received by an individual U.S. Holder of Common Stock will be subject to a preferential rate if such dividends are treated as
qualified dividend income for U.S. federal income tax purposes. The rate reduction does not apply to dividends received to the
extent that the individual U.S. Holder elects to treat the dividends as investment income, which may be offset against investment
expenses. Furthermore, the rate reduction does not apply to dividends that are paid to individual U.S. Holders with respect to
Common Stock that is held for 60 days or less during the 121-day period beginning on the date which is 60 days before the date
on which the Common Stock becomes ex-dividend. Also, if a dividend received by an individual U.S. Holder that qualifies for the
rate reduction is an extraordinary dividend within the meaning of Section 1059 of the Code, any loss recognized by such individual
U.S. Holder on a subsequent disposition of the stock will be treated as long-term capital loss to the extent of such extraordinary
dividend, irrespective of such U.S. Holder&rsquo;s holding period for the stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
received by corporations generally will be eligible for the dividends-received deduction. This deduction is allowed if the underlying
stock is held for at least 45 days during the 91 day period beginning on the date 45 days before the ex-dividend date of the stock.
If a corporate stockholder receives a dividend on the Common Stock that is an extraordinary dividend within the meaning of Section
1059 of the Code, the corporate stockholder in certain instances must reduce its basis in the Common Stock by the amount of the
nontaxed portion of such extraordinary dividend that results from the application of the dividends-received deduction. If the
nontaxed portion of such extraordinary dividend exceeds such corporate stockholder&rsquo;s basis, any excess will be taxed as
gain as if such stockholder had disposed of its shares in the year the extraordinary dividend is paid. Each corporate U.S. Holder
of Common Stock is urged to consult with its tax advisor with respect to the eligibility for and amount of any dividends received
deduction and the application of Section 1059 of the Code to any dividends it receives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sale
or Other Disposition.</I>&nbsp;A U.S. Holder will generally recognize capital gain or loss on a sale or exchange of Common Stock
equal to the difference between the amount realized upon the sale or exchange (not including any proceeds attributable to declared
and unpaid dividends, which will be taxable to U.S. Holders of record as described above under &ldquo;<I>U.S. Holders: Distributions
in General</I>&rdquo;) and the U.S. Holder&rsquo;s adjusted tax basis in the Common Stock sold or exchanged. Such capital gain
or loss will be long-term capital gain or loss if the U.S. Holder&rsquo;s holding period for the Common Stock sold or exchanged
is more than one year. Long-term capital gains of non-corporate taxpayers are taxed at a preferential rate. The deductibility
of capital losses is subject to limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sale
or Other Disposition, Exercise or Expiration of Warrants</I>. Upon the sale or other disposition of a Warrant (other than by exercise),
you will generally recognize capital gain or loss equal to the difference between the amount realized on the sale or other disposition
and your tax basis in the Warrant. This capital gain or loss will be long-term capital gain or loss if, at the time of the sale
or other disposition, the Warrant has been held by you for more than one year. The deductibility of capital losses is subject
to limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, you will not be required to recognize income, gain or loss upon exercise of a Warrant for its exercise price. Your basis
in a share of Common Stock received upon exercise will be equal to the sum of (1) your basis in the Warrant and (2) the exercise
price of the Warrant. Your holding period in the shares received upon exercise will commence on the day after you exercise the
Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Warrant expires without being exercised, you will recognize a capital loss in an amount equal to your basis in the Warrant.
Such loss will be long-term capital loss if, at the time of the expiration, the Warrant has been held by you for more than one
year. The deductibility of capital losses is subject to limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Constructive
Distributions on Warrants</I>. The terms of each Warrant provide for an adjustment to the number of shares for which the Warrant
may be exercised or to the exercise price of the Warrant upon the occurrence of certain events. An adjustment which has the effect
of preventing dilution generally is not taxable. However, you would be treated as receiving a constructive distribution from us
if, for example, the adjustment increases your proportionate interest in the Company&rsquo;s assets or earnings and profits (<I>e.g.</I>,
through an increase in the number of shares that would be obtained upon exercise) as a result of a distribution to the holders
of the Common Stock which is taxable to the U.S. Holders of such Common Stock as described above under &ldquo;<I>U.S. Holders
&ndash; Distributions</I>&rdquo;). Such constructive distribution would be subject to tax as described under that section in the
same manner as if you received a cash distribution from the Company equal to the fair market value of such increased interest.
For certain information reporting purposes, the Company is required to determine the date and amount of any such constructive
distributions. Recently proposed Treasury Regulations, on which the Company may rely prior to the issuance of final regulations,
specify how the date and amount of constructive distributions are determined. You should consult your tax advisor regarding the
proper treatment of any adjustments to the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Information
Reporting and Backup Withholding.</I>&nbsp;Information reporting and backup withholding may apply with respect to payments of
dividends on the Common Stock and to certain payments of proceeds on the sale or other disposition of Common Stock. Certain non-corporate
U.S. Holders may be subject to U.S. backup withholding (currently at a rate of 24%) on payments of dividends on the Common Stock
and certain payments of proceeds on the sale or other disposition of the Common Stock unless the beneficial owner thereof furnishes
the payor or its agent with a taxpayer identification number, certified under penalties of perjury, and certain other information,
or otherwise establishes, in the manner prescribed by law, an exemption from backup withholding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
backup withholding tax is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund
or a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability, which may entitle the U.S. Holder to a refund, provided
the U.S. Holder timely furnishes the required information to the Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-U.S.
Holders:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Distributions on the Common Stock. If
cash or certain other distributions are made with respect to Common Stock, such distributions will be treated as taxable dividends
to the extent paid from the Company&rsquo;s current or accumulated earnings and profits as determined under the Code and may be
subject to withholding as discussed below. Any portion of a distribution that exceeds the Company&rsquo;s current and accumulated
earnings and profits will first be applied to reduce the Non-U.S. Holder&rsquo;s basis in the Common Stock and, to the extent
such portion exceeds the Non-U.S. Holder&rsquo;s basis, the excess will be treated as gain from the disposition of the Common
Stock, the tax treatment of which is discussed below under &ldquo;<I>Non-U.S. Holders: Sale or Other Disposition</I>.&rdquo; In
addition, if the Company was to meet the definition of a USRPHC (as defined below under &ldquo;<I>Non-U.S. Holders: Sale or Other
Disposition</I>&rdquo;) and any distribution exceeds the Company&rsquo;s current and accumulated earnings and profits, the Company
will need to choose to satisfy its withholding requirements either by treating the entire distribution as a dividend, subject
to the withholding rules in the following paragraph (and withhold at a minimum rate of 15% or such lower rate as may be specified
by an applicable income tax treaty for distributions from a USRPHC), or by treating only the amount of the distribution equal
to the Company&rsquo;s reasonable estimate of its current and accumulated earnings and profits as a dividend, subject to the withholding
rules in the following paragraph, with the excess portion of the distribution subject to withholding at a rate of 15% or such
lower rate as may be specified by an applicable income tax treaty as if such excess were the result of a sale of shares in a USRPHC
(discussed below under &ldquo;<I>Non-U.S. Holders: Sale or Other Disposition</I>&rdquo;).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
or any other taxable distribution (whether in cash, Common Stock or other property) paid to a Non-U.S. Holder of Common Stock
will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable
income tax treaty. Any required withholding tax may be satisfied by the withholding agent through a sale of a portion of the shares
received by a Non-U.S. Holder in a taxable distribution or may be withheld from cash dividends or sales proceeds subsequently
paid or credited to a Non-U.S. Holder. However, dividends that are effectively connected with the conduct of a trade or business
by the Non-U.S. Holder within the United States (and, where a tax treaty applies, are attributable to a permanent establishment
maintained by the Non-U.S. Holder in the United States) are not subject to the withholding tax, provided certain certification
and disclosure requirements are satisfied including completing Internal Revenue Service Form W-8ECI (or any successor form or
other applicable form). Instead, such dividends are subject to U.S. federal income tax on a net income basis in the same manner
as if the Non-U.S. Holder were a United States person as defined under the Code, unless an applicable income tax treaty provides
otherwise. Any such effectively connected dividends received by a foreign corporation may be subject to an additional branch profits
tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder of Common Stock who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding, as
discussed below, for dividends will be required to (a) complete Internal Revenue Service Form W-8BEN or W-8BEN-E (or any successor
form or other applicable form) and certify under penalties of perjury that such Non-U.S. Holder is not a United States person
as defined under the Code and is eligible for treaty benefits, or (b) if the Common Stock are held through certain foreign intermediaries,
complete Internal Revenue Service Form W-8IMY and all required attachments (or any successor form or other applicable form) and
satisfy the relevant certification requirements of applicable Treasury regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder of Common Stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain
a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
or Expiration of Warrants</I>. The U.S. federal income tax treatment of a Non-U.S. Holder&rsquo;s receipt of a share of Common
Stock upon the exercise of a Warrant by a Non-U.S. Holder, or of the expiration of a Warrant held by a Non-U.S. Holder, generally
will correspond to the U.S. federal income tax treatment of the receipt of a share of Common Stock upon exercise of a Warrant
by a U.S. Holder, or expiration of a Warrant held by a U.S. Holder, as described above in &ldquo;<I>U.S. Holders &ndash; Sale
or Other Disposition, Exercise or Expiration of Warrants</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Constructive Distributions on Warrants</I>.
An adjustment to the number of shares for which a Warrant may be exercised or to the exercise price of a Warrant may result in
a constructive distribution to a Non-U.S. Holder of such Warrant. Such constructive distribution would be subject to tax as described
under &ldquo;<I>Non-U.S. Holders &ndash; Distributions</I>&rdquo; above in the same manner as if you received a cash distribution
from the Company equal to the fair market value of such increased interest. Any resulting withholding tax attributable to deemed
dividends would be collected from other amounts payable or distributable to you. You should consult your tax advisor regarding
the proper treatment of any adjustments to the Warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sale
or Other Disposition.</I>&nbsp;Any gain realized by a Non-U.S. Holder on the disposition of Common Stock will not be subject to
U.S. federal income or withholding tax unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively
    connected with a trade or business of the Non-U.S. Holder in the United States (and, if required by an applicable income tax
    treaty, is attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Non-U.S. Holder
    is an individual who is present in the United States for 183 days or more in the taxable year of disposition, and certain
    other conditions are met; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company is or
    was a U.S. real property holding corporation (A &ldquo;USRPHC&rdquo;) during the shorter of the five-year period ending on
    the date of the disposition or the period that the Non-U.S. Holder held Common Stock. Generally, a corporation is a USRPHC
    if the fair market value of its &ldquo;U.S. real property interests&rdquo; (within the meaning of the Internal Revenue Code)
    equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used
    or held for use in a trade or business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder described in the first bullet point immediately above will generally be subject to tax on the net gain derived
from the sale under regular graduated U.S. federal income tax rates in the same manner as if the Non-U.S. Holder were a United
States person as defined under the Code, and if the Non-U.S. Holder is a corporation, may also be subject to the branch profits
tax equal to 30% of its effectively connected earnings and profits or at such lower rate as may be specified by an applicable
income tax treaty. An individual Non-U.S. Holder described in the second bullet point immediately above will be subject to a flat
30% tax (or at such reduced rate as may be provided by an applicable income tax treaty) on the gain derived from the sale, which
may be offset by U.S. source capital losses, even though the individual is not considered a resident of the United States. In
general, a Non-U.S. Holder described in the third bullet point above will be subject to U.S. federal income tax under regular
graduated U.S. federal income tax rates with respect to the gain recognized in the same manner as if the Non-U.S. Holder were
a United States person as defined under the Code. We believe we currently are not, and we do not anticipate becoming, a USRPHC
for U.S. federal income tax purposes. Because the determination of whether we are a USRPHC depends on the fair market value of
our U.S. real property interests relative to the fair market value of our other trade or business assets and our foreign real
property interests, there can be no assurances that we will not become a USRPHC in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;If
a Non-U.S. Holder is subject to U.S. federal income tax on any sale, exchange or other disposition of the Common Stock, such Non-U.S.
Holder will recognize capital gain or loss equal to the difference between the amount realized by the Non-U.S. Holder and the
Non-U.S. Holder&rsquo;s adjusted tax basis in the Common Stock, as applicable. Such capital gain or loss will be long-term capital
gain or loss if the Non-U.S. Holder&rsquo;s holding period for the Common Stock, as applicable, is longer than one year. A Non-U.S.
Holder should consult its own tax advisors with respect to applicable tax rates and netting rules for capital gains and losses.
Certain limitations exist on the deduction of capital losses by both corporate and non-corporate taxpayers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Information
Reporting and Backup Withholding.</I>&nbsp;Generally, the Company must report annually to the Internal Revenue Service and to
each Non-U.S. Holder the amount of dividends paid to such Non-U.S. Holder and the amount, if any, of tax withheld with respect
to such dividends, regardless of whether withholding was required. Copies of the information returns reporting such dividends
and withholding may also be made available to the tax authorities in the country in which the Non-U.S. Holder resides under the
provisions of an applicable income tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder will generally not be subject to backup withholding on dividends paid to such Non-U.S. Holder as long as such
Non-U.S. Holder certifies under penalties of perjury on an IRS Form W-8BEN, W-8BEN-E, or other appropriate version of IRS Form
W-8, that it is a Non-U.S. Holder (and the payor does not have actual knowledge or reason to know that such Non-U.S. Holder is
a United States person as defined under the Code), or such Non-U.S. Holder otherwise establishes an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the circumstances, information reporting and backup withholding (at a rate of 28%) may apply to the proceeds received from
a sale or other disposition of Common Stock unless the beneficial owner certifies under penalties of perjury (as set forth in
the previous paragraph) that it is a Non-U.S. Holder (and the payor does not have actual knowledge or reason to know that the
beneficial owner is a United States person as defined under the Code), or such owner otherwise establishes an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
backup withholding tax is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund
or a credit against a Non-U.S. Holder&rsquo;s U.S. federal income tax liability provided the required information is timely furnished
to the Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>FATCA.&nbsp;</I>The
U.S. Foreign Account Tax Compliance Act (&ldquo;FATCA&rdquo;) will generally impose a 30% withholding tax on dividends on the
Common Stock (and, after December 31, 2018, on the gross proceeds of a disposition of Common Stock) that are paid to: (i) a foreign
financial institution (as that term is defined in Section 1471(d)(4) of the Code and the Treasury regulations thereunder) unless
that foreign financial institution enters into an agreement with the U.S. Treasury Department to collect and disclose information
regarding U.S. account holders of that foreign financial institution (including certain account holders that are foreign entities
that have U.S. owners) and satisfies other requirements, or is otherwise exempt from FATCA withholding; and (ii) a non-financial
foreign entity (as that term is defined in Section 1472(d) of the Code and the Treasury regulations thereunder) unless such entity
certifies that it does not have any substantial U.S. owners or provides the name, address and taxpayer identification number of
each substantial U.S. owner and such entity satisfies other specified requirements, or otherwise is exempt from FATCA withholding.
Intergovernmental agreements entered into between the United States and a foreign jurisdiction may modify these requirements.
A Non-U.S. Holder should consult its own tax advisor regarding the application of this legislation to it. FATCA withholding will
apply to dividends paid on shares of Common Stock, and after December 31, 2018, to gross proceeds from the disposition of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTORS
CONSIDERING THE PURCHASE OF SHARES OF OUR COMMON STOCK ARE URGED TO CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF
THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE APPLICABILITY AND EFFECT OF U.S. FEDERAL ESTATE AND GIFT
TAX LAWS AND ANY STATE, LOCAL OR NON-U.S. TAX LAWS AND TAX TREATIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a018_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters with respect to the shares of Common Stock offered hereby will be passed upon by Sheppard, Mullin, Richter &amp;
Hampton LLP, New York, NY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a019_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of ADiTx Therapeutics, Inc. as of December 31, 2017, which includes the balance sheet as of December 31,
2017 and the related statements of operations, stockholders&rsquo; deficit, and cash flows for the period from September 28, 2017
(inception) to December 31, 2017 included in this preliminary Offering Circular have been audited by dbb<I>mckennon</I>, independent
registered accounting firm, as stated in their report appearing herein, which report expresses an unqualified opinion on the financial
statements and includes an explanatory paragraph about the existence of substantial doubt concerning the Company&rsquo;s ability
to continue as a going concern. Such financial statements are included in reliance upon the report of such firm given upon their
authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a020_v1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a Regulation A+ Offering Statement on Form 1-A under the Securities Act with respect to the securities
offered hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information
set forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the securities
offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained in
this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering Statement
are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract
or other document filed as an exhibit to the Offering Statement. Upon the completion of this Offering, we will be required to
file periodic reports, proxy statements, and other information with the SEC pursuant to the Securities Exchange Act of 1934. You
may read and copy this information at the SEC&rsquo;s Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains
an Internet website that contains reports, proxy statements and other information about issuers, including us, that file electronically
with the SEC. The address of this site is <I>www.sec.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shareholders and the Board of Directors of ADiTx Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheet of ADiTx Therapeutics, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2017, the
related statements of operations, stockholders&rsquo; deficit, and cash flows, for the period from September 28, 2017 (&ldquo;Inception&rdquo;)
through December 31, 2017, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2017, and the results of its operations and its cash flows for the period then ended, in conformity with accounting principles
generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on
the Company&rsquo;s financial statements based on our audit. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audit provides a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note
2 of the financial statements, the Company has incurred losses since Inception and requires additional financing. These factors
raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans with respect
to these matters are discussed in Note 2. The accompanying financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    dbb<I>mckennon</I></FONT></TD>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newport
Beach, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
30, 2018, except for the last paragraph in Note 7, as to which the date is July 3, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BALANCE
SHEET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
    31,</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ASSETS</U></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT ASSETS</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 85%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL CURRENT ASSETS</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TOTAL ASSETS</U></B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>LIABILITIES
    AND STOCKHOLDERS&rsquo; DEFICIT</U></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT LIABILITIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,566</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation
    to related party</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,334</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL CURRENT LIABILITIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,900</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit on private
    placement</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL LIABILITIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,900</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITMENTS AND CONTINGENCIES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; DEFICIT</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock,
    $0.001 par value, 3,000,000 shares authorized, 0 shares issued and outstanding</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $0.001
    par value, 27,000,000 shares authorized, 7,100,000 shares issued and outstanding</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in
    capital</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">145,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL STOCKHOLDERS&rsquo;
    DEFICIT</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(59,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL LIABILITIES
    AND STOCKHOLDERS&rsquo; DEFICIT</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENT
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Period From</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 28, 2017 </B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Inception)
    Through</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December 31, 2017</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REVENUE</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPERATING EXPENSES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation
    and services contributed by founders</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,086</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
    expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Operating Expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET LOSS FROM OPERATIONS</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER EXPENSES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Other Expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; padding-left: -0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss before provision for income taxes</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision for income
    taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET LOSS</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share
    - basic and diluted</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.03</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average
    number of shares outstanding during the period - basic and diluted</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENT
OF STOCKHOLDERS&rsquo; DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid-in</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accumulated</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Par</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deficit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deficit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance September 28, 2017 (inception)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of founders&rsquo;
    shares</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock option compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,086</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,086</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of services contributed by founders</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,900</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,900</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance December
    31, 2017</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">145,986</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(59,900</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENT
OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Period From</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 28, 2017</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Inception) Through</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December 31, 2017</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 85%; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,986</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adjustments to
    reconcile net loss to net cash used in operating activities</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation
    and fair value of services contributed by founders</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,086</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes in operating
    assets and liabilities</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable
    and accrued expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,566</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation to related party</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,334</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Cash Used In Operating Activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit on private
    placement</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Cash Provided By Financing Activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET INCREASE IN CASH</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH AT BEGINNING
    OF PERIOD</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH AT END OF
    PERIOD</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supplemental cash flow information:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for income taxes</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest expense</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &ndash; ORGANIZATION AND NATURE OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
Background</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADiTx
Therapeutics, Inc (&ldquo;ADiTx&rdquo; or the &ldquo;Company&rdquo;) was incorporated on September 28, 2017, under the laws of
the State of Delaware. The Company is a pre-clinical stage, life sciences company with a mission to prolong life and enhance life
quality of transplanted patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
and Uncertainties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a limited operating history and has not generated revenue from intended operations. The Company&rsquo;s business and
operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal
governmental policy decisions. A host of factors beyond the Company&rsquo;s control could cause fluctuations in these conditions.
Adverse conditions may include: changes in biotechnology regulatory environment, technological advances that render our technologies
obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition
from larger more well-funded companies. These adverse conditions could affect the Company&rsquo;s financial condition and the
results of its operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 &ndash; GOING CONCERN ANALYSIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Going
Concern Analysis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated on September 28, 2017 and has not generated revenues to date. As of December 31, 2017, the Company had
a net loss of $212,986 and will require significant additional capital in order to operate in the normal course of business and
fund clinical studies. The Company will be conducting medical research and development and the time at which the Company will
begin generating revenue is unknow. As a result of these conditions, there is substantial doubt about the company&rsquo;s ability
to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue
as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification
of assets or the amounts and classification of liabilities that may result from the matters discussed herein. While we believe
in the viability of our strategy to generate sufficient revenue, control costs and the ability to raise additional funds if necessary,
there can be no assurances to that effect. The Company&rsquo;s ability to continue as a going concern is dependent upon the ability
to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&ldquo;US GAAP&rdquo;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those
estimates. Significant estimates underlying the financial statements include the fair value of stock options and fair value of
services contributed by founders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentrations
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation.
At times, the Company may have deposits in excess of federally insured limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
and Cash Equivalents </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less when purchased&nbsp;to be cash
equivalents. As of December 31, 2017, the Company did not have any cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize revenues from licensing or manufacturing when (a) pervasive evidence that an agreement exists, (b) the
product or service has been delivered, (c) the prices are fixed and determinable and not subject to refund or adjustment, and
(d) collection of the amounts due are reasonably assured. No revenues have been generated to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs consist primarily of non-capitalized development and maintenance costs. We expense these costs
as incurred unless such costs qualify for capitalization under applicable guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation costs under the provisions of ASC 718, <I>Compensation&mdash;Stock Compensation</I>,
which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC 718 is also applied to awards modified, repurchased, or canceled during the periods reported.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation for Non-Employees</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants and options issued to non-employees under ASC 505-50, <I>Equity &ndash; Equity Based Payments to
Non-Employees, </I>using the Black-Scholes option-pricing model. The value of such non-employee awards unvested are re-measured
over the vesting terms at each reporting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies ASC 740, <I>Income Taxes</I> (&ldquo;ASC 740&rdquo;).&nbsp;&nbsp;Deferred income taxes are recognized for the
tax consequences in future years of differences between the tax bases of assets and liabilities and their financial statement
reported amounts at each period end, based on enacted tax laws and statutory tax rates applicable to the periods in which the
differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax
assets to the amount expected to be realized. The provision for income taxes represents the tax expense for the period, if any,
and the change during the period in deferred tax assets and liabilities. At December 31, 2017, the Company has established a full
allowance against all deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 also provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax positions.&nbsp;&nbsp;A
tax benefit from an uncertain position is recognized only if it is &ldquo;more likely than not&rdquo; that the position is sustainable
upon examination by the relevant taxing authority based on its technical merit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basic
and Diluted Net Loss per Common Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding
for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common
stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number
of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of December
31, 2017, 240,000 stock options were excluded from dilutive earnings per share as their effects were anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2016, the FASB issued ASU&nbsp;2016-15, <I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts
and Cash Payments</I> (&ldquo;ASU&nbsp;2016-15&rdquo;). ASU&nbsp;2016-15&nbsp;will make eight targeted changes to how cash receipts
and cash payments are presented and classified in the statement of cash flows. ASU&nbsp;2016-15&nbsp;is effective for fiscal years
beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable
to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company
is currently assessing the impact of this ASU on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the FASB issued ASU 2016-18, <I>Statement of Cash Flows (Topic 230),</I> requiring that the statement of cash flows
explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash
equivalents. This guidance is effective for fiscal years, and interim reporting periods therein, beginning after December 15,
2017 with early adoption permitted. The provisions of this guidance are to be applied using a retrospective approach which requires
application of the guidance for all periods presented. The Company is currently assessing the impact of this ASU on the Company&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU 2016-02, <I>Leases (Topic 842)</I>, specifying the accounting for leases, which supersedes
the leases requirements in Topic 840, Leases. The objective of Topic 842 is to establish the principles that lessees and lessors
shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows
arising from a lease. Lessees are permitted to make an accounting policy election to not recognize the asset and liability for
leases with a term of twelve months or less. Lessors&rsquo; accounting is largely unchanged from the previous accounting standard.
In addition, Topic 842 expands the disclosure requirements of lease arrangements. Lessees and lessors will use a modified retrospective
transition approach, which includes several practical expedients. This guidance is effective for fiscal years, and interim periods
within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently reviewing
the provisions of the new standard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that
amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
Inception, the Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;) has provided services without payment. Accordingly,
the company has accrued $51,000 in compensation for services rendered through December 31, 2017. Future compensation is being
accrued at $15,000 per month. As of December 31, 2017, the CEO is owed $51,334.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to year end, the company entered into a licensing agreement and various debt instruments with a related party. See Note 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 for services provided by founders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 - STOCKHOLDERS&rsquo; DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preferred
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized the issuance of 3,000,000 shares of preferred stock, par value $0.001 per share. See Note 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized the issuance of 27,000,000 shares of common stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2017 the Company issued 7,100,000 shares of its common stock at $0.001 per share. In addition, the founders provided
certain services to the Company during the formation process in order to develop a business plan, provide legal services, among
other services. We have valued these services at $63,900 and recorded such amount and the par value of the founders shares as
an expense in the accompanying statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2017, the Company commenced a private placement for the sale of 1,000,000 shares of common stock for gross proceeds of
$2,000,000. The terms of the private placement were such that a minimum of $250,000 was to be raised before funds could be drawn
on, and that the technology licensing agreement (Note 7) must be executed. As of December 31, 2017, the Company had received $25,000
under this placement but had not yet met any of the terms required to close on the funds. Accordingly, the amount is included
in long-term liabilities in the accompanying balance sheet. In 2018, this amount was transferred to equity upon the conditions
of the private placement being met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, our Board of Directors adopted the ADiTx Therapeutics, Inc. 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;).&nbsp;
The 2017 Plan provides for the grant of equity awards to employees, and consultants.&nbsp; Up to 1,200,000 shares of our common
stock may be issued pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and
expires ten years after adoption, unless terminated earlier by the Board.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2017, the Company granted 240,000 stock options with exercise prices of $2.00 per share vesting monthly over one year. The total
grant date fair value was determined to be $437,793 The fair value of each stock option granted was estimated using the Black-Scholes
assumptions and or factors as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 57%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend
    yield</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest
    rate</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.94%
    - 2.01</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life in
    years</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">151</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate assumption for options granted is based upon observed interest rates on the United States government securities
appropriate for the expected term of stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term of stock options is calculated using the simplified method which takes into consideration the contractual life and
vesting terms of the options, unless the options are expected to vest in which case the contractual term is used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the expected volatility assumption for options granted using the historical volatility of comparable public
company&rsquo;s common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected
volatility for future stock option grants, until such time that the Company&rsquo;s common stock has enough market history to
use historical volatility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dividend yield assumption for options granted is based on the Company&rsquo;s history and expectation of dividend payouts. The
Company has never declared or paid any cash dividends on its common stock, and the Company does not anticipate paying any cash
dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
estimated the fair value of common stock by looking at a market approach which takes into consideration the value of development
to date sale of stock to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an analysis of the stock option grant activity under the Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining</B></FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Life</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock Options</I></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding September 28, 2017 (inception)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding December
    31, 2017</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.82</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized compensation expense related to options issued of $82,086 during the period ended December 31, 2017, which
is included in stock-based compensation and services contributed by founders in the accompanying statement of operations. The
remaining $355,707 is expected to be recognized in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &ndash; INCOME TAX PROVISION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Tax Cuts and Jobs Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act, or &ldquo;TCJA&rdquo;, reduced the U.S. federal corporate income tax rate from 35% to 21%. As a result,
carryforwards have been calculated to recognize the effect of future rates on deferred tax assets and liabilities. As 2017 was
the Company&rsquo;s first year of operations there was no need to revalue historical deferred tax assets and/or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2017, the Company has available for U.S. federal income tax purposes a net operating loss (&ldquo;NOL&rdquo;) carry-forwards
of approximately $60,000 that may be used to offset future taxable income through the fiscal year ending December 31, 2037. If
not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership
change as determined under the regulations. The Company plans on undertaking a detailed analysis of any historical and/or current
Section 382 ownership changes that may limit the utilization of the net operating loss carryovers. No tax benefit has been reported
with respect to these net operating loss carry-forwards in the accompanying financial statements since the Company believes that
the realization of its net deferred tax asset of approximately $18,000 was not considered more likely than not and accordingly,
the potential tax benefits of the net loss carry-forwards are fully offset by a valuation allowance of $18,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the
deferred tax assets because of the uncertainty regarding its realizability. In assessing the realization of deferred tax assets,
management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which
temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal
of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration
of all the information available, Management believes that significant uncertainty exists with respect to future realization of
the deferred tax assets and has therefore established a full valuation allowance. The valuation allowance increased by approximately
$18,000 for the period from Inception through December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components
of deferred tax assets are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets &ndash; Non-current:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected income tax benefit
    from NOL carry-forwards</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,000</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets,
    net of valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income
taxes is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Period from </FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 28, 2017 </FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(inception) through </FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2017</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal statutory income
    tax rate</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.0</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation
    allowance on net operating loss carry-forwards</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34.0</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective income
    tax rate</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 - SUBSEQUENT EVENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to year end, the Company amended the articles of incorporation to authorize the issuance of 3,000,000 shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2018 the Company entered into an unsecured promissory note with a related party for $40,000 that accrues interest
of 4% annually. The note is due on the earlier of July 22, 2018 or in the event of default, as defined in the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 12, 2018 the Company entered into an unsecured promissory note with a related party for $50,000 that accrues interest
of 4% annually. The note is due on the earlier of August 12, 2018 or in the event of default, as defined in the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 2, 2018 the Company entered into an unsecured promissory note with a related party for $10,000 that accrues interest of
4% annually. The note is due on the earlier of September 2, 2018 or in the event of default, as defined in the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, $75,000 of the above loan balances were repaid with proceeds from the private placement funds described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first quarter of 2018, the Company received $262,500 in cash for shares of common stock under the private placement at $2.00
per share. Of this, $25,000 was received in 2017 and shown as deposit on private placement in the accompanying balance sheet.
The Company also agreed to issue one warrant to purchase a share of common stock for each share purchased in the private placement.
The warrant is exercisable at $2.00 per share and has a term of 5 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with Sekris Biomedical, Inc. (&ldquo;Sekris&rdquo;).
Sekris was a party to a License Agreement with Loma Linda University (&ldquo;LLU&rdquo;), entered into and made effective on May
25, 2011, and amended on June 24, 2011, July 16, 2012 and December 27, 2012 (the &ldquo;Original Agreement,&rdquo; and together
with the Assignment Agreement, the &ldquo;Sekris Agreements&rdquo;). Pursuant to the Assignment Agreement, Sekris transferred
and assigned all of its rights and obligations in and to and liabilities under the Original Agreement, of whatever kind or nature,
to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 1,000,000 shares of our Common Stock (the
&ldquo;Sekris Warrant&rdquo;). The warrant is immediately exercisable and the exercise price is $2.00 per share. The expiration
date of the warrant is March 8, 2023. On March 15, 2018, we entered into a Patent &amp; Technology License Agreement directly
with LLU (the &ldquo;New License Agreement&rdquo;), which amends and restates the Sekris Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to year end, the Company granted 825,000 stock options to various individuals. Of these amounts, 525,000 were fully vested upon
grant and the remaining vest annual over three years. These options have a five-year term with an exercise price of $2.00 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 1, 2018, the Company entered into a consulting agreement with a company for project management services for $13,000 per
month plus any additional fees. The term of this agreement shall commence on March 1, 2018 and shall remain in effect, unless
earlier terminated, as provided in the agreement, until May 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 14, 2018, the Company entered into an agreement with a broker/dealer to provide financial advisory and placement agent services.
On March 14, 2018, an initial retainer fee of $55,000 was paid to the placement agent as an advance for out-of-pocket accountable
expenses with an additional $10,000 paid upon the filing of an offering statement as defined by the agreement (together, the &ldquo;Advance&rdquo;).
Under the agreement, as amended, the placement agent is entitled to a commission as defined by the agreement, based on the gross
proceeds received by the Company in the offering that are derived from the investors introduced by the placement agent, and warrants
exercisable for an amount of common stock of the Company equal to 10% of the shares of common stock sold in the offering for 125%
of the offering price of the securities. In addition, the Company is obligated to reimburse the placement agent for out-pocket
expenses in connection with the offering as defined by the agreement. The agreement may be terminated after 6 months by either
party.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Part
III - EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418007626/s111621_ex1-1.htm" STYLE="-sec-extract: exhibit">EX1A-1.1**</A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418007626/s111621_ex1-1.htm" STYLE="-sec-extract: exhibit">Form
    of Underwriting Agreement</A></FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-2.1**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Certificate of Incorporation</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex2-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-2.2**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex2-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws&nbsp;</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-3.1**&nbsp;</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Promissory Note issued to Sekris Biomedical, Inc.&nbsp; </FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-3.2**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant,
    dated March 8, 2018, issued to Sekris Biomedical, Inc.&nbsp;</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex3-3.htm" STYLE="-sec-extract: exhibit">EX1A-3.3**</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex3-3.htm" STYLE="-sec-extract: exhibit">Form
    of Underwriter&rsquo;s <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-4.1**&nbsp;</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Private Placement Subscription Agreement&nbsp;</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-
    4.2**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Offering Subscription Agreement</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><P STYLE="margin: 0"> <A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418007626/s111621_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-
                                         4.3**</FONT></A> </P>


</TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><P STYLE="margin: 0"> <A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418007626/s111621_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
        of Warrant Agent Agreement</FONT></A> </P>


</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex6-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-6.1**&nbsp;&#9642;</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex6-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    and Technology License Agreement, dated March 15, 2018 between Loma Linda University and ADiTx Therapeutics, Inc.</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex6-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-6.2**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex6-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017
    Equity Incentive Plan of the Company&nbsp;</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex6-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-6.3**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418004406/s110141_ex6-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreement, dated March 1, 2018, by and between ADiTx Therapeutics, Inc. and Canyon Ridge Development LLC d/b/a Mission Critical
    Solutions International</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex6-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-6.4**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex6-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escrow
    Agreement, dated July 3, 2018, by and among ADiTx Therapeutics, Inc., Network 1 Financial Securities, Inc., and MVB Bank,
    Inc.</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR>
    <TD STYLE="font-size: 10pt; width: 10%; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex6-5.htm" STYLE="-sec-extract: exhibit">EX1A-6.5**</A></TD>
    <TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 89%"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex6-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consulting
    Agreement, dated June 1, 2018, by and between ADiTx Therapeutics, Inc. and ICR, LLC</FONT></A></TD></TR>

<TR>
    <TD STYLE="width: 10%; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex6-6.htm" STYLE="-sec-extract: exhibit">EX1A-6.6**</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex6-6.htm" STYLE="-sec-extract: exhibit">Amendment
    No. 1 to Engagement Agreement, dated July 2, 2018, by and between ADiTx Therapeutics, Inc., and Network 1 Financial Securities,
    Inc.</A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s112118_ex11-1.htm" STYLE="-sec-extract: exhibit">EX1A-11.1&dagger;</A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s112118_ex11-1.htm" STYLE="-sec-extract: exhibit">Consent
    of dbbmckennon</A></FONT> </TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006622/s111403_ex12-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-12.1**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006622/s111403_ex12-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sheppard, Mullin, Richter &amp; Hampton LLP&nbsp;</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex13-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX1A-13.1**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006217/s110889_ex13-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
    Presentation &ldquo;Testing the waters&rdquo; materials</FONT></A></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"> <A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006622/s111403_ex13-2.htm" STYLE="-sec-extract: exhibit">EX1A-13.2**</A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0"> <A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000161577418006622/s111403_ex13-2.htm" STYLE="-sec-extract: exhibit">Video
                                    &ldquo;Testing the waters&rdquo; materials (transcript)</A> </P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;
Filed herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;
Portions of this exhibit containing confidential information have been omitted pursuant to a request for confidential treatment
filed with the SEC pursuant to Rule 406 under the Securities Act. Confidential information has been omitted from the exhibit in
places marked &ldquo;[***]&rdquo;and has been filed separately with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**Previously
filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form 1-A and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Loma Linda, State of California, on August 17, 2018.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADiTx Therapeutics, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Amro Albanna</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Amro Albanna&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Offering Statement on Form 1-A has been signed by the following persons in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Amro Albanna</FONT> </TD>
    <TD STYLE="width: 2%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 15%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 17, 2018</FONT> </TD>
    <TD STYLE="width: 43%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
        Amro Albanna&nbsp;</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
        Chief Executive Officer,&nbsp;Director</FONT><BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)&nbsp;&nbsp;&nbsp;</FONT> </P></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David Briones</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 17,
    2018</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
        David Briones&nbsp;</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
        Interim Chief Financial Officer</FONT><BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer and</FONT><BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer)&nbsp;&nbsp;&nbsp;</FONT> </P></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Shahrokh Shabahang</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 17,
    2018</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
        Shahrokh Shabahang</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
        Chief Technology Officer and Director&nbsp;&nbsp;&nbsp;</FONT> </P></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Leonard Bailey</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 17,
    2018</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
        Leonard Bailey&nbsp;</FONT> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
        Chairman of the Board of Directors</FONT> </P></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Options: NewSection; Value: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-11 CONSENT
<SEQUENCE>3
<FILENAME>s112118_ex11-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
11.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use, in this Offering Statement on Form 1-A, as it may be amended, of our report dated March 30, 2018, except for
the last paragraph in Note 7, as to which is dated July 3, 2018, which includes an explanatory paragraph as to the Company&rsquo;s
ability to continue as a going concern, with respect to our audit of the financial statements of ADiTx Therapeutics, Inc. as of
December 31, 2017 and the related statements of operations, stockholders&rsquo; deficit, and cash flows for the period from September
28, 2017 (Inception) to December 31, 2017, and the related notes to the financial statements. We also consent to the reference
to our Firm under the heading &ldquo;Experts&rdquo; in such Offering Circular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
dbb<I>mckennon</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newport
Beach, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
17, 2018</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ,@"7 P$1  (1 0,1 ?_$ +(   (" @,  P
M      D*  @'"P0%!@$" P$!  $% 0$               <! @8("04$$
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M%[B1U%QL0C.55M/BU@I64(I$52'75B2E.D+HIU13(!2G$.)0T X)X7?>C_\
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MD_=5NUP+:L:5UU=7\ECEC8%&<JT)'-V#6KT)C%.HYR\0590E;2.L90>R4#B
M^D.@-A?6*^QK->A:^R022:P\8SCT2%(4  K9 B8CT!PXF, B/RCH#Q>;L153
M/&',HX5NC%N]J>5J%::#/MUT$UR#'6B&=Q*JX)*%,0RS070+)B(?-4(4>L-
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M8PB(B.@%YN?QM6W Y,WJ[8,Q4'%]CM.-J_6ZQ"3MLB4D7$;$2<;>G4P[:R(
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E[J]4/OOW9UA[7]'H#KZA[G3^'/6'^%_=?7_4^D\_RZ ]1H#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ]@%; P$1  (1 0,1 ?_$ -D   $$ @,! 0
M       &!P@)!0H" P0!"P$!  $$ P$               ,! @0%!@<("1
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MP$I@,'](;ZOJ*N6E*-*4:4HTI1I2C2E&E*-*4:4HTI7A<2+-MN"BP"</^6F
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M5OC#+]E_R58OAKGGA7**C9#%^?:%;'JX *5?6G4X>QF\/Y?Z<L98F;%0/D5
MWX:A:)EY@BLV/*QYOY;J3W7X_<:G) YN2,=-M/,S-E! H"L4HE -_P"(2B #
ML(:C(J?B*?*$LL?)IE<1+\AP$ $2IJ!OUZ[&)X#^T-55W7ERJQHXY.8XTMVL
MV [$=EV'P\T@?3_O$ZB'[-3K,#P;@:Q),5EXIQ'XUGB'(H4#D,!RF#<#%$!
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M5(F9%T4Q3(."*% R2I#E$2&(J4P"4P"(& =P';6*16RO3^,I!1$"JMU .D<
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MQ,("(CKA11";D FN4:F L";5][2_U2_T!JNE>X4U-WFN(I)#U%-,1^8D*/\
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M)[22>)/K/Z;RWU2KJ-*4:4HTI7,BBB0]R:ATQ$-A$AC%$0^0B40W#0$CE5"
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M:2<93T+O:'Z42W H>3')H$_AUO7-VO7448*IQJ4.K:OHTI1I2C2E&E*-*5]
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ML.3TUG;9MD>UY2 '^<\BD$,KHQD4!T8 JVGGS!!(JW#7K*O/%  (B   B(]
M  W$1^0 'CI2N?E*=YDNPWFD)WG2V_FD)_7.G^^4G7Q$-M+&J:EM>XL:;_)&
M5,88<K*MTR[D>AXLJ"*Y6JEHR);H&F0/JCD,<C1.4L+^/:+/#D*(E1(8RI@#
M<"ZJ 3RH65>9I XCY5<8<_/EHK!G(O!^8)9!L=ZM#XVRE3+A,D8I@4RC_P"S
MPDP[DS,"%. BN"0I;#^]H58<Q5!(AX BG[U2KJ\[EJW=IF2<HIK)F#82J% P
M"'[=*4R=RP\PDB+/(0 :NNTYA0_Y:FX#N7MV$-C;[;> ZN![.PBWW\_L-4M;
ME51G(WB(=1:1LE#BB1-D2%5S)U=(I6\;.[;G5<0Q.B+"5-MOY(=J#@? "''Z
MO!WU#?2/@=113]:^5,$>-U&+R3X"62'*[6;&7X8<@\_#%HICR".;MZV\FOJ+
MR]F>+I?S F>?939(LMKM+C]@6<_%)#V:S>2,<RR"RUG*I*H*JH+I*(+H**(K
MH+$,DLBLD82*I*IG ITU4SE$#%$ $!#8=?+^:&;'F?'R$:/(C8JZ,"K*RFS*
MRFQ5E((((!!%C7O".2.:-9H65X74,K*0592+AE(X$$<01P(XBN&HZDHTI5AO
MMRYR/C;,7^'<R]\JH9:]/$E*L?9O'79J!_TW(%[OI2^YE,HP5'IW"JD(_N!K
MU]]&_FBW1?F-_H_<I=/3O4&F*Q/NQYJW^6DX\O$NT#=Y>._PBO.'U+=!+U/T
M5_J3"COO6SWDX#WGQ6MXR>O1PE7NTO;XJO:R)5"W.GS< &R;Y5OZN'7$-C-)
MR.-ZN*7*/B79VD!#?ZAS!\=?7=24:]?.*1!(A7U5EL'7(USH,4[<;ED6)!CI
M%$_11%TT$454U"CU Y#D$!_+6=6IIX=*4V.8;.2I8]L<N)^Q0C%9)#J("*JI
M!*4"[?'<=*4VN/84],Q9"M5R]DBK%GF943?28TO.F-(NQ4$?XDC.2I[C\$PU
MA.VIR>RMK$NB(#MM7Y^_N"9N5Y <OLUWQ-Z+V"96IW2*B8%#'1)6*2JK LCM
MP$1 J<@\;N'8[=!.X$?CK9PKHC [:XIFR^-DNW[(-A[!4,Q$"@)A'8  1$1^
M !U$?V!J6L6OT#O:5Q&GAOV^>.<*HV]-+7*K.<KV !3!-4\IDN0<65 %^@&,
MHV@W+- !-U J0!\-:J=M4IKEFWQ>%BJ".)%_OX_GM5C>H:S:@=S-Y/93Q2YI
M^%>,6+!S9R;R;"SER:5<JU:<,L:84J4M"0>0,S3=:LMWQTA?G46_L;6/@:NC
M-1BUAE53$%T@V;.E"R(M^)Y5#+);W0>/M]/3EZH?^S]@O',!5<@6BW5C)]DY
M*<=<DWWBM&9*Y(5M]7\M4O K1* R/BF@4&@R??$8/Q^KCV]QB*L;72$9RZK+
MU)W3U$4#EK(2#8<JMB4-[S<QZ?@+6_V5=CJ*LBC2E&E*-*4:4HTI1I2C2E,I
MR2Q"IG_CUF_![>=6JS_+&*[O1(:U-CJ)N*K89^!>-*U:$%$1*J1:N6$S5Z42
MCONA\?#5RFS U9*NM"/3N^^W*M/UN26B(C,V6;[F9G7.5,;F'#LW.8(3Q?E+
MEIR.POR#H>:*&6+KUXSH-/I]!XUQV6K_ !;511ZDSWGZW)L@;/G#19/S-'M'
M3D.SYV5GI-+(^4Q)#<A<W_WCW'A87X7)-=N>9'G7NOF7T=TOT9F[3L^!B]+8
M)Q8IL2 1SY2MI]_)?]IO='  +J+/\3&^[HZ "N7!2@!0!94 *'@4 .8.T/P#
M6[/,UU(AN@)XFPKHU2KJK)]WKCHGR,X*9:8,(_UMTQ0U3S113))%.\"1HR*[
MBQ1[<P@)P+,TQ>00,4O[Y^SY!J?'?1(.X\*P=QA\;&-OB7B/L]"/MJLW_MX<
M]*SM!RA@23>BLKC^<:7"L)'4$1+5KSZD'[=$##_8LK-'JJ;!L!1>_CJ7+2S!
MQVBL39Y=4;1']DW'L/ZZV1+2QE9.*78Q3@&JSDHI'6[C%$J9@^H $H@/76(K
M%3=20:W# ,+$ TQZ."%53B=[+;F,(B82E$1$1\1W$1ZCJI<GG2UN5JSS;!<&
MGMZAXNL/QV#MU34:K:E VP_44-A,W.L(?US;Z7-+4H6^/JHVV[(I =OB8H&'
M_*&J7I85G6D!#LS%,UCFR1RB':8B10, _#80 .NE+"HP9AYY</,!W%#'>5\_
MTFNW]>0BH@](C4Y^[6QA+3QBE@HJ;@*%"VB2K\I-]V[-L^3;KNB_4D0X==7!
M&-1&9 ;#C52')/G?%<T\N.>,?'#EG!8=P-,Q.0L,&S?B[+$#1<O6OF:]PV_R
MGB['\J25*UO&/>/D/&L7#.:E6!8V6EK@B6#!RV22<%7E50/6:A=R_$&R^GYO
MS =MZ](N'XXY&FXQKQCP](9!Y 7:\\*N6F-,:<>LH7R&S1"0E\Q]*X7Y:X;M
MW)FOV=S-X8A,49 Q\ZLT@ZMLXV02?.D52HO%7"**]W9QY59S/"U_TV ]+\ZF
M?>N&7.7#V6L/<C.0=>DO<1GJ/0L[,9[)V-W83F6,;)7WCY)T2EX8JN!+0>NU
M:>IE7R"H1Z>[UA%M9[&X<*/9B*!0I!+:&4\*JR,MB1VC\WIW^JHZ-,?O<FU2
MO8UK/#;F7)WFK07M7X>A[95>.]ZPQE[%%,XN4&2L^;K+C#D#EICC*M4"WA<9
MUS6U))*::&?>:J?M>,NX377'?Z_PXU2S=M^[\>'=[*F97^9GN-1&1H3CMR&R
M!@?C=>L1X\R1F7/=F<8;D<QS[[BAC'&AIB.Y1O;:C>J;B5Q(6_(,I&5F2A*Y
M&K(,+"SF>U8K<K$BENE;WJ[6]M)N+>T</PX?K[+5(_C=[C6865EJF.N:^.*C
M6E)^O8(7FLZ8J0F82A8?R/R8(]=X2P+R4I5OE962QME:Y19& B\B)*9@6TC,
ML&CP8XSYB9S:R"UQ5Z2F]FY>GI[3[+W)B E$2F 0,41 P"&P@(#L("'P$!U%
M63SXCE2)N%+C;6R.DND1-V4HBBX*4 .!@#H B'40WU4&U*I:YC<9':2DE?*[
M&B2PQJ9E[''M4=BV",0*/?,-TR!]<NP2+NJ !NX1 1ZG('=X1^K?Z>(NI,"?
MS5Z)@MU+C)KS\>-?_5PJ/>R$4<\F%1>2PO-$"3=T&KUI].OG,^RY<70'5$U]
MDF;3B3.?_3RL>$+$_P#(D/P7X1N;?"QM5Z @( (=0'J _,!U\N001<<J]ZD$
M&QYU]TI7>T=NX]VTD(]PHT?L'3=\Q=I&$JK5ZS6(Y:.4S!L)5$'"13 /S#4L
M&1D8D\>7B.8\N)U=&' JZ$,C#UJP!'K%1RPPY$+X^0H?'D0HZGDRL"K*?402
M#6U_@W):&7\1X_R2@)"KV>NLW4HDF.X-9]IW1\^V^&WDS#18 #^KMK[Y>5_6
MD/F)Y>[1UG%;Q,[#1I0/V9TO'.O^[,CV]5J^1'7G2\G1?6.X],/?1B9++&3^
MU$WOPM]L;+]MZQ6-5/T;FF^4[^RC;*5O<8=/H5,/NI#&D$T@WZ G)I+>'PUV
M1$VI!WBNOLA=,I[CQJ5NI*AJ+7))0TP>@44@B/ZIMT0U<IE'J9D5VFJ[W_ &
MR9Q_9JC&RD^JKD&IPO>:;[FKDT,-<6,ZY*24!!:GXTMDI&F P)B633B'+:%*
MF;H '^YKH 7\=M8<8U.%]=;'(?PH'D[E-?F\@953^8NH95=01475.(F.JNH(
MG65.8>ICJ*&$PB/B(ZW%<,]O.N9&QGJB3(F_>]629$VZCWNU"MR;!\1[E-*<
M^%?IX8T@$*GC;'=5;$!-O6*'3JZ@F78"D2A*[&QA"E .@  -?AK2DW)/KKFZ
M+I0+W 4MM4JZM:KW+Z%3+CSWM#'*G(YEQG6=\6,!6'"%Y8X-O]]O@MZ5DG.Z
M.51K^5Z*VD3XQI,=*V6()9FKEL5%[Z^.64<$(D"*NFW_ &6??,!,2"=L=EE#
M$BY# =A (/K''@1[#7:WDGYI;7Y0=<-U=O/3^V=38IP9\?Y/.75"&F72LPX,
M-<8Y>[<AB 5-F$^?9^QVZA^/V2,QN21YF?*#.UARC1Y>+M&2KA&6W$E9JM/P
MYBO(L5-9==.L@! 95KN.QM<8U>^45E&3;=!!)-N1(H;A$,420EBY1%4L>9L+
M7/K/;ZZZJEF7)RILM8TB265W"+?2@9BVA;_LJ+!>/*PI^EN6%S^V6ZPM<5[P
M+./O[BH.)128AR/'M$NT=3"MIN4<MA9/$9Y1TJJ)XQ-88PY")+@<5 ,$N@=]
M8_BGB0.%+IWFO(Z%G>8Y)7,;I7F(DK^I(RDK9YN+H2U?HU1Q_;A,T?+L1E&D
MQ(I9%;(*"L!F[)-HX='[TP*GIH'V4\1K=E_]GZ:3%EY4S578R]K=TVO/:<G8
M,ITR$9L;.X/;ALF+H*0E74E.?] >&;U*7<Q*Y 71$5&C15JY-YA5^PCP_OH9
MB">'#_;^BDTOG[+M3R-?*-*0L'<;2]N4!$UYA5D[+.T^L1,=AJ+O$Z=LV8,"
M6AT[EWKPHBD<Q@1[U' G\HGEC70I'"K1(XX'OI?47D?8[3=:I#V&E1U'K=N&
M#BXAW(O)>7=/[-+4)&XKP;2R0#*2I;:=9N_/;EB'ZS%ZX9H>M3.8IR)&M*@#
MAQJ02$MQX#]5Z:"P<DLST?(?(:!D'6-["@PY XVQ-@VJHU;),U:C(V+ L!E>
M=8(5^BQTI,7B81C3.Y$Z8J1Z#<".UE'B+1!%$W$)=WW#&R\N)C"X&7'%"NF0
MM[T(E8:4!+FUVM=0/>)8* *]';=Y;]&[YT]T]GXZ;ECO)T_F9^Y3F?#C@O%N
MDN#$QERG2/&C+Z(@;2LUXD6%Y9'<(&/]PN]S&,K-EN.Q51T:K2.,],S79F\E
M;;&A++7*YY2RIB1"K1#=&$4/^F8B8QF>177,FM+.&RWHVS15V8@ABIU7E283
MYZ01>!%AI,UW:^MY)(M(X?"#'J)XL0=(4M:M_/\ 3WL6)U-C=)Y&ZYQW3-ZE
MR-NA*00E!CX^%@YYGD)D \:2/,$*K=8$=?&EE2$,*3I^?6>XAJJ13#<;?I5W
M$9ARM%+UJGY'KM8DL,XOL=>IL(I GF2JV.,=7N2>/'9I^R(QT9#E(F11!9NJ
MBY-#_JC=(U-\=97*RRC2DBJ88V5%TW]X%R2=<@54X7!!!K8#R$Z"RY05WB7
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M!M"R% 4UWC%0S%W4+5B*22CVTOA?(6/9%U1\@X<F&L3M%H2&,K= NXC_ *4
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MM GK7C* 8,4W[X2!L*Z_F+"'B;4!8GG68J*O$#C3GZI5U&E*-*4:4HTI0 B
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MVGY,]:-T+YA8.YR.5VO(<8V2.PPS$+J/_C?1(#V:3WUKP .X .PAO\!#80_
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MB@#Q)!NDB_D" _,D9,15UM(MEW"6>*+<?$EQ!)&7)D^(+B&,ZM)6_P#&M<
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MPW#;<!^(?,-*4:4HTI1I2@!$! 0'80Z@(=! 0\! =*5K1\E,4Q&3^?W,4D]
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M5Q700=MG#)VW0>,GB1D'C)V@DZ9O&YP$#H.VJY%$'*!P'8Q#E,40\0TN15"
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M9:E,X=K6/ULKD]N-B3EWL>QKM"8WZ->U5RUBT$)@KN'? 82*E;*&7*9 03
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M<?A/.K=QQ_'@.D?Q%XC]%:!(;_$IR& 1 Q%"F(H0P#L8BA# !B*$,&QBB "
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M^UP/IZ?EM5B>HZFHTI1I2C2E&E*Y$()S%* @'<8 $QAV*4!']XP^!2E#J(_
M-!Q-J$V%ZU<[[FUURHR7.<WK)DRLPF"L,Y2M.,^.]CL4*O:,1<-WD6K*U1K<
M.=>"+2W38VC"7.^FR2,HTRE'':N:)#.8KT;UJT5>/3Y*BPM6"S7:YY^G+TY'
MUDU8=[2>)DV%;SKR@:8ND\&U;DS8,?,,2X:7NDY=ZS3,18:K\Q#,)G%[RPM(
MV1@L.9.R3;;/8Z?%@RCD&]9D&*R;)D5SZ1&*0CD*F@5AQ/+T]/MJWP $1
M1$1   .HB(^  'Q$=1@$FPYUD$V%SRJ@7W'.0B&2\C-,5U=^5U3L7.7:<JX;
M*@=I-7Q8HM9-4IB")%V]<;E%DF;J'GF<"'00'7R8^LCS=BZVZRCZ$V.8/TYL
M3N)64W2;./NRD$<&7'7^"IY:S*1V5]#_ *:/+E^E^F7ZMW6/1O>[*IC#"S18
M@]Z,<>(,Q_B,/W1'ZZK>ZB(  "(B(  % 3&$1'8 *4-Q,81Z  =1'7C.Q)L
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MD29FDDPCZ;5453;"]MEO? E"03<@=>U147"@=$DE#;!JQG1!=C:I8H99VTQ
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M)2+7,4!^:8#MKNW:OKP\M<E0-XVC>L.3MT#'R%^PB6)K?[M=7;A])76\!/\
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MZBDTFI%E7#]D5DJ+A),ISMRD$5 *'75C^9'0B123?U3$:.*<PMI?6?&75JB
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MA11"94VZ2'$W$9T<DZH1++K0"*7$(\!YO\V9-0$5>#C[P/D:(J13(\G%1SN
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-5-&E*-*4:4HTI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img003_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img003_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ [@(F P$1  (1 0,1 ?_$ ,(  0 ! P4! 0
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M (1'_;N.G5I0X?[NOWZ%+4)?M[]JPQE<1L#:@<IB>Q+LAJI9T8IU]>FVH/\
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M[K6^;K<=XY]N3L(E5QZ7+PS/?[$<E7PD\8<C V!."F_\DU0_-Y <A%RLFO\
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MLOIJ:&LKL(!?X3,K,=23UD:91A4Q9&3S8[;?93Q(LF8XR(H!M["TZH :JKR
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MB;^J_BFJ6%H.Y217W$A=[E5>I.[,C*IG.2YEPS)?;CQ&F'+1HG"($,(C'>R
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M*^BZR9(<X\9H8>@3AQ6)8Y!(!1%YZ#)&6VT._:[)ACW&"]-Q<<;3;;TWU/E
M>TI_S&2H1&)W#.)D#,G.RZF&:Q'FFK1M)(M&G5!9<W%=A[5%YESN0E7_  [:
MPZCZ5W&:7&!@=)EM^FU2S0_4"]ETXT=96)[F>&R[G!)/-$E9A6HB[]4[",51
M/AOK=P[+3>JLN!G^<P\P \=OA/5X3U77W,^/'>?=)[&D1I$:1&D1I$:1&D1I
M$:1&D1I$:1&D1I$\ZO\ 5?HVXWZJ'N_N3:8<=>S'$Y2OR0 FHS#7&.%-)X]]
MU\A*WZ_QU@?ZS\9]1^V(AXNX@;I@SD^=R)=5%JP<!B5.-&P*.9FE?5,HH$9M
M[H@E+<ZIMMOK2+E"[/P^$V>W=V)F./*D*7#CX0,9?J1MKN.DMUQ]"1MKZ@$
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M9G.;HP\IZL_L<92-[+/:+'%%%&/;)P0R@KZHC7%^+MHB[_AVZZ* !1B?./\
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M)=S<?92 Q;$%12^*ZGQG8@+G25\FY "!)3RDPQ[C]IAZ.Y]RS4K>T?5=@?\
MM<^S?,3;<0>YI#A-]@;=>NO+OZA$P\7;9;KTF+.(6/T//O%)RQC*'WZ9"8&
M@I%@PY-+9L1XH&@HA$KA"AJFZD2*NM-'IKRNA/6=;F(OM#33$OO-69$:XHXT
MOR-1J*%CSSZM"J2'+*RGMA506T+H@(+1.K\=EW^.F]*VQ@9F.FQ_TP;/JR?X
MS:<IG$YRB/ JNNV^;4L2-&%M")ORR%#^XNZBRP)N)^"JO\=>D)=ZR,F>/;8U
M&I\9)'N$IDJ\< !;^AGG)MH4ESL450$G-UTP'"3T9E*T2)\%ZZJW5K;[9E'
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M5.PS%1ZJJ>NM2WLI"L=)H=5-><2.>46W;&[LA>[4F"Q71F^QH&A!1BME))!
M4(7%>4E)"Z[ZMOL!QLZ8UF/B@"S3K,>\B?2'74-,Z+#I+ES,+Q?)YS^LBD;A
M=Y%\H(8(NW447\-7<)1L<]\S@?N3NW) )\96;>ECO4RO,M.!*=-LHQ(YL#0,
M]Y"#J(B+Y#4.BIJ^MF8L#T$J-2%<D:XE)R%^%;8S%N ;D=KT%T)S!$KKC4B/
MN#[1 VFY&AC\J(B]"U>!D$GK,0 UF!V:PH-;)FV4%_ST\J,\DN.XV@/-&;1H
M;!"GHX/JF_XZSH[^YC,SWU5E<XUQ/7C]A1-E['/9N3&Z,+[6/;^K2*FRH'^E
M6*]J*G\!VUV*R2HSX3YQ\!R!TF6>K)&-(C2(TB-(C2(TB-(C2)^:']TPQ)E_
MI^\:-1G8#!)[IL"4Y-FXVQ"C,AA/(Q..O.O$#0;#Z*2^J_'62YB:6/<$R_A^
MNPYZ SSX+?)PK9+42C2'D\I6E"7/;(I-9"$B)I25IE !76EW(-U4/1476)+5
MV#.-V/";MQK<[?&52L!JV6+&DRFY<UADG!4%<=?:$S,G2)&D1@.GKWEL.^R)
M\=>^Y63)8L;U>,FNLQEJ97LG"LG9\E'FT*&=9,FBT)IOWOSB4(Z=QJJ=@ X6
MW55UEMJ]TGU#9V$W<>\ "ME)(E\PL0J8\J#Y7%7QFCBQ!*4"+Y%3S*X.W]M$
M(OE[$3II0@4^T=5&DUV!"N]1@F9)XYA_D3P5->\ZXC30Q'&GO'';=38B,BE-
MNJ^:EM_AV5>GPUK?TUX'02'#8^\/C,K\<P>3CF/2I.0&4NUFK$ES0:B=Z RV
M"-M(*MMB(+XQ%%7;9%%=?.<M;"Q=>L^^_;+AM5&Z2QIU8YD,:KJ63D08<"PL
M[&,*2#B,S"-@Q:DN/]B>-R.!$*(H*BJOIKA<CE6594M@]Y]?P^)7?:+00/#Y
M31?UM305%'7K'BNK#&9(^M&.Z(SS=0398D/N)O*>C=?GWVZ==<B@*UON#J3/
MI7%X.%.@ Z"0AD,N!-8DQ9$-1C3!-%(@\C ND:JQX5$^]-AZ_!==ER[+ES^7
M\);0I;^IJ<S#BYKH;MP]'AQ8\B6$I&HOE[RC$\F_>Z6Z+Y4:%.J>NLJ^PQV8
MTSXS5?3MH.P>F<C)>-+YQB*T[9-T%@^L=(L0HTAF>XXHJ82F&@9",TQXBZ*:
M_**IU1.NNK7>R./:. !\9\ERZ@RE&'JEU<2TN9Q[ARNFQH63SUN(9655=V)1
M7;:.VZT#7UMUW/C'<D,HK8J)JK2+\OIOKK6<AN57[?(]2X^'\)\?S.'R>.WN
M5:#[9)V5X%G.;\I6;^,<<1\6HY4P&V**OM&[5BF^@!'Y$2JNYX-/R^TA,@$1
M.0YN@[F6RK\\EZTN^-*0TAR:6NH5[-; OP_A+.S3C#(;/(<@O;''68T.FF!7
MP(DE)53*=FMHB!)DQK)])IN(V3;KG?V..$:)LBJJ)UZBUB"ROZ3/F'KK0M[@
MUSI,9KFK".\S K.YZ<XQ("U$A $*7&!U5?;4$[U94E[=T1.NM-*EK0K]#,#;
M';3M*7*QUC((M=+9E.1YHT\,CCRU%5^H;?6.:LKMNH-O-;(N^^W\M2L.QF5=
M!*+% 88\Y(O&HE*0JB(3<.WBSW1FLNHJAYF&B;>$7%W,&R!ON0DW0576.OUL
M=TV8RHS),BFN01? <XZO)*\R"#(1\3;&3&51!)(M"YWP9#2=BN[;;EL73TO0
M(I.1]\@RC&)%S--&6TMJBQC_ $#862VY4LEOQNQ+%II&;1F*H[B+5@!^5M17
ML)53IMJ3>VPP/XRM:D1MR]91<"R5R#D%M44D8G6P[OI&9"N$81I&Q3H38)T*
M,V^*DNZHO8:;>FL/(HJP&QKF;J+2&PW3$[3/8??,9M[U/978UJQZ[(ZWW&<1
M1;V&IIW6%-&RRK-IU441^I1KL(57;N%13KTU;P!CD*!*/W5TLX97^W0STWT_
M^_\ Q_\ QK[[P^$^!'>:M)[&D1I$:1&D1I$:1&D1I$:1&D1I$:1&D32:[ 2I
M^&D3S0_UFZ9ES]77W3V9Q&I+09GC'U3?>K9)W\6X0U'?5=E539<!%3;XKKGV
M'<YSXF?0\'_T9G7^U3,S;JJ9F,(L>4W-IS3U)E]]]'FWU7HJ.=J+_'KJ8J3$
MZ(%^!_=(2S;'(N/VK]?"-'8034DH\Z2=X=BD11U3_ V)HG5>NW37*Y*A"2LZ
M'&NLTUUEV<7/I?VK]>8-S(S).5T5GQ(VLM9(JO<Z\G4W(HK\O14VU@SW,Z(=
M"-0-W>9OX(S3XY:PN*L4>DMP\;JI^=9E<-HJN.6KK),0(#CVRJXKCCB-B'39
M-E^*:R<CI-/[>J>Z67J3.\'VN\/IB-!B*V$0/S?D%2N6W)/#VN5L.0V2U5<T
M6PH!2&=C-%V7?IZ+JI1A0!X2SG7[B:VZ SYR1,9IL=?R*:B#-L;"[BP&G ,S
M57GPAMG':%$)QUSPH#2CZ]^H7@*R8[]9'AM2%&?"9%>RO"$J^(9MLN[LO+LC
MG61IMW  1'ABB*&G3?R$6ZIZ$*IZZN8!6VCH)1RVW7M_AS_*8\>YNX.=S#9U
M<8"F"VXS !UM=V(D.("))<<<3=&R%X]D;1.I=-9F #EAUF_]JJK];X]4CG@6
MEE3.79",=!J;>HBQM_\ K%]:K@=[S>RH!$"*O3X:Z-))J!/6.=<$J]OL)>W(
M5=OS9R)8  $K%]4U[9 0_)&JHC @ "GS#YB(B5%V7?UUZ=&W=YBXUA3B9K.,
MD_QE:S)M*W/\GL5$2ARK_',E(D$3[A-J$+<1-TV;)I6=D5?QWT)+')D#8PIV
M ^G65#WZD#UOQM-)?Z9#\]T!$R<D&_&CJYV"*?,K30K\W5.NJG5?K_%-/[4/
MS3+9XE%B?Q[[A,;:;5B#,PK[V *TJ(LIRQ*)&BD($*DBQ2\BET[=_32JQW3#
M>,KY[)59[G_U)#_/-&XO$^.(RK2.6'MKJON$EI204@,6;=22.INJD'<:HGHJ
M(G76JGVE7#=<ST6>XZ-Y3KJY*GN6U4Z]C[SIO8E>PL;-MD4<EL5[-+%2O)0!
M?[0.S&3[>FRKJN\5YWIU G24!F"'Z<2.K_(H\[%ZV\GPB*PDOSFY5D2*+QV,
M1AL9#) B$A=@HA+O\RJO\=456NX.XYUF*PI0YV?5.O\ RJYLENCF'*>0(=S4
M61_)_P"W:D6"1#<39=^X&757;XHGXZ[' .5;XB?/<O998&ZM,H,Z48,?&FZU
M7AB294*+(?(B1)[$Q4;;EHCFPML^0TW3?HFMFQ5^GO*"S!3\)$M=9N8AF=UB
M5XZIQYSOW:J)?F99>[D8?C"9*C;C2;HNR]-"2& '0SGACN(F//.%1*K/N=S%
MCLO-.B\4J&VRHM.-$V:BZ*]J-B]VZL]FM2"!J9FY5CJFA\9ZU?L$/R>Q?V8F
M@=B'[4_;V?;_ ,J'Q/BBH/\ --=%  HQX3@'4DS+C4IY&D1I$:1&D1I$:1&D
M1I$_+A^[0@+/_3GXMCHXK;1>[3CHY'RD;9MIA')6XNB)CNWOLO7INB:SLJMQ
MW)\3+N/Z']/4F>>[15SDM](BV33,821#%1\". .Y"B(*['T3^*ZX=-3,=?IE
MSV/N/QF1F+T<>J@MV)P^C*KV-K(:B,S%%5/ZF02$AC%0%VWZJ9=$34.0/;)"
MSJ<9BR 'PD\X5;9-;R686)T]5CC)-./V%\2I%$64%4<=2PEJ/@BBVBIL'SKO
MM\=8#RPI((.9T$5UU0:?"7Y3PJUR8U-L[%9*0D$1>D"T4=6&MU^M5A! RCJH
M[MKU[DZ]==+AMO ;L9"SWW)!Z?"3_P 29 V[>65D4HBQ^ PH-N1Q2(DAXE\:
M)&107="54ZDO3UUN?70])[QD9+MS=)DK'R^N=KHISYSZ/^1U%,6XQNR6W'D/
MR-M2%9Z"V':H*0@J)OZZQ\E*4JSCU3ZO@OFS*GTR4L0EX3R%%2-&Q^PM+1(S
MT*<]6-J+48E:=20^+"D0,DQ'7N1&R(55-^NOC?W*BET-P'J^/A/L?V]K1:"3
M^7,0LGPB^NY\]_(;.4D'')[M5!B(]]&#<:)W)';$65$3 F]C4E1/)OU77S=-
M_M#SS/NN,5=!C42+9>.1I5;-LU5UR/&DEY(K#0B^UXA1!)_N0MT<%%ZJB(B?
M'?6Q?W&UORF(]OX"=)>.IU4&0BM'%"ZB7=3NVW$EF[(CR !QA45UL_(@*B[$
MV*_,BKMMJ?Y2C\O._P",T,"*MIF0&4-3,Y#'G*W'5?K:P46PNFW66I\Z>ZT$
M4R22J$X-=$C[BX._9V[[]J)JVCEV5MMM&6[?"<"_BTL2Y'J^)D:XI@ME;9HS
M$I$JA=27)KHJ.N^=AA(KXIWOR&4,7Q;\9>(A55+;IMOKJ-R+77=7ICRG"YJU
M;?;8>F=C?M<ORQ[.8K63AQ^+U59+!I;3(8<FNB5]K6/%9.Y<M@S.?;8E,FR(
M(\['> B41\6ZJJ<U*7N+56:HS9/;6?,<RU*TVIC;]LA#W$<JP,ARG.<@R,H>
M4VMQ9Y393KX776V+.PC^9*=^!YHS" W&9:;=;\0 XXG:A=?7[;]LIK2H4V [
M0-)\/SK-P+#J#.K:?B5>5-"R&#.%O*U2=.\#J=RN10-)(1FQ%=W!<C"7<*]4
M7XZA=8%O/M_AF/:$XWNK]9D/PG779+0I"D-%%&030#_0R!/K)\*JB*78I*2I
MNNZ?[-4/9G)?ZC))6ME2NWU2:,$C59Y<Q:OP I)#D-EN4J&KD=UTFC8<GL(O
MS(Z[VCW#_P RE^*:Q9LK;=^$F:%4$$> F_R(V_C4FKRS$"6NL6RG-37'6!E,
M.R$/<VWHO05:D,[JB(B_+_'73HKIL!][PTU(F'D6O6P"ZB6?D-S59=CL:Y:=
MCX]G\:;'>9?\Q_:+")&!6G11L@%Y@%#94 B794U"WCFOU)H#)5\BFSTXPPZS
M8B!$IL@H<ZK2@DR3J+;=G:4663@_3W+(*FZM.MBYW!T3R"._JBZY^;6<K;](
MZ2]61CA3K.RGV&81CD_WU^SW),<MY:5[7N6XI?:M650?I)R9;7O2L=MH0EO$
M*8V1HV2IV.(8DGQU?1Z+T*]=PE/+4'CL/(ST[/\ \Z^\[3XG$^Z1&D1I$:1&
MD1I$:1&D1I$:1&D1I$:1&D30XO3;X+OO_P"&D3S5/UA979^K5[PRG$Z_$AYM
MAL@&6FT)$!OB_"%)IU55-Q,U5?X:YO()7D!5^D]9]/P47]#GOB=7]EE:(S&E
MM..D]%N'[@WT)4W1QQ5;C*X*HBBVWT_@NO/?'C.F+:P ,]I'V69#'N7G2EH1
M/6$1^3Y11-H;JJ91$$T5?*+H)LO\4ZZS<E5*Y\98OHU67UP+X</JIW)5BV3R
M&\W%K84DA2,DAHU29(!I-C)\(Z]H>H[DJEZ:XS'!Q-Z\6Y@&##!$[.OTYN*'
M>7LRSO/;\R>J[C*H+4\0%%86@HR2T<ABVJ(A-..(#?\ 'MUEY%]8&"IS)UVV
M\<X4C<)^A[#66[JUR&S1A(X-,G50_&J>!N(Q&*-!5%!-V_!VCLB>FHJ05!$A
M9NN)9]23F8F^Y<4AIAE$K8RI<&M*-"\+HM]CB.JT_*=;1/D\KW]*[;JJZC?]
M5<U<*L(K&P>D=)V*\1U,'$N'<'K6(;<0:7%:]J4RT6R.3T;<GSGU5?ZG7)#B
MD2KZJNKK/K,SV/N<L.F9U%9_?..Y1?6O>X](MK_Q.(:]Z1FCM5>=-5#93-TS
M15VZ)V_PU654ZGK.MP&>JL/^$R5?;)#=:Y5D,,B*_<\HJY$JP?[E1#<F*R"@
MGHA P6P)TV15UT.#4;"5/T#I.?\ O-U:@,O?K+HY#IAB9WR)<"""J6F1W:N>
M-?\ ,E4K].;2J/<JJJM"NW_*N^HV+M<J>HF;BV'],$7Z-?XS@Y57 \%G-L)!
M-A95^&I#4D06GW9K,5XQ5"7N[8A.**JG7?4))G8>GM+P]U53'R"[XXGQ1+Z%
MBKC@*GN8#(-AB(^@=NR>-S8E5/PU%_HE_$M>IP4.#(IX]GQ(M;[D7F'4^GH>
M-8J2? .[9..3T6/V+U0NX!5.OP3;4., :_G/>8!:XW^$L+.,:>O,%HFOJE<^
MC]IU^P^+;OR;LY)/L(;CH+T_MHV(IT3JFM.U=F>^9&MDK4?X@?NG7/P[7RWL
MCR>ND"S-BYKCD:4,UWP@#=M %MZ,3QN?*#S*D0HJ(JJG368,68*>F9]!:M:5
MK;7]6V0;D=):-TV4T4]M0*NMEOVVV1[%8<<;.%:=FZ?*V)DVI+U[MD76@4!1
M^6-#UGR_+NL:WK,/,RH8;=?G:*\\=D554RJ<6D:^G=6KE++E-ON*G>KORIVH
MG5?CKH<$,BMGQ$Y=HLR-DOC-;L;;%Z&17JH.2L=KYT2&YW>))L=ELI<9G94^
M;R-]R)Z=RZVDYE8W[3OEDY.H9-BU=EL4=[=F #HMDFZ=P)VOMB6ZJ1]XKNB_
M%->8US,8&ID=W&80<SQ.1&>:::D0(A1Y0("^1Q08(25T5_Y5W7?^&K%8DC/:
M9G7W-P;H!I/6&]B38,^R3V>LMJA-M^U[@007;;<!XMQ9!Z?AVIKI+](G"?1R
M.TRLU[(QI$:1&D1I$:1&D1I$:1/S&_NLH$ZQ_3SXPB0!-7C]UW'A=Z$#;;0I
MA7)"*X^XY\H,BJ]5ZZ@Z@5E1T/625BIR)YY[,?Z&\?B):5C[B$*2+%7@-AE&
M]A<2N,5!MWJB_/MLJ_[-8$ 0#;VEF2=3U,GW$;*IA*KCP/3FFQ:+:8;3S4S9
M=E=*(9-..B =!1%1OKOK%RJC9E^YFZKD"MT08P0,R7(F4O9!*4$:@23BBP,>
M(#2I BL(YLTT^TTJ-O/M-[?)MV)\=<?\Y;"&"^V#X?SGT'O,!A?IEO9-FSK6
M]5]0S$*0^XCCR;-/*8*H^$W$%%%II$V1$W$>[;6I+GK^C'V2/NN9=6/\AY.M
M,.(5<)2C6",R'K-G9L(D0")"?;,10^YP17L55ZDFKZ[^18V-,?"6CU+K,EZ>
MOY#L!J(3PQE@(VCK3BR?/)&.@(OG<1%)SN45ZHJ=?YZ\Y5-]@/\ AF_A\E*,
M*#KYS+;@B7E>#9-7WV*,/V4V-(;6VJFFG98W$=XD::"-5[-D38;K_<[21Q%V
M^"ZX]G[:]W'9,'=K/K^-^[UU4)N'J).3\YEGS!P#F]EB,;GJLA8Z%!=*=L_1
MU-E&DO-+"DLQ)Z3*45617-MS'@:(753YBV!%37YWR4LXMS56H2X/\>D^^_:>
M93;6NT@+GO.LG*YDZ-,O)-?4NLC9RFR:9(5+M[O[[C2,JBDX*&BIMLFR(FLZ
M&YK,HA"S[*EZ!6/4#GSD35.+3KVOLJQ(UF=N_(66%:$-P"9!S<24QV FD<W1
M>O14376X]')LM#8PDAR+^,HPQR?*3M@.%\@S:ZJPV.KD!EON@-_3Q'W+)R--
M<<-]@VXK9FX9$ZN^Z^G\M?0K4 !IKXSYSE\WBHK$=,>,RJ3VFV?'<2N@V638
MG40[V 5R#S\YN+8PH<<67HK5Z%BW#<K7[#RDXR#9.FZG511%37U(_9Q9PO>1
MESCH)^7<[_W16_,-#*=.DO.&?M^QCCV23F;U=]R1*9OJROHZ;'9DEN#)FC'"
MNMY>12'X+(_1#WF30!,#?IV(J[Z^<HHO'.%9_I_#OGQF'E\I;%!!T(G6/S5(
MD9))=<K[$I$6F$I33OTQ5\9RT"'%@6@.0U1%826S%0")$02[!+9%WU]#:YJ<
M!-,"?/6"MP5'TDZS$UP)=D2PZ\P"9!9;FP5;)$>+L%4GQ097921?(8G\%]4U
M2JABUA^HXD=H-?M?@$N#&:%B?&.J;6.PXVK-O*!\%:>G$+Q?Y5''$14165+9
M%7?N3^.VLC@.XSV,]4!5"CZ1)'L*2MK/L;E"G_[%Q)[Q09L=I05E&5;2*CQ$
MK4EDV.XNW;O P14ZKJ[DHHIWCZA)@E>DJ\R'C]UCH-@(/0LAC-$V;BHZ[7VD
M;O*8WW?(O<T\/:G1%5LT_#3C,7J#-US(@#4X!)$PPR2HE4,\H[\5N96?5FX+
M;"IXNX25.U%W1#:<1%_!47716PV(5?& -)RV*AB3*7&O:ND<?2/63H=)<M&S
M94E@#<V,I@O<SV]OBD-.BJ=XO"7>";;[INB\IJ[38<_3C26\>VI&);IB9^?I
MD9E"J??][10AVSZQ<A]PG$]7-BB3=A$D/N9;7!$"6TYXB:?$E1674%2!1]53
M=-54&S]4JO\ 3F6\LG].S#Z2#/5.37Z"-!/B0>L^Z3V-(C2(TB-(C2(TB-(C
M2(TB-(C2(TB-(FAS^E5^*)TTB>91^N*^]4?J?>\PFI*,NW.:8N(&BJBLM-\4
MX*TZ2*/H7R]$^*KKC\]BK^X/J$^GX-B?HL=\3J+C6[3L>/";0G&$C$VJ'OVR
M"(UW<-/\*_A^*ZQ4_F'UR[:,9G"HJF7?Y'6T<(@/ZR:RV:NK\D=AI]1,E)=D
M$& 5%V]-;BH8!3TG17Z1\))^4VS4^[*DJG18Q/&8Y4=>TTSVC86S*&4N6A /
M83\F1UZ[]P[:XK*-Y';)G1I9FP"=,3]/?Z<7%(<8^T^/DMLPL>=E$.PR>4;@
M(W*BUSW?XVW4Z=JJTTJ]=NFVLKOD[2!@>4L85!CD'.?&9Z\)&^_C^2N.B+;;
MCT9(JHBH)+(#ZY!W7JKA-&B+MTU1A\^GI ?&@ Q,8.:XD?)?<!38]$<07*>G
MJ)=D"H@L S%>=L";=_'O5T47\5VU:M8M(]SJLL>YUJVC&TCPF=SEXL3CQ'##
M<XV.RY>S:JH.$$0@ "V]%<7HG\5UIOK51N'6<]#ZRG8&=+7(]L-?:BS'!?-&
MAO6+S6_]PI9.*^RTA#\H[$NVZ^NVLE'YEVQOIGTG& ;A@'H!,G_9JMK9Y^4@
MV6G22YAV2.$2$1R"!IT0V7Y>T7#5$_EKZ/C5K0OY?4_.?,?NI3V5+?5DR\;V
MWA2L[S\7XZK%BS,DV;<<<-4>FRS@NN;;]BH;J=4_AK!R@/>/RGO#=!QE'Q_C
M+?Y*03Q.F<C1^]V#^335Y555-MZ>VV^'JH=HM"G;\4VVUFV$ZCI+'L3=+\YG
M;.=_I['9[PB,5,QH!Z_.XXXR3!NJB[CX2+I_!=5NEGTXTEM%B[A,>Z>5^6\&
M]PSK<<"&\:JJ8_[1K]:W]8VTT H'^$75,D^"H.^E:FM=O27WN&M 7Z<2[N/J
MERR/[4^#;AV7MCSFK<CO*G<HCY[*$XT!=1 Q MT^"IK1QU>VWVS]&/OF?D#:
M@(ZYG5SQ<XS"MEQF0<=)[JR&*B4VA$D@A:)?I@(E02,"!.Q4Z]-5VT&N_"_3
M.TMY_2KOZXD0W=O*F9NS,GR4D.6[]G3W'>(>+RQVCC/-D"#V(1=@FB>J[;_#
M73X]?H]?6<3E>R*VL_%GQF(>:4!.UE\^;K4.TK[>?#\3CI X^<4R'J*MINU(
M9)-B^/X:U*H7I,2LK(&7O(&L,Q)BD@U)25>FXN_]=7MHB=ST9XMY5<1IMOV*
M2[=$1$ZIJ+N$Z]YFY+E< =#F:,8Y&QNMR-IB>Z9X=:ND^48T7OK'7Q0I+'8B
MCNJ.*7:@^OKHKA^DQ @'7O+"SV;785E$_)J%#<Q2Z:?1R(;:J#3#H$'D:VWW
M D3NV7^E=6I]0Q*+-JJ2G4SUR?8I(:E^R?V?R8__ +>3[7N!9#'P7Q/<78NX
MWT^'R$FNF/I$X%@&\GSF5FO9"-(C2(TB-(C2(TB-(C2)^6_]VQ:RJK]-WC<H
MTHXJ2_=9QW$D$!]BN-.85R0YX]TV/;O 57MZ[)JJYBJZ1/.U@2*- ;?=FM&K
M?:)HX\*FA?\ J+XFA5/E[NFZ[:SJ@*@^4GN.)?\ 1Y% -F7]*S-ER +PQY)B
MZK$4>U%20;Q;"7D%%00%%V5-].4-E0(ZXGM2._(7PDY0_P#MC%1=DE)69.A-
MV\V5',A;KZ=YY1%'&U1121,<1 :0MB4EW37S3\GW+#6V, SZ\4^VHW],2RVK
M,;^R9D1V7+.;-$&8%,V3RN06^\FVT/OV62_*1.XE3M!"5%Z[:S>\4L((/M Z
M2A6#6[1]&9F?QW@95]>MGDC,;Z@08CSHSUBA.@K:#V1E8:/PML /1-EW5=U]
M5UV.(ZL 5^DR;6,C;5QB9E\;N5TBPB>!BNBQ ?"&\Y#D2'IT>.X*&\@F) U&
M$6NG1579>NNP,,@!&DH#JUQW$YF3\G[#C$^#?4F0M>,& 8@UK"BS/8-YU?*P
MC[3R29#!"*=P;B*FJ;;(J[TW;**Q[6/<;KG6?0\7D#VUKTP#I*M><DGQ E-;
MM)8VU3DT\&)C$]HH@4UHZ49PXTI@YCX62BU*0B11!D%]5[D3;D<O]OJ+>XR*
M7(\)]+P?W%++_9)(L [=/LD:3+7"J7,K6;EM6K07D*SE4AUL^GFK%/S.+]8+
M$<UBQVUW^;;Y@#X[ZX[T<1']:>KRZ3Z*G]QY&SU6 :_=]L@)GER@<RABKQ"D
MG9+/;E%]UR-Y\G:5M@%05CM_,V_9O,)W[ VX@JH[;[[:DJ+8Q%:@(!X=XL_=
MV!]MF!:98\=^Z!..7V;=IVMI<CHY;[-=9PJ%8<=^&Z#X,3K%)[UB8..BJ"XR
MHH0 JJG75%7'')K:JW.CZ8T.-)RN5S;4?W01MVXP9</-G( \XTF.UV!I-KV'
MU1VZILL)@81OS'0\MR%Y'CQFCB2I*N/-M"VR,=AO;8^NW1HXEO#XYV,Y]7<Y
M[3YCDW<7E.;& %O3328Q9*TO&=G58\W,K;U^MLIM>5E7*S,J9!,P$<,8W:PQ
M,1F*^7;Y5ZDO5-];ZZAZ;7'KQ.9:S+Z0?1.M_D&5=P;.YGI+(ZRYL9(L?YMQ
MPX1S3% =<$OZXP2!45 R0DW^&^LG-]+@CJ9G7(;XRUQF*%XTY9$Q4'%C@IV,
M3O**1N]L<$$3W<!7G'![Q153L)5^&LR7;00W>:67;@CO)AIV&XPQ'I(NE+!@
MGP,>Q8LCP/D45!5%[3!UDE[E%?5>G5-5,]88#QD)4KJ6]>0JR)(; I54\OVI
M\!%M28[TE(0J/87U<1\?F$E[E:5?7?6MP+:MHZ=Y)=I^J4 V)B&T[6MM2 "0
MGG@ 8D[#)TU<-Z*O5V0C:DO:*HI(/3T36%;+.,NW&4[3T@$@(?MEN9I1TLVN
M1X8?U7F?7[DW]4D<JR<*JC<MKSBT*,N%_6V2*F_35*?NC(Y#CT_"5V_MBVH"
MI.[/C(-D8C;K)5EI^L=::CO2D9LI48 F-"WWKXW9)^(&NTT111SHH]/PUTA^
MY4.GJ$YC_MEV[0Z S)W],W$I=+[^?9G.^XXV#SON?X?#[4S=P9A.,%FU<2HR
MU&\Q*30#NB$6Z$J;+JGC6"_E+@$*#-'*5J^$48C(\/A/6+'X_P U_P"*Z^Z'
M0?"?%CJ9JU[/8TB-(C2(TB-(C2(TB-(C2(TB-(C2(TB?%1"147T72)Y@7ZZY
MD_\ JP>[. Z1I!<S+%#DJA"BBB<6X(HB JO^(E]?QUR^:BOUG6XEB^U[9Z3J
MQ@0&_J8C3"( (T\XV!(I]K0HNYF6R :].B;^NJZ^/6FJYG9 ]($T3$?JNY^O
M=5E^Q T&6R!-&#.W88CV[JBO JJ2)\$UZ5L!TFRFU'.#T$EKB7#)F:93@F.1
MHI39=S?U<6&TTJ^*:_*ELM'(>4EW!68Z$JDO76*[C$#>N<F;5M"=)^N;F>0U
MQGPICG&L*2,-V]=I\2;.,0-RFJB! "?=FR *J(!1FE;52W3<_P".N,X(8YZY
MA'-C%CXS('A.4+N'*XT* EB?W,&_5$8&*S&BM!ZBG:RWONGKMJY3Z1)-<%)7
MPF+V3OPXW+7(>;=J[/RJ_'1%\-E?(I<*""#W)\J.[*@JGQU-5 .[N9-[":P1
MX3)/D7(VL=X[O'R#QPH%6C8=SJ*OC\:@VVJ)_4/EV_GJ=VM>3X3)QF+WD-TS
M.D_-+UV[L\AL7$)J(CS0.NL$:N#X44VH\8F^XE:=5>O36+C?^H/]O"?4HZ4\
M?:.XG:9[,8+$+(CG("M@P./]C3^SB-R9-6S8CV.B@JXKB.KOW>FOIZQE-9\?
M^]%"H5,YS(M.:XRO),ZR80)34Z6\Y)^7YGK2WGRVHP[[J*F:#LB^J^FLMU!:
MPMVP)1Q@Z4A6/JC);J*]&Q##Y$?Z>?/J,:D2#+O;!UAJ]C5[B-I_1VMRI"&1
M?U)J=505,-UERC>QW$Z"2WR/*KY==B4N5)$4JPR"O7L4NUYT;IJ*RI$VB;@@
M,%MZ]%UFY7H.5\)#ANSV[6.@;$QHS"T2-A%A]&(M.6.4S"\TM409T.AJICS3
M8--KV+V27MTWZ*@HO77/#E]3UG:=0M@ \)JXAO)D_EC@OZN5V-Y3[>,VJW3#
M_P!>1/IKQV*)HJ;$6RH IZHNM7$<UON7&97R=5 [8_G.KJ?$OJ6YI'3BI2RZ
MNRC3VQDHB/DK,DOI#!-D(?*C2HJ$J;B6NFU:V?FL/7B5+S'=-CD870?"13RO
M%?C2<SGHXC+R3F,NKVP/Q]IBXCDED%';?O"27I^'\-5+8VHTTF6]D9=A/I,P
M^Y+R<+9@;3L)'[22P4I6C/9AXXPQVG5<7Y'/(H?-JY&)U,A4U%:$9U^,PFS^
M-D=-:'9PX\MN.V?D=#O[Q=01[O(BBFVY_'?47J6S&[.DR<@V,0=-LH#>4UN3
M1@@R/#7S5)'2;<50,'QZJ:'V=A*B)Z;]=$J6O.W.LYUUM9P"3D><YC64HE7*
MQ/*'^VN&#,&NL3[";_N 2B!.*FR(1KNOX:N3ZI6&4J=N9[#GL# &_8Q[,@:-
M'&@]J?M[!LQ7N$P3BC%$ A+XHHHFVNHOTB<BP^H_&9<:]E<:1&D1I$:1&D1I
M$:1&D3\JG[O3Z9/TUN+BDL!(%/=OQLH-FJHGD7!^2T145$794'?5%_TQ/./:
M!I\1[(8QV1[3:[&T;1Q1%24BW12Z)^/]2)J"_0/A/9DOQG1S+>)%BM@D3RFK
MJD\8_3I&ZJ<I379&&P%/F5?AU37*_=>:]581<;^V9TOV]'>X-9](Z35G69_F
M!(F#8^(KCE/-=>MY\=4)_);9O9EHGY"*AN5%8(]K#:KMNO<J:^=X=1LM:SF:
M6'48T'WYG?YG(+@U)C32<K%#;JW1L'YR,N17HS391MOJS)P5 TV%%)T613HB
M?[-=)K,)[(5=H[XU^V9J%*("?JF0V)Y<)W#,2$ZLXC1&V6'3,P%27M0WP$23
MR$?52-4V]-;.,R(@/?[IZ^\L3,_L+NQPRB1MF(D^?9Q7_*D=EDW8\F0UL3B=
MR]%VZ;=5Z:ZE5JE 2=96..I;W&)#F3#1SJF1!.9(8["D18;:A*'SOQIZ-$3Q
MQG?ZV&'^WYAZ[*FJK%5W#9Z3?2-@R,S#_G+F&W9R&FJZ%IR\L8M=]KD50F+@
M3AD/J<9DU<5IL?$YVEY#7=%3JB[:]M>RP]!C $UCEFD>XN/<\9A5EW*O/O)-
MC.C9;=TV.J3OVI:Q:Y9EG]-6LN18<99D-645IAIOL78E$U1%)577)Y"*C:KD
MXGO&Y')N&=^A,N+ <AYU\]750KB9/HZE@$?B8ZT03D;C.>0?J(HE&5UPRW0B
M%Q%V7UW35%.]@6  [2WD<BSBD6;LV>>HF94&UY)Y)*CH9>*2<0KH4IIYP(M5
M<G+LI",[N3ILNY69)><=C(J;-N*UT1=M6<;C*MI)SDZR[E_NO(?C#1=1X'^^
M3I7<J"QE$#%X=\M#$I*XP;D--&V<UB(,EQ1F0V$1EV6^^9 J^B!OMLBJFM7(
MY)-)5P-&Q.:M0&+,G<1DR&^4\KMEM(=A!DLRR@+)MGIC*.BDEZ8;3Q#)3?R=
MDAE%14Z]N_3IH;E-:?"7.2^,]IB=E$H,DJ\CL(TQ8H$"2I%=W,''=<9<4[*(
M"MHIL2/"7>R2]O<2==9.0$NPVNDHL]*Y3^IVE&X^LZ>^B.T]K+\XPW6W'HX/
M,'*E0>SO@363>%? 9@OB,TW%#'YMM<JQ23I--5E;U_G:6#PEWLW\N/."I?>;
M^Q1FI<)I4%QV0+@&3L1E2$12.3I**H0_*6RJ/X:\6E'!-F1CIB5,7W87&V5Y
MJU:F'6UZ]S<N1'>2+,:4FVGIZ(1M&UW*C12_&G:1(B*H[]$5=M;>&VS>+?I(
M&/OD.256H,A]?>4^X2=6-Q+6KL8M?816R:F1Y<A&/(:-F1MJI-^(N]4^5'=O
M(B]%W3;7COM!( (\YF0&ZL,Q(8'M(_G6DB\AJ27R5TAUX4E0ZV>X)2&U^=TV
MHPCV27 3;M4.U454_'7/"'DV%<*,:_RFJMWKT4DY'>0YF WT9N14R4.WD2([
M5QBUS/57J^P:%.QM!:$NR.2M!VFTX2H#PJA"GKKH_H@E8+@8S.?=R^0 S(1G
M$G?]-6LL;3]0SV!W5Q)<0T]V'#211ABTTD24SF]6Y(@2HS(HG@='^GT1$]/C
MK17@.J@ #<)S??O>EGLZG3RUGKR)_P":_P#'7UQZSC8Q/ND1I$:1&D1I$:1&
MD1I$:1&D1I$:1&D1I$:1/,!_7 K'[S]7#W>P8+2DZSF^&G(-%[40?]*\"<15
M/M7H(IZ:PW(UC$=LS=PJQ8QSF==]?CZQWY2/IO(.*W&B?X6A5Q[^Z9;(B)L
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MSVK^9OZ$RX,HSS)\3%(5C0BZT:]Y?122E26XSZ*;(,OL.J<B&"D),]^YB/\
M06RKJMZ&N(*]I>G)VJ5.V7+B?.^ V[<?'\SLI%:1-,LPLA83M=KY#A)]*%Q#
M=%HY 0B^4WVT1X4V5>Y474.11R&3*XRLJ)I?(<G629:3!& _ RV76VM0"NQ*
MS-<?G,6\:2W(5'(DJ<_#-P9;*(0]R+L3>Z]R(HKJ%5R/6*KLBWRGJA FR@]^
M\B>5,D5]N$8V([4RK<BC#G XR"/-*"$)PWVT-B8#@CNFZ=R[]>O77C\6ZO\
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M#:*@7CM<PC3R!>L$0Q$\7E$'D='YE'T%5[55>BIJ18TTK=CUD])3_5Y35MH
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MA_'1Z[=/: /C*#R*W&'.#,*<^QR?4R&V93OW,1$"CS :=COM,&B$#;Z.BAN
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M#4,-X3);170P%9R#-OCK*4!V=B[QBW#NT8>:15_MLV$%36,XA;?(3@.*"_\
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MM>>WYRU[]Z[<2SIO[/?V1RY#$H?<S[HXKS"(B$P]Q</>G<BKW_\ 8G7NV_\
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M8M:2'9+_ +GO=8#CI*1$$CBM23?X=Q8"2JB?#57Z34G=]W^V9&!)!!QB*_\
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MGL:1&D1ID=.\:_*->#/>)\5=O@JZD!/&.!F?.[UZ+T1%_P!^O()PNZ?47?\
M^OX;Z3T:@'QC?KZ+_/7BG.?*>$X(TC?KMLNI8GITC?KMUU$')(\)[C3,^Z]G
MD^:#6(W_ (+I/<3[I/(TB-(C2(TB-(C2(TB-(C2(TB-(C2(TB-(C2)L>8O)V
M>(]M]N_IV_S_ ):J-I#[0I/]E_\ F^XRL.2V,'^V[_Y?O$W=_P""^F^KL28.
M5W35KR>SYNOX+\/P^.HDG&0-<SS.I':?=2GHC2)\W]>B]-)X#F?=)[&D1I$:
M1/F_\%UXQVC,]Q-"N;+MLOHJ[_R3?_QU%'##/0?V_P#C(%L.J=V^Z:Q7N3?9
M4_@OKJ0.9(Z'$*NR[:\SJ? #,]QIF$7=->J=RAO$3R%7;X*NI 3QC@9C?4<^
MK;Y3T:B-]1+8S@9Q/<3XI;;=%Z_'7C6!4#^.-/C/.^([OX+_ /2ZD[A?/&/O
MGN)]1=]-WK*8[ Y^,8GW4IY&D1I$:1&D1I$:1&D1I$:1&D3 #)N:.1<(Y-YO
MJL;KFLXG7'N#X"XKQ&CR;(IU5CF(P\]XAQFQM[EMZ+#L9$:OKY@OV$B-':[Y
M3A&@J+A]Z29=OLY/]9G \MB,YS\0A QW(GEY]A&<Z[:*[=/"SD-QP->X9=Y[
M;2,:Z33']R?-U66<6>78#QO&Q;A_EO%^(N0IU%E>32[C)9>7/8*,?*L @3*5
MN/70*2)R- 61!M'7'Y,AF2+;H@+1NTTVI;33<?2+>195K^$UNZ;C_E8H2N-<
M$9D#8!R'X^#N3V\GM^8@<>>@.#/EM[E.=P,[BGXNX^>Q6;[C+[VVXY'L\WOH
M>1RKB-F=MAE3R/:''H)=7$Q89M9Y)E8TCL]61,F75)1;6:D-11R!]%]8<>*@
MEA@_\/;Q$FS;69>I5@/CG'3[9)6%<^Y;,R^JX[R_&L?9R^+S+><1Y=/QVUM9
M&.*D#AEWF.IR'' M(;5AVSJQ^+%D19*JK#ZO*+K@B"E"FQ;D-@T466)KW-84
ML?AZACYQ<?9N]G!8BJIR1T M+ #7N"ASVU&,SBY=S[R0.51,'X_P7&K6]M.>
M+WAR/8Y)D-E74M/54G#;/*C^:6K5?62I\SQR#^A2!'42=4P+S G>HPIN]ZYJ
MMK#;G4]#CPGK>E-_F!]LHL7W$<F6TJLXS@8=A@\UO\@Y_@]B_*OKS_3"% XX
MQG&<LN,T9=:KDRN=%G5^:5,:/6>-MT9LEQ#D>%E73]8-?[ KP!;4]@.N,)::
M2#T.2RDCMCKK/;?R*[;7U6O;H.OJ4-I\,Z_#26KD?NOY%IHD6JG8G@V%WU%G
MV9\=<G9_F%IEMAPQB=]B]7C-]CVUSC]*EQ7P>1L?RMF7"E6XU\2O^FD,/NN/
MHT+ROD5OQ&YK>BE79?5U.RPUDC&="PR.^",SS'_Y%G'&K5UHY/;%BAL#.N5S
M@_#23W6\P6LD^7HTBMI)#_%W'6&YFU-HKF184V0S\FQ&^R20S7RW(K1I3,OT
MZ!%D(*F^P\AJ JB#J\@J"2.A/W3PG"!^QD1L<_\ .>6V66M<?<;\?N5F!\9\
M6<BVC^59AD$.9E<S/\0L\KG87C3551RV:B;4M5O8-C-)QAPI+2*QT<(:./<C
MNSMD)E1CS(!^&-<1R%/LKM(W,"?D/AKF<.![D>7^0)>9VW$?'F#3,,POCGBS
MD])><97>5F09C#Y(PB9G1XC30J:GGP:.ZJZV,VW]=+==BF]( ?#VBXX-CFJC
MB7<EB3;7R+*\#_(M9)U[>O ^![8E-5K\CDI2@Q6:*WU__4:Q1]FS)^(E2H_=
M#DF566:Y-58G45/"/&W&F#<M9+EU[863^7WN-YOQB[R7]HQ?':UA8$>ZQ^"V
MVDIR7)\3J/@#0J7>0TBTH.1[A!;C\HTG'?%=5FX'P_-"^.5/E+SM_6)PU!#/
M2+,]M;'KQXYRF3Y&1MB7O;RW)X5K(J,#H.0+>RXKO.4<1QGC27G\^?3N4WY>
M=##L\EW&&0HTBTEUN1_4,O5#<@Y+L"5'8BN.(R3MO)1A1ID/G3X3Q3Z]?I&G
MSEVSO<WGT+C>GS* _P ,Y5'NL[=Q>ZS_ !F=R-8\>\7U3&/R;59W*%&U2R,X
MQNT*W8;KB9?"-'BG*;>ENQ@^58A6]VHC.TK@_'R_VSU@#4S$CJ, Y_E*E?\
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M;>ZR"]<L6X4=MNX:L;=3ANBT@Q489$!V:%-5<=+*<9(].._7 "Y.@U;&YO\
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M?CEA69'CUWC=WC,VSAQGVHTN$\<5^*TXTX)BI%11Q_T]0HJP*PC#SRUK6?\
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M .R0);9^2->_WX^_/WRD5B\2+^6OMP\;BYYG_P GI7+C"K]1X&_J?RS]-_\
M['TO9Y/I/F\?;W=-M>6"O<-?AF>U]#L^>/#MT_RXESXY^3NZY_*7Y:[_ +J_
M^8/R[]K[OOFR?5?>?MO7[MMMY//_ 'O^;7IW?BSCM/1MR<8SWES:\DHTB-(C
+2(TB-(C2(TB?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img004_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img004_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!7 'C P$1  (1 0,1 ?_$ .(  0 ! P4! 0
M       %! 8' 0(#" H+"0$!   & P$               $" P4'"00&" H0
M  $$ @$"! ,"" @)!PL%  0! @,%  8'$1(A$Q0(,2(5019187$C,W:V"8&Q
M,G(V%S<*D:'1)%65U1@X\$)2PK49*<'Q8I)#)2:F=Z=IX8(G:#D1  (! @,#
M!@<,!@8&"P$    ! A$#(00%,1(&05%A<1,'@9&Q(C(4-*'!T7*R<[-T%3<(
M"4(C,S46%_#A4J)$=?%#4Z,DA(*29*0E165F)Q@H)O_:  P# 0 "$0,1 #\
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M=.Q5\5P":99 R"M/86,X!X_JVG-(@<&HO8LGJ4*;(L"C^6G=WHY6]OCUZ8!
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M1R]57IU7 *S & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"B-B.E:ST),(LC7=7/G'>2QS
M?#JGEL('\>G7HJJO3 *+T]__ *5K4_+3S?[7P!Z:_P#]*UO^II_]KX ]-?\
M^E:W_4T_^U\ >FO_ /2M;_J:?_:^ /37_P#I6M_U-/\ [7P!Z:__ -*UO^II
M_P#:^ /37_\ I6M_U-/_ +7P!Z:__P!*UO\ J:?_ &O@#TU__I6M_P!33_[7
MP!Z:_P#]*UO^II_]KX ]-?\ ^E:W_4T_^U\ >FO_ /2M;_J:?_:^ <L$%PV5
MCB3PIH47J]D5?,.]R=$^#W6$Z(O\"I@$K@# & , 8 P!@# & , 8 P!@# &
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MC'/:O:!<>S/YII=#U6.ICY2FW'^J^NV:0LN;=[XVUY)*LV?5:%E?4RC@5%F
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M.3I-'&Y8WO?'U5TBX!;NQF\L@\ADA:P/R% "#LVUT+AG-W.[B?I$'&]RFO[
MRZ)?'IWI#-I@$01D495LAGC.3U>K% UMA>4:>HI!H;3?HH7ZMQ3=71%R/OFQ
MA6>TST.R#;75WINLE_?>@'+,C#>0ZICG0<UL"R#>6^3J!'T=_P F7-A:CQ)R
M-6[W5P\!OHM>M+.RMJ^K^H%GMW5=IE"$K*V<:VUL268F2P&@>K/+5L;245,
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M5USZ>-L-#-2!RF'W]I875M-&XATC6/D:R&/I$Q/!7J!CZT]MCR["A+89K%I
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M-/%6AC"VM5L4_P!3G&,@F@CE;!:$N6:6![&(Z1>]S>KE50+GL:S3S7@GVX=
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M6P=> $-&4SRGM].5%'%'UB;!.]&P=.QC'.[6)W+U HA]+XU<?#L$6MZJEA6
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M6R4(  @M<7')#Y!#4K$:@Q$;AE['Q]JHK.OR^. 8WVF#@#44@U[9-=U<!D2
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MH?M>O5Y5I7F>WO\ SE]H";/!7:(790[H+$2DRN].M42D3XVJB'0N\M4>B=,
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M/(QK87/<]B. BZ_W 5A6^$:417RP'6<&CR:?3J/-#M=C]Y*>YM[Z>TI#91G
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M3V+V>;*LBN[']49T3 +WP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , T[6^*=K>COY7@G
MC]GC^' -< 8 P#1&HBJJ(B*OQ5$3JOY5P#7IU^/C@&G:U/#M3I\.G1, UP!@
M# & , =.OQ\< =/C^/Q7\?V>/\"8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MY F& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -%^"_D7 *)9W-5$=+&
MG<J,3^2U>]?@B(YR=RK^!,C.$GYUMI1Z2G2>]6<E",O13VGE>_?E_O<6\=5>
MT>SWVY[<Q=W.B(J^;.0:$U&RZ;5E-5LG'] = ]WE[9:12*A\T:HX =4C1?->
MJLZ/Q9Q%=R5GU+3Y0[:2I+"K7/3F;]PVB_@/_!Y>XQU"'?/WIV(1X,R34\KE
M[JW8YJ2\Z%Q0>V&RC_2?1B>* ^PG.+>3,U/F[O+A?U>R-JK\6]>G<[\+O'KF
M,+,'&#WVW.3JV\7M\AN0S6?]:S,'9L*&7L1W+5N2K&$-D=U84PI3F.UWLY]V
MW*GM$YDU7F/C&\:%?ZX:R$JK,EG2GVW7B'L6VU398&/[2J>SA:[M56JX<A&2
MLZ.:BYS,AJ.8T/.K4++IE:4FN1X[.C Z)WF]UO"7?KW?YC@'C2W&_?;:RES"
M.8R]UIN-U7<9=E&3\Z&Q[&SZ2OLJ]YO%GO;X4HN9>,;&")Y$,5?N>FDSPK>Z
M)M\43'6>O742/1R=C^L@T_:C"AG-D8O151,W:7J66U7)0SMM_JY.G2GS'S?=
M]/<YQ=W&\=YK@OC6S*Q<L2?8WVJ6LQ8KYMRW7:GR\SJF=PH972=.JM\?%43H
MO1%Z]/%%Z*GX\N$HQ2JMAB=*2=:J=J7HR14Y3)Q@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8!HOP7\BX(/9S'XF?OLO?WM_L<]O.MB<:AJ/R7SE8[)J.L
M[FZ1GDZ$#3581>Q;)$*Y%]7=M$LV1 -7Y63/\Q>O8C7=<XKUF>D:=%6%6]<=
M$WL2Y^OF/8/X)^X32N_GO-N1XKF_X6T2%J]>C%5>8W[CC&V^2$7N2WGBZ426
M.'SO=HV4W9K>PL[0PJR+./-/+.-(D)/L#S2'DEV!Y<JOE*.,G>Y\DCU57.<J
MKXKUS#D8WW.5[,7'.4FWBN?PGT*7\MI64C8T?1[4+/#V4M1M6<M#",86TH0Q
M25:12Y"NI:)LL3B36JOFQ](V.^55;T[6OZ?%51/Y.4[^9C&XXQBMWK.\\-<)
MW,YEWG,[-SG*M/-I2*?FK;R+"I;EF!-5D.18_E<_\W)TZM=&OAVI\.CNOV_9
MDL/^)_:.EE?H[:]-?<V'4M<TF6D9N68A!J]LWN>%<8]#;QWMO0?HQ^[E_>"<
MF>QCFJNW_5I"KG5;5 Z?E#CYQ;H*[=]1BFZN<BR*L,&R4ZR.D!(5/E<YT:_F
MWN3.P</:W?TO/QRR5<E<\W=KL=?272ELV&"/Q$]QG#/XD>[J]IFO6[:XKR-J
MY<RN<W5OV80MR:M-?IPG*F\VT^9'TR]6MQ[ZCH;P6*2(6[IJNV%CE_2QCV@$
M-C#%*GP22.(AK7?C1<S?;;GEHS?*JGS*QRE_(3N:9<HEEY..#K5J4HM8I8)K
M!ET9(1& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /(]_>LGNCXW]ER,
M56MEWSF%LC4^"L9K6EJG\+7+_CSH7'Z<LE8N+T5<]XV??EBYF_8XQXFRUJGJ
M\LGE*\^%V_\ ">.B@I_5R^I(1WIF.7RVO:B.D5J=>J?A8J_;F,,UF8R6[;K5
M&\+A#AV>HYMYF[&F7B_TMK709 7HG1&^"-1$3\2(G@B?@1$RW0<J?K?2J9JC
M9AEXJUDTE97/[O/RE&>%">*Z&7KW>/E._P"@[X]WQRK";3I^A[Y9]:TC*ZIE
M)9>Y'_B6JQ=,%X=ON&,"H)ZR2>-7/CE:U>QR*J]4<BIX*O3P\<NF4NV[F;LQ
M@FI*XMIYYXBL7M RF;R\W*%;4H56Q]HG!*N'+)-]!]<SB=KOZM>.955%\S0=
M,7I^#IK5;U7IT^*K_BST':DGE;<>:*/E!UK+.SQ#GMZ3<HYBY!\U8W)X^$R/
MD3@C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#1?@OY,!'DT_O3%:EEHG
MLH8_Y8HM[YBDF5?L1VMZ3\J=.GS.[%1,Z#Q_*,=/LPDZ2[3WC:W^5)H2U;O(
MXE@JNQ#)Y1R?-^MO'D38V.%J11-:UC6HQJ-3P1J?#\:9B.33DWTGT'Y>U9R5
MM6,O!;D4E7GIA4T7)7M*J6ZJ&YJ].OAXX)U/<6RK(2]JF68,_:K6E1L[X7+\
M7JG_ #%^SHJ+G,T^Y"&?LN3IYZ,>]X'"]G7>'LQ&VO\ BUNS26U[LDWXE5^
M^L9Q,O\ _&/&S53Q30=-[OQ+]VJWPST;:=,O;KRQ7D/CFXA2AQ)J2CC!YV]N
MOG2NR1D;)RT# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#1?@OY,!;3RE
M?WH7^@/LV_7;ES]F].S'/>/[/8^.;@/R@_O"XM^HY3Z6^>/O,52])]9OO6P9
M*1& ;7_HY/YJ_P 2Y-8]NL?.KR,X.H^PW?FI_)9]7;B?^S7CK]0M-_9NNSTM
M#V:SU+R'Q:<0_OW-_6LQ]+(R-E4M P!@# & , 8 P!@# & , 8 P!@# & ,
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M52T# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M+3?V;KL]+0]FL]2\A\6G$/[]S?UK,?2R,C95+0, 8 P!@# & , 8 P!@# &
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MMTQ\3-W<W\/\>-Z*Y5XR>J-4<B_!?X\EA<C<58["+PVFN3@8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :+\%_)@+:>4K^]"_T!]F
MWZ[<N?LWIV8Y[Q_9['QS<!^4']X7%OU'*?2WSQ]YBJ7I/K-]ZV#)2(P#:_\
M1R?S5_B7)K'MUCYU>1G!U'V&[\U/Y+/J[<3_ -FO'7ZA:;^S==GI:'LUGJ7D
M/BTXA_?N;^M9CZ61D;*I:!@# & <3W(BHU51.J=?CT_Y=.F2SE&%MSDTDN<I
MN;[56UM:,7V-[L6QGEU6IS"@"5D\@EILY0BG1-/:C4FK*(17L'L#!/F0B:5W
MD#O^162.142Q799O/*N7S$\O:AC*48[V\N;#FVG/4,C:I+.IN3]%=/.^CH,-
MG[[PE77C]<M_<5,)N4%BRLFKB.0Z\$V"U?*V% GTXX\5=$2L[T:D3X5Z.5&J
MB_#.BW.,N#,KJBTN6N1N:TVXJU<N1A5M8X.F*VI<YVFUH7$DLA]H6],S%S24
MJ]JK%R4$N1[Z5*=.PRY'9;+IB>9?'R;-K$<D+9KUX$0EW3-D<U%)M8@&L!M:
MR+JGFD11#R#HO>]DC4<YO;[<K^B14\S)W;-^B36--[EPKACM.KW=R])]DJ27
M)M\']1E2*9)6=Z.8YKD:YCV.:Y'-7KT5'-7M<U4Z*BI\47+\KT9Y;?BTURM;
M%X3B8[VZ]O,8!J_<!IQ%9%86LQ%)/+)8/G#>"=8Q@5X>TV6HCVU@<"&\<, V
MSK5;WR*B1ND:WXKG4,IQEI-^;BXW&\>1\CIY2]YKA_5;6"<*8<L=KBI4Q?,3
MQ7-6BAPK.3:%1.C;=2&"RT-VAE=#K<@D5_/9!H#ZBO@J$/AEG?*UK60R-D\6
M+URX?Q5H&^X+>[1/%4Q76N0XD='UA04I*.ZZ8X8UV4YZ\E-M&2=?RKI]F<-6
MBV;FGEGSU@XA%=8"3O*'IEV#N\LF")5%)INA4$J*C)HE^17+D?X@T*7ZUR::
MPIR^(D>FYN*K?I7H:V;/+@1@7-NA64HD(5Q(0XMM&^.9*BT:%"W9F2OH4,.>
M*T8'ZHL+FP^:YJN>G;T151%D7%^@SA*;4U:A2LFFDJ[*O8JTP(K2\ZZJS1/E
MJ_(<4?.?'\B=S;>=B/\ )6N5U-;L^\+";.*E'DUE)0F?7HY;:5H[5&\SK(]O
MV.;UA>XPT#*J,KF\M]5C5>DN=<ZZ5@1>E:ENN5Q)VUMIC1TKC39X25=RYI;0
MCRY+=\"5E'-L%DR>LLH" :V&SEI9I)QY16RQS06L#X71*WS&N;U5.GCG+M<2
M:%F<O/-6YUMPCO/H2YR6.E9VY<5JRGVLI4CTO;3Q8D?+S3HT"'N(N7CP5?W@
M0PPBIMH@/-U-S_O&+ :X5("3ZIC%=+#&KY4C17HU6IX<9\5\/1MN[)R5M-K>
M>"\WTL=F'+S%5</:_*2A%)S:@TEBZ7/V;IS3_1>R5<#>O,NF)-"(IQ+3R[)M
M0+6.H[EME*=+7K;C] 90XBE$)JD4B*=6-A?"CG(_HURI.^*-#C<=J6^KJVQI
MBNM;5X2"TG59*L5%QY^3!T>-><I8.<]!(:JLM)D66.":M=)36S8[^$JT2E&G
MUGH(KM@@(M7MA8X5)>KGHOBUS561<6\/-54G1B6DZK&3A+=4T\5L:PK1I[,.
M<Y">9]3%([93'+#(&'*.-%6W#[P@XZW-HX*V*E=7,)4R2R!DB;&BK-W1O5T;
M6-[\C'BK0)RW8N3ES+'W-I(M+SDEYZK-<V*V5VK#8<2\Y\?JT?\ ][$J^0&6
MPF8E';^96!P7$E 7-=1H*[Z,E=<1+"1YZM\I6]7(C?FQ9XCT+,YN-B$G6CJO
MA)WHV9=OM)1:BG3QJOD+FV/D?6M5?%!?FO$<X1A\[HJ^P,@! >4T+ZA8D!C3
MP5P*$.[?-E<UO5%5?E3KG*U#7]'T^6[<<J/Q$MG3\S.367HTEY.;G?063!SO
MJL<)\MG"<%+6V^TAE0B!&7#1:;5;CZ,9LMC)7#S-K:EY"HJOE\&HJIU7M<J6
MS*<4Z-/>6[<IU-E:6F9V4:>:ZTP3577F5:M]!<"<S:(Z<N!+MK& $70Q=A,
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M9=/^Z>"<]&>6U&Y*U3<[9[-E-XMWB^23[IL!EE=.ZAMMBUAD\G\N<;6[VQJ
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ML-WYJ?R6?5VXG_LUXZ_4+3?V;KL]+0]FL]2\A\6G$/[]S?UK,?2R,C95+0,
M8 P!@&BIU^U4_)_YER#52*ZD;>Q/^D[_  __ *9$-I\B'9\/%WA]G5/\F2N-
M76K%52E$;\F(# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MVKT,UFHYM7'<NS[3>K;[.E*4Y%6ON'KBQ;N9:%O(S<7"U#"G3BSO7^[:1/\
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M_P"?9'UZM>JO6LFXJCV+X*$]GC'7(W=Z]",GO*KHJM*5:5VTJ6>OLMU'TG%
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M;VECO9V_F4O6&W2ONNK+]3X)^1,@45LPV&N , 8 P!@# & , 8 P!@# & ,
M8 P#R*^Z#_B/YU_^J>X_]LDYH5[[/OBXA_SNYY#;YW-?=OH_^10,+ 1!D'!P
M6)<M>#,1%$8; .A<PHSW(DL\8KI(6D/8SQ[%>SK^%,QGI%C+YV_;L9U[MFJ5
M>BIWC5,SF=/R=S,9"._?HWN\[IL,OUNH\4PWLE;/OE[8EBPV:LKI]'C!KS3!
MZTL@2%UQ%M93((%GAC7S4:]/%/!>[IF7LKPYPAEEF.SO1=_L$Z>!T\9AO.\4
M\;YE6)7<K*.7]8IO*2?Z23Y.1&$_#IU3\'3X=.J(J]%_)F&8*$<_NV_02G0S
MC;<Y.$KBI-P5?<.]O[MK_BXTC]7=X_9^?/4OX.OO+M?-W/E1/,_XI_N[_P"?
ML_)N'IK9\6?D3_KYN1_QT_B+RFM.'[&/6SG7X+^3.03K:>4K^]#?T!]FWZ[<
MN_LWIV8Y[Q_9['QS<!^4']X/%WU'*?2WSR!1KT?W/3KT;^%$7HB)T^9>G:BH
MF8EN0M7+\8W\(5]\WS3NSL2GF'[3"WYG3A@?H9Q7PEJ-SQ97[DO ^R<GVP>B
MR[=K9]?R)/!7<G<@ON2@;#BE=,IWQ7<[-.IX'V10]4Y+29@;U>K89V*G?M.T
M+2;MEYA)2CNUVTJ]F[X-N&)KD[T.^#CNQQGF]!EQ%9T_)W[T;.9R]VPY/(Y?
M<WH9B$FJ25]THF]U2DE7>P.HO-U%4:UR/>TU'4$:X".RJFDU<PV2Q,U.S.I*
MT^YU4DZ97$E/UVU)E$1TWY]$B[9>KVN5>IZED,MI^;E:RWHO%]#?)X#V?W+Z
M[Q!Q-P#E-:XEO9;,ZA=<HQOVH[CO6+4G;LW+D/T92@DX\\:/E,2/_1R?S5_B
M7.%8]NL?.KR,R1J/L-WYJ?R6?5VXG_LUXZ_4+3?V;KL]+0]FL]2\A\6G$/[]
MS?UK,?2R,C95+0, 8 P"&NZH2Z!.J[")A%?9 $@%P/\ Y,PY<4HY,3_'Q9)!
M*Y/PIUZ]<GBTB%B]<RV=CF%Z"2QZ4ZF!N);QVH1#\.;:0D.Q:L(@&KFEOCC^
M_>E@-2"BN:R1[FH9;UM6V(>T&8JS0$1++V^5,QRP=')3>U,N.H6K.9A/-PCO
MQN+%+D>VGCV&/=L]JZ;+[UN'/>(S<'"+Q=PUR)Q'/HKZI)HKN'>K:MN(;Z"X
M0EJB$5TE>L;H?*>V5K^O<BHB9:[N7[;5;><5*0C)>-,O6E\7W,IP9G.$G::A
MFKMJ>]S.VTTO#0SAR)R$_71(]>UL>&[Y'V2*<33=9:Y%=.4^'HMS:^7W/K=:
MI.])C2Y49&UC/+8KI7QL==]C4GMH=>R&5O7)^L:E2-F#JGU8TZWL*?6M9@XM
MXM$UQEZ*$_7-=+>1M5XQ/1-MI?//M-FM87$"-48FW+F*F8Z6-.UW:KD1/"G4
MIYZ[V^<>:>QOP&$9N7>0Z'1N8$DC,N]RTE#?NQ8VU, $*,(NMUEN-8[>3I[;
M76P6$RDSS5S&.>^<=L3".U[G+D"D5EMSMLU35%TJ!#-N IS: ;9'F#61!.Q:
MC?ZG5[A-;:['2U,-?5V+-@>E=.Q.DJ,1SH8?,C10+PX\Y8NM^Y <$X$&JU([
MCT[:J8:&SBL+J1\.ZS:U$3>0J&,^G/? ([N$8\F%JOZ>8LC7(@%NU/N.DCJV
MV]IJA+Z(,#55L#XK>$N\G-VBHOKD2,2D#J!@RO3PTCHY'++$LCY&JQCE1V <
MUA[CR:JOGL)],@-0/4YMP.CH]K#NF0BD':W6TU;"T %\RV)A6SC)/'*R!8(H
MY7IYC5B\P"CD]SY$)5&')HY#3BCVT^P5ZVA,1=9:FW%G0TOEO)IAP80K0^JD
M\OU\X!'8C^L*+&], H1?==,Y:P*?CNQ;L'<65LM(*=8+/K-= 3KPL41\EEKU
M4QEO(_9H'^7(D(3H6K)&4]LD2N RSRWR=/QH55R15<ERXFBV2QAKF6 =:.21
M66&JUL<1))(!DT/F/V'JV1BM8Q&+W->JIT @+_E/9H:[674M-1)8E<XA<2[5
M%9W-AZ .)9B6FGTA<52DQ<DL;(UA;-%$U'OZ*BK@59CND]R>Q5^K:_%L.G-N
M=GOP]>GH?HIDBCW4>P7&UUBE60=?5%$4CPVZI*_RX6FK*V2/HK7J]&@7UN?-
M95%0<8[G#53C5>TUEU9VU 6H"V2OCUU#ZRO=8HLHP:#W$S/43HG9Z9KG]/#I
M@% SW#GM-L "-0"<NL,,=MYXNS*57Q2";H#IC_NPY*5DUY')-8,(:^5!$8C7
MQ.3S&], @R_<K>QRRD@\>G$UY5Y'K5%Y<EPZ0J\C+VU]A'8$1TJCM:+3Z@\E
M?01V#'*7"B3M3O1 )=/<*VV%E:%K9]9;AF:N^Q!(M@TG J=KM-+%UDHN7T-A
M K;]VT2,58VO5OHI^QSG-:Y .;B_G.ZVV#4:;9M?J@MOW,6*WJAZ2U)-JCZ
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MWKT3KT_%G%G]A[[KZOM?]DRY#_[>;J[3^->TICN^M[M>7=IA3FIR&[_P(_\
M\>__ -I\E_\  ?\ L_\ =)O_ -<_^^/^]C_P(_\ \>__ -I\?^ _]G_NC_\
M7/\ [X_[V4I'_<0=8>S_ +OCO\UO3K_51T^*=.O7Y>G?T^/ADLOL"L=_L*UP
M]';_ $YB$_\ [;]E/M/XN]7W7O\ ;^L[FYR^EA6GN5/V(USZ=]'I?HOIOHOT
MJO\ I'H?)]!]+]''].]%Y'YKTGHNSR^SY.SIT\.F7J6[NK<]#WCS9F.V^TLS
MV]>UWO/K_;KCX:UJ7'E,IC & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
=8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img005_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img005_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ GP** P$1  (1 0,1 ?_$ ,4  0 !! ,! 0
M       ! @<("0,%!@0* 0$  @(# 0               0,"! 4&!P@0   %
M P,!! 4'"@,"#0('  $" P0% !$&(1(',4%1$PB1T2(4"6%Q@3(C%E:AL4)2
MDM(SDQ47\,%B<R3A<H*RPD-3@S0E)C9&\:+B1&24-448$0 " 0(#!@,' @4$
M @(#     0(1 R$2!#%!46$3!105!O!QD2(R4@>!H;'!T>$C\4(S%F)R@D-3
M)!?_V@ , P$  A$#$0 _ /W\4 H#C,H!1#7M"_3I0$@H41 +]1MV>N@*Z 4
MH!0"@% * 4 H!0"@% * 4!A#YQ/-\R\I:_&$I/8TK/8KF,W+QL^NP-NFF*;&
M/25CD8AJHLW;N7LE(+E2*4YK  WH#S(?$!XL9*2C#,,<S;!Y6$E'\'*1$_'L
M!<-YE&'2GX>%%RQ?N&9IK+(Q8/Z:W XF76N3J%J \&E\4'@Q4,D498SR)*,,
M?8SBA'43B[F57?R^-G8H3N.%CV(KO8Z3A7S\J#KWHI"%&YBB(!0'1NOB38FG
MG;"-D,(E8? 5\9PG(CYV,C#SI$5\N?ST>M$OX^'E12BB12D OXCDZBEEK)"D
M C0'KI/XD7'<-!SLK+\<\EPAXS'<0S:)3F8R+:$R?!\U8R<E"Y!#K!+*I@HJ
MRBE!%DX\%T!@ -HWO0'B83XG&"2629(>7Q'(L;XY8-&,MBV8JMTY)7+XU_A,
M7EO@?T]HY \"_24E4T"E6WE<&, $$O6@/<OOB+X#%R9,3=\4\J*<@-(O)9[(
M\*+%Q*<IC6.8[!1F4*SDD[-*&B#-WD!*HK-")N!,X$1* %$M =3R#\2SB_'R
M*P^)Q<O-Y!+X&XRW"'K])LWQ>9E28H;+6F./W;=^>08+.8T!LN9$J)CE$A37
M"X@9]<6Y:OG''N#9HNW18N,NQ:!R!:/06\=NU6E8UN\<,VCD0 7!&ZBHAN'4
M0"@+CT H!0"@% * 4 H!0%![6 !_2,!?30&(_G!YWR/RY<3L\[Q:#89#,2?(
MV#X.A'2+.4DD]F7S24.=VA&PJB4K).6!5?%!!$P'4 H@% 6HS+SR0O"^+X')
M\NQKN1D\R=G(HKC&*2^,H148;(6F/-Y!QC69OB9&GXCY\D4Y0%02E.![;: M
M\?XF.*CR(,<;C[)8SBF.1S(DWG4HS(VDRN\*RZ.Q*6?QT*F\7%;&F+J0!1RZ
M4$IBH)G.   !0&=W#O+6-<TX=]_,3(_- J2\Q$QDD[0\!K/(1#Q1G_784US@
M[@9,2;VJP7!1/6@+R%&Y0'O !_)0$T H!0"@% * 4 H#B5 "$,8"B.T+V"XB
M/R6[: P>\UWFFG/+;D' S5I@Y<SQSDW-Y&#SR0:.P0E,(PN'Q^1FIG.8YB-_
MZRE"J()"Z;$ 5 :B=0H7+0&/V-_%)XE>Q,"ID49*N)3(G.1R9"X$V-DT='X*
MPSN0P;%\M!0P)+2K/*7K(H@1OO41,80$ M0%W\5^(9PCEV<1?&T*CEJ^5SZ\
M"SC8XL.05$W\T\?,7[)P!G'L+XJ9B*LBF([T45""&Z] >(EO.7RE 2O,V4O\
M/P)?B?A?FR*XCFF[>2E&V>/X]_[BR7RIJ9RH:(\9!_)IJ$9"D4ZJ!3;1O:@/
M18]\1'BS(\8RO*C8CR-CL=C>%M>1@1F8:+1<R.*OLK<X<Q<)BWE'A$%G4LV,
M<$U-ABH!N$=;4![KBSSR\?\ *')&,<<0N*9JW1S5/+3XCF[YG&)XO-J8.#-/
M)6Z'AR*LHV68N7A4RE60+X@@(@.VU 9MHJ'/UL)2D !-I[2EQ P@ = L% ?1
M0"@% * 4 H!0"@.!178HF6^AKWZ=EK?-0'*4X" #<-?H[?EH"J@% 4F.4FIA
MM0'SG6M:PV#YKUK0>:>7F8N="V#3DJ)'+9C%)( 9+QZZ:39TH-DW9C@ [0OH
M40O7*0TTY1SVU7BB%+'$NGXQ1 @@!A*I;:8H 8HWZ:W'K6H9G*4;@ C_ (UH
M": 4 H!0"@% * 4!!A$"B( (B "( %KB-M "^EQH#&?S+\YNN!.-!SUEC7WP
MD5\HQ7%8O'BR(1:CE_E4LC$('<.#-70>"R64$YO#*(F +!<: L8IY\L7P+(Y
MG >;\8D<2Y'@GZJ2D%A;:0SB+DH9+%PS4<I9R35JU68Q3;'@.9R#M)(R:I!
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MD7W..48SR)#H9EER.9N6<[$Y6QQB>F3,6Y$.64L8>*EB7\2VC0*L*^TZB8
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MLVF/8+4!O9QB93R+'('(4"&2;S\3&3+9%2PJHMI1B@]106$-!51(L!3"':%
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M$M/$%&)B6$4@8X%U;1Z";1N50Y0#Q%BHI% U[VMI4;BB/U_H>@H6B@% * 4
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MSB'R*4B-V-3;B&DFP;D (<P)K::E< 4?:&P5AI(*3H]A%UJ,6S#V2S#D&'=
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MPN6W@VJG+<>__'IJSQCDNFV\S-I:65.LFW% 1$=!&X=PZUCFEQ9%$0  &H
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MS8E:Z:J^('7KK\^M1U+GW/XE=$1M+^J'H"I6FGJ\7<E')S>-3.,H1PDEB (
MZ[0TZV -?H[:AQMV71S?ZLU[EIOYJM(K*05-$D@,);@;PDC*JW^1(H"&VW4:
MK>J472%6:KM-RJINBYE&XJ1_#4*4J@A<"V$IA 1M<Y#:D/\ )62[ATOFE'#W
M&W"RKM(J6/O*CA<0W$*&G2P!<->RI>KCJ_\ +#!;,.1N1MQTT.G/&3QQVXE.
MTOZH>@*BK-&[MP*@TT#0.X-*R5RXE1-T*HYDJ-BX]XU/5N?<_B35\6+CV#^7
M_AK):2:7B)79TEC3,Z(VXW(]-)I5H0)R&]@2EW%T$;:CVZB/S5AUH1_^R3_4
MUITGL="KP^@@V$=+A9%40$![;@%AO6J]??S4BWE3-J=NV[2I+&BV/D4@4E_J
MAII:P!8;]+#J UFN]=#_ )%[?$V]!HXSVNM?U*1*7H!0] 5?U;C^;-+'FS3N
MN-:))(J I0_1#T!1W+GW/XLXV<;CFG%NE2;CWCZ1K'-+BSD:(7'M$;?/4.LE
ME;:3(E&L6EMH4[2A^@7T5$=.O_R2?_R*%8;VM_$!;<  0@F[ VWO\P!J-;#A
M'2QZ^9R4<:-U+HV%'%RP*A33MN$ *8/T?#.'Y_9K5GW'J8QC@7-6FJ)JI3M+
M^J'H"J+.ME<N=%_4:T])*W'K9FXKGQ&TOZH>@*V\TN+*1M+^J'H"I4YK8W\2
M1M+^J7T!4]2Y]TOBQ5D@ !T  [[:4?5N1=)2PYLLMQE*M"1,/?7%/5WK%VDG
M)X\6;"L[VZ#;O*(@!C;?U2[^OT#;I7(^/G>@NFFJ</\ 4LI9M[6F<1+& ;D$
M!*-AW$ OSV^:J)ZV_8>9MT*G.S<PBTF<NA?JZ?-WU;8UT]5%S3:2=#%6G;PE
MC47'O&K^K<^Y_$FB%Q[Q]-8N4I8MMLHN-J6!2( (W$ $>\0N-15F%62 B&@#
M8.SL_-54M;&T\CVHNA&J392<A3"4%1 1/_#*30YKZ:B&HC>J)=RDMBQ-F-JW
MO9S&;G2(7Q$@(6VFX W"'9N$0N(ULW.X3E9C14>4U[%VU'4N+:<4SBVDT$"E
ML/R!4Z+7N/\ R5?O-[4VH7U2U1>[ JN/>/IK-RK)M;V::@HX;T18.X/145?%
MDBH)% *G-+BP5!N&P%,)1 ;E&XAM'O#NI3-@]X7RO,MJ/1XWE$MBDB$E%*>"
M81)[TU,(@DX3#ZP@G?:8PA\G6N)[CIXRBTDC=MWI2WLS8PK/HG,F!%FBY$7Z
M1"@\8G&ZB1M+FMH(%&NG7M,[<\U-AOJZLG,]\0^XOU@$?D_^O=5>=)XF=N:E
MM*@ ;WO]%%<A+!;2UTIL*ZR,10%)@"QATZ#J/3IVCW5#JTTMM"'L-?'G7\U7
M#7EWQ%D;D5L?(\HFC+J8?A\:L1&;EU6I!.HH9R&L1&D$-5%/94#I7:O1_IWN
M?=+O0L-YEMEM2>ZJKC4Z7W[NL=#9<WM5?U- F=_%,\PN0/5T^/X[">+8))3<
MP91\$A.2G@_HJR,W(;R'<%#]%,HC?H%?1G;OPOJM98C=ON3C3'%KWTQP/$.X
M?D>=G5JRG@Y4.BQ3XG7F@@W0+9)(8EG4<94HN8W(\49@JHC?[3W9W'IMW34%
M Z'L.WK7+7OP[IM'8=R'432^YF-OU[=E?4&U2IM=\N'FJXU\TD8X:XTP-@_)
MT2B5>8XXDWA%B2K8I?M93$'-][QCH)A)J8H!\E>)=Z[)?[1J\E]J5&Z22IAN
M3Y\SV7L'?(]PTR@G]2,A!W -K>R!A((#U24+?<01[=0KB3GQ0"@(,(  B)P(
M4-3"/:'<'RC5UC:__4JN*J5-M3FO'MXV2G)J38P&,PC%:1FLBE%038QC-(H[
ME%2W RXJ&]DJ91W&,.E:#M.[J,D4Y2>Q+:R-=JEH],Y[,/@:I.9/BF!$2+B(
M\NN&0[EG&G78AR+G[7WQU)J$$4S.<?@2F*5E&@<!%,5P,<U^M>E=C_'UWO$:
MWVU#*J154U7B][6P\DUGK1QNW()_08KD^)+YO2.R/PY AU$BF,L>+4Q").Q6
M$PW]V]SV%.J17H6YBV *[^OPIIN@KW^2J7W.F'ZG37^0;WBLC>%=AF5P=\3S
M'\RD(_&?,9A\9B;A[X2"')>$E(VCT7:J@)(&R2"*8Y6R**IP*8Q!L &&]>>>
MH?0-_M-;EGYH-?2]N&VC._\ 9_6?4E&%<9,V@NF8MO!4370>LG;5L_C91B;?
M%RC!VD"S9[''&YC)JIB&ZXC8VE>8SM=&_1U6.*>X]<TVH6LTBF]Z_D? 4VZX
M]PV]%<K<:=*;*&K&&1M<RJJS(4 H">SZ:Y'JQAIHK?1_Q*M.O_VI2W(Z?*,F
MQ'C[$)OD?D:?+BV$0!!*_E#F(JN\<%L*,9$1_P#%D9!P8;;2:DO<:T8QC?GT
MXIRN2V+EO?N6TUN]=VCH;5$TJ+%FHWE/XJ6=/I%W&<#8# X3!H%4(TGLQ:H9
M%E,D4IA*9X8ZA2QK,ZJ8;O -<Y+VKT_TY^,9=QMPN:EMNXJX52HWA^NZIY%W
MS\ANU!VXNE"QT7\2SS;L';=ZOFL!.-2'UAYC#XD8U0+Z%%)LC[R)?D*;ITKN
M.L_#.EM/K14\]/N=/A4ZYH/6=W63:K@;#/+I\0[ >:YJ(P'E.!C^+<_DS UA
M)Y@H/W GI$W2.>IJC[S$KNCZW,( %[!7DGJ;\?WNS)WHIRM\-_OVXGIG;?5+
MU*C:;W)&>KIB\C'*K1XFHDLF &7L&](2#]4Z1AZIF+82B'4!KJVAEX;Y#T#0
M+Q4,RX'!4F0H!0%10 P@ V$!&QKW^K^ETUOMJ5/IO/P(;IB=?,SF.8C S><9
MK-ML9P?'6Z[B9G) Y/="IHIB5HR:(:++Y N!OLT0ZC81#2M7++N%Y6X1<FWL
M7OVG"]R[JM%%RK2AJ3Y=^*ED)GCN'\O^!0F+X^B8A6^89VW+.9)D#<A1*613
MCA S:),J<+@0X!<H]]>N]@_%=[5:-ZG4M2K+"B:HL,'CB^9YUW?\A>&M24'2
MG]3'UC\3+S?-'"*[C.X.41$QA)&/,,C%6"GZK4&Z22:Y@-T*8!]GK7<;?X6T
MD[76>?-M^I[N1U*'Y*N3N)-[69W^7KXD.#\JRT?@O-N.LN-,NE3IQL)G6+.%
M"8?*2:YBE(G-L70&"-=%/H!@,!"B.M>6>JO0E_L4I:M23TV91RT>:KX/AR/0
MO3WJ]=SNK3-XN+E\#8N]8N8]XNV<^%N*5$Y54#?8NT3DW(/6YQ$0=(N4_:WD
M]D*Z3'29E5/ [Q:[@UMVGS#\]ZR5CI8\3D(:GKK+PQ(K(S) 27 #"IH('$J0
M;CJ%*-A2*'><3 %47UJ)1I8='O-:\_GC[RQ'F,\S_%7E9C4BY8W=Y?R1+M1>
M8_QK#+ @+%$=H(OLOD WJ1\:<3E$2E+N.%[#I6[V'TGW;OVKC;M-I/\ W.K6
MVE*5VG$=\[IY?I7<?U<#4[E7Q0?,_./Q5Q5WAO&L81144(_&X!!P[13U$I5G
M\J!E77LZ 80#<'97NEC\)5MPCK,]9)4:;6'Q/()_D*Y9ZE'BI'U8+\4KS'03
MU(<Y983R=#N#^*X9S<&6$D5$R&LK[G+Q9!$CM0A;%$P;+UK]Z_$%GM^E<M.Y
MJ>6BJV^-,"WM'Y&N7]3DF]YMRX'\PG&7F7QAWD?&JCJ*GX@$U<NXVF!(>?@"
MJ$( N882F,:2C!4W"*HA<"A7B^M[5=[+J/ WL9T3JL$Z_P"AZQI>\ON-I:B.
MS9\"[AC"8QM2CM,)0,3ZA@"UC%'N'\]:IREF>=X@*%DOJ%#$^UDT!W[PLHX;
M-6D>V7>23Y\J5LQBHYJ05'#R1>F$$D4-@#X9!]HQM*X_50U<W2,FK;=%^OZE
M.KN.U8SFL+GCXGF+XA*2&)^7+$HO+G;$HMWW)6<IN"QCAT@H*1B8S"-MP/$T
MC![*J@@!PU&O0_1WXS[GWUJ<FU%K9C6OOJ>:=W]6^#GEBW@_;]S#-7XF/G -
M( ]-R)!IHE,)C1A,/A_Z8%Q'[(4BH"YV$Z!8>RO2=-^$].IM3ZG4AA]3I7?A
M4ZQ/\F75+)54J93\-?%-"9D(['O,3A$6HR?'\-/D# &JT8[C!N  K.P2@>[.
MD.WV#%$0KI7JK\97M!.NG=;<:MQ:;;X)/<=M[+^07**J\3:X46;V,B\@@)=E
M.XWD$:$I!S,991A(,! #68GN.]P2]CA<=I@$*\W6'RO!K!K@>B6K[NXO8U7X
MGSAJ%]?FJ3D86ZKD30R*BE$P@4# 01T XA<"C^L(#II55^,I69QA];BZ>\E;
M54\)RMRSQQP+@IL_Y5E%4FKQ<R.-XQ$&*:<RUTD41*C&E-__ %ZI@LHK^A5G
M8NP]R[A<5F%7+>]R]^/['!=Z[K#00<MR-0F?_%8YQFG:J/&6,X7Q; "N?^GH
MA%?>:?(S(82D,_DY,I6Y7:P !A32 YB_-7M?:?Q#K-=IH+6RDY-8M52?Z5/(
M>Y?DF5B^X6ZJ-<#QN/\ Q.?-A#NTEIR>Q+,8PRI1=1V28DR326;W#>@1Q$HI
M+-2B&F\1]GJ.E<Q<_"6FT5F5V&?,E7&39PL/RA>GJ5!O"IM"\LOG#XP\SWC8
MN$>'&?+3-%1RIA[IW[U$9,BDEX@GQ&2,.WQ50"X)'$3#T#6O%^_>F[W8]7FD
ML\,S69;D^/\ 4]B].^IUWFRK%<6J_ RI5WI*+-U40;K)B4BK<I#'1;*DOO1*
MZU [D+_:%[!KA3LQQ4 H#Z6C9R]<(M&:?BNG"I$T2" F*)C#KN*7VBV#7?T)
MU'2LXW5:JY;&60N=.,I<C![S,>?GCK@*8D>/L"AV7*W*$7O2F)1V[V8)BSZP
M68/"H""DQ)(#?Q 3$"@)0"NQ]@])W_4&JC)?)8;Q5/F?!I[CH?J'U;'MRDE7
M-[]AK=F?B4^;:4>&=M,RQN#;&W&288_B$>B@B%P'85HL59PY12Z;CB VKU.[
M^'K%GIN6>MQ<6>?P_)%Z_&>*K%T+S<7_ !4^2F+YA'\V85C7(N,JE!-_(XM&
MEQO+TFY1NL^;D34,W=K-RW.*5@,:W2N#[_\ C+P>C;TK:G_Y5DN9O]E]=7-3
MJE&;JJFWC"\QPGE+"(?D_C#(D<CP3(+M$WIQ*63QYZN4"BQGVP?^$D$3@!-@
MV&UC=M>0O03[;<EIKB:G6OOYKD>TZ'6+7:=7DZ[COC"(CN,78<; 8G3:9/[+
MIV;@3W?34FX4T->Y]0H5GPY#D>*X1BTIGF?3S;%\*QL#JR<J[4(7WYP">]*'
MB&H_:O9E?3:!=  0JNWH7J=3EBG*<MR_B^1HZW6^%M.7 U$<J_%6S1R_=1W
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MF.P@(ZF,%P!0X#9'QA"^PA/K%."8A>_97U/>U"O1C1JAX;"ST84WU9-A"XB
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M!V;\K=S.]E3TV<D],K?(I&MVY=Z\NIQ-33Q<;23YBY.@@/B#?8:V@:=H] K
MO#A*,D865QG*(Q">Q;*F,A#Y/"+$ R$BQ5(!4C" @(>](".XA[=0K5L6U9UK
MU*=)5K[>\T-?8\18=OB::^>?A@9S&/9/(O+>]9Y_B:BAG)L'D7J3+,\=36.)
MRL$R.A%&8:($]A(R9P.4 #0*]=]._DU]JBK%VL;BX5:W['_)GDO?/0,]?-SC
MBFS"A3RE>9YM(%BUN >3B+F,) V0#APV)81+M,Z*L*9[6^M?7K7INF_)O:+,
M?$0N1ZTEF>*VO%[SI&K]%7I?X%%_)ALX8&5W"/PPN7,K?LIOFUW'\180BI=X
MP5<I2&>RJ0CN*DPCVYU&S,XE&WVEA#H.M=#]3_F+7RFXZ+,X\J_T.V^G/Q_.
M%'..)NMQ_'\8PC%<>XZP&&3QW"L-:$91$4F4I'+IVGJZFY18@;%W,T/\4 $1
M :\9^:5R5^3K<FZ^ZN-/BV>I=KTS@\KPR_R/O&XUD<]-TVC3MU#M#O#MH9E0
M;+W,4!1#54AB[@,F'U@$@_6 >ZL9_0_<0U54+&>8SRY8!YI<1BH;,73C&\YQ
MQJ4N%<C-D2F68(B<PI0V0)I@*SMB)K=+@4M<KV#NUSLUY78*MK%M;U[OZ'5.
M]]D7<+;@OJ9I7Y,^']YJ,!D54PP%QR%"$5,+/(N/#-YAA)@%_=WB+%N=O(1Z
MGA:*)JE$-U>X]D_*6@OVEI;\J6)+'-54^-#QWO'XXN14]5%5<<3P6,^2WS69
MD^3:1O!^;MA,L5$7D['!C[%J!M#+.7+]=(@)$#43V$0ZA>NP:O\ *G;NW:1^
M"N1;2W.K^";-#MOH.]<:S1>)MC\JOD'@> )MER5R_*Q.<<KLRE4@<3@B@[QC
M#W()B"$@_DCE%.7DT3:E$H%\,^O97A/J7\D]R]33EVB]F\'-YJNN.7%;CTOT
MOZ*7:^X0U\U],9*G_LJ&?3IXY>O7KMXL=P\>*@Y<K;"ID%8WUBA;J!0Z6KJ*
M22HMAZ1X:WP.#_'6A9;LQMNL=I6G]8/F-_S1H7'8Q<@XBWK1\U*8ZK=-0QD2
M@FH5PB8@IKM5T%1!-9NX2.)3E'LZ5JZK3==1GO@ZAT<)1>]&KOS+?#:99W+R
M.?\ END(F'E9/WI].<23KPK*-7EG*IG+EWCLBJ4&B7O"BIA%$YR@4;;>VO0O
M2?Y1N=E<='>;45A7_0\I]0^C7W*ZYI;361-^4'S1XZ\-%RG!'(IE4U13*>/B
M D&BIQ&P^ ^:&5260O\ 5-?H.E>S6OR-VG4PA=U-R&=+#%?OC@=!UGXYN6IP
MI':F7SXG^'#YE>09-M]ZX%GQ'BQ#-E'<_F;A,CHC<RH>*#:'14.JY< D([ .
M4  ]=;]3_DZ,;#MZ"69TPI5_PJ<QV[T+.-&T;M^(^'>/_+U@:7&G&2#Q1LNX
M/)91D\B4I)O-)=J4NYU(*%L7^EE  !%*_0--:\)U/>-9W[4O6:^N>#RQ7!+^
MM6>I>G>VOM6BE8V.4Z_LE_(]^>VX;&!01L8QP#:4QC@!QV%'H4N[;]%5G/$4
M-BW])%"P\?R=QM@?-O'TAQ=R>P7<8X\<#)0\XTL>:PV933VFG()0;G!0Q;%.
MAH0X (]1K'0Z^[V_N7B;7U);-SX)O=[S@^^]E6OTCDU]2_L:2>4_AL^8; 7+
MA[@44TYGP\5%S1,UB#M,9\Q1.8R99V$>>$NU5*W$-X%N G ;5[WZ=_+MK3V%
M!MQG':G5?OL>)XS?]!W>NY4PJ8]17E$\SLR_/'L>".116\9-%([V%,Q:^*H8
M"G4.NN)$RD 1U&]K5W-?DOLKMO4N['KS57BJUW[SC+GH"[UG*F+9L7\N/PS'
M6/3L?F7F5DXY!%D"<BPX@Q]<CYY*O&*X'1/E,P4ZC>+:@)0 [=$UU?T@KQ7U
MG^3M;K7+RS-*/&C7\4=X[)Z(N6TE)8FV&0=*O5R@5%%HU:((MXIFWMX#"*;)
ME228(@&A4T$2@0@=;!7FEF<[B5VY_P DL7[WBSUJW#IVHV_MBE\%0^ >NF@=
M@=U<E:^E%FXJK7>T@FH(>QE(]:DIM[/U*O4/^=3#ZU[S;_\ I92(=G:-OS]E
M;%RXH*K->W!MT/M91[V5=(,8YJ+QVH8B94BD,H &&^J@$ =H%#76N+U6N@[4
MH[C?C#+&IF%QQQ<TQ9 C^4(#^;5 %3;M2,P$/X:)AO<;:#75M7JE==(?2;MI
M;2]I"Z@<0VF,6U@Z  6L _+7#9:3J;1RU8"+AWA1-/815+:6ZSC/XC#(X5W2
MOB/U0,#)B0P&67.("!#*IA[0$ UKZ=*MA9O3QA&3]R;,)7;<4WF54N)A7E&5
M2F52)74LJ*HJ%$4FH"(MFQ;:E 0T*:U=R[1V:WK85O\ ^.FZ6'\3A7J_$IJZ
ML.9T35Z[8F,#1V\:EZ@5H[71+?NL AI6YKNWY&M':>:$G12VJ-=]=U#7GI[$
MOD5*-'U+R<D[((.Y!\X"WL$5>KJ$N/88ASB A\]56.U7M!+"YF6^CK7]BF.@
MT]IYE3#W'6@&P!,F @(_7_U>GK7+N]:=IV^F^HU@Z?S+7K)Y'IXQ>1X;!8!#
M</4._KKWUJ99<&4T8HXR6YF=O"6)%1EEP9?5$AK?YJSA?>E>=Q<JX;*E-]-P
M^7%U%A_P.OTU8]9;FJNVT_<39OS7RM.A6FHJD<#H*'07 ?87(H9(Z5M3;3%L
M([JU-3">O486VX977A6OQ-B\[<X+!5.R//3!B@']8DO# +7%VY\0!#ZPVW7L
M-JS79I*W_P D*M<?['"])=5/*\M>!U9CBH<5#F44.;4ZJJASG4'O,)];ZUJ1
M[?=MMJ4LR?.IRT91MQP2;*:Y"UIH6UFWF+O2GABD*RNJ4FJ+8B8T2%59)<&9
M50IDEP8JA3)+@Q5$WK*DIQZ;6"-64*7'<5:C_P"E:-WM^;YH[3=M:FJI),^E
MNLHU-XC=99LH-A$[9=5%01[Q$@@%9^33Z>97%\RJU7]MA5JH6KN*2J?0I+S!
MQ5(>4DSH&)J47[D1,(_\O41JI=GN?>D_?_8ITUFU;EBL&=:0-AO%-<ZW4IEQ
M%:U^TU[C<0'6EOL\4_F:;J7N:@_D&HW'M$;]W;>N2MP6FCEA5HQ45<=)40JO
M)/@S.J%,DN#%4*9)<&*HFI2G!YDG@87)98-K%I ?9 3 &H?3^3Z:S\/XC&>!
MIPU%S?&5/<2W.X;&%1NLZ24$;@=!T9#;WZD,40TJJYV>-Q.$9I5YK^A?'5N+
MS2@VO<=I_6ILZ8MS2\D*9OK)^_N+B =Y]]K6[.VM;R!UKU8U]Z_H:T]9%W*N
MQ*G_ *O^IT]_;,(  B81$YCD4,J)KAU6-H(?GJQ]B5E=9W%*=:4JGM_0YFSK
M[?0I&&6?NH5?E_RJVWV^W#YVU5'&7M5>G=PBZ5X"W;5]S,THK8C>I!6E*JS-
M_J*IR2X,PJB0ZU3=LSG14="JYJKFG:Z:;3VT*@(!@&]C '_5C:QOEOT 0J8Z
M))YD\39GJ%?M?.L6?:A(R;4@D:/Y-J3KX2#U8B91[ *"9K6M5WD7F/\ FG>C
M#)A1R2KOKL=30L6[%MR<X)NN&!QN7L@\+9\^?."= *Y=N%?ET*8PZ5G;TUOM
M_P L:37+&IF^XPL/Y+,FEPB_ZGQE*-@MJ =+ 8-.[VM;U5.$-5J%-1R0HELI
MB9V[T=='Q,X].:>6C5'1;\?>180'6MJ_H[>3Y7&O(R<JX$UIV[4XQRT,EE6"
MV"L\DN#)JBKL[/36K*-QW''*Z<:&C<N35QT3:!;E.50BAT%BA<BA#G3$+=NY
M"QP&];-OM\;B^:21G&^UMB_@=H$S/ 0I"RLF(  !H_=;1  ZA<][#;2^M82]
M-QLMWNO&47C3,G3E2A3X"Q.3NR2JW4Z\YSKJ'566.=QXY!\1<PK7#2XB(W&U
MZLC*-GY)PE)+E_ OCJ'I%EM0;]R.(;W'6^OIUZTRM[C9TEN$:N5,<13)+@S'
M5.L_DQ52*9)<&9U0K*-MN24EA4B4DDVMM"+#T ;#WC<0] :C4W[$?]E"F,WM
M:.Q9O73$!]T=.6^[^(+=PN@)OFL(7&]<3<TE[4/HN3C%[W@ESJ9R5N_!V912
M4E2I#B5DG8&\>4E=H!:RCMPJ4=;6$AQ$I@_-5VG[=X1_-<4O<TRN&BT^G>:-
M&=<&[<(?5O<1$--X];G^6N4E'2NU6VEU_P!/U,YZIJ#@HNA7M^7_ !Z*HRRX
M,H\0^$O@+6[:99<&66KV>5&FL-Y%,DN#-BJ*BCL,"EKB6X?M!:H:FODHZ2P9
MK:B<HY<E7CC0H$A1)X)B[B"?Q;E,<HE4ZE$!+T$+4GZ<TR7BHSAU-M*JO\#=
MC*'1JZ.? [()::(4I"RDF )B01M(. *)2Z$ @;]+!6A#MGBYR<IQLY'3%Y<U
M?>L30>742>>.$=E4?,L\<NE5%'#ATL*H@(E=+*+%T"U[J"-JV8-:)*#:G'EC
M_0MA"W;_ -J.,P#[/MF/8+ '4"!^H7Y J[JPU'SVHY4N5";OS-.*PH46&IR2
MX%5&*9)<&76\(XD4R2X,LJB?EJV[H83L*[5=1IU6_:'J94Z358HYT7#A(Y3M
MUEFQR6^T:.%6IAMVK 4Q06&N.LZ*<YY;E<G,UYPMMUIB?:I,3"AE 4E'RB1R
M#O 7SP-PVU]D#VUK&?8[MN\[\;J:;JE79R6!7.S!I88G5AKKKKK[0B)Q$0U$
MQC:F$1ZB.M<MI[L+22OP<W[JG+=N=JUA+*BD &M)1EG<E%J+;*+DHN;HUM8[
M:W+;22J0FJ$UKO:034$/84B-M1T .HC65'P95!-+'B2&XW\,P%-:X&MN ORV
M[0I'Y9)RP1MP:E'(FLSW'<P..2F12*3"&1.\<B<H.53E,!&I1#54X!]4H!I<
M:T.X:B"3RRC\38MV9+:G\#-/ >.8W"F0'*F#F6<%*=TZ,%Q(8P>T1(;7^33L
MKI>HUDI.B;?+B;DK5+3P^8N<3_BV^CI5"FY;3*VJ;CFH7B@+?YQ/2D!%BI#0
MSJ:D5 $K0B)#&(D80MN<;0"P!V5%F-)8E5R#H89R\#GD\\4?2F/S;ARN83&N
MV7%-OK?:@(AH%=BTVJA;2BL%5'&7;3;YGP_<;*PZ8Q+?0W7Z]G4MKUSGFD-\
MH^WZE/AI$_<G,/PO._RS^JGFMK[HD>'9'W)R\.N+S=NW<DH(?2 !<:>:6]TH
MCPS(#"\M'IC$Q?LVMU@'Z!$+!3S6'W1)\-+F5?<G,?PO._RS^JGFMO[HD>'9
M X3F/X7G?Y9_56,^ZVZ?5$>'9'W)S'\+S0_[1%0Q?0 7O57FMO[D3X=@V%9<
M4HF/B\F!2ZB(-EM.R_3IK4/N<)X*2'AF4?<W*A-L^[$J)@_1]V5OTOUM;I4>
M-7$GP[>]D&PK+!V@&+RVO3_=E0O<0*'4.EQM5EON,85;DOU(\,^9QEPK+3@
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MZ(\.Q]R<Q_"\[_+/ZJ>:V_NB/#L?<G,?PO._RS^JGFMO[HCP['W)S'\+SO\
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M)% IKAH!SFN &$*Z_-IOF<IO.T*%@ ![Q_.-:K^M?^Q.XKJ\@4 H!0"@% *
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M\)(]R 1114QU! "@*A@ J8*GV#LWJ$3 1V@ :]* ^V@% * 4 H!0"@% * 4
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MO':G-63<ZR,&WF\WR*!QG'Q4F4F4BRCFN*&<J13F*3<MU%6#PIW9A,);@(@
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M% !$ U$;!WCI0'$9=(@B!C@ E"Y@ZB4.\0#6@*BJD/MVFONOMT$+VZVN&MJ
MKH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@*!3*(WL B WUZ?XUH"#$
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M>3<1YFPC#>3L&?K/\2S&":S^.KK)J-5E6$@F.TSIDN4BS=<AR&*=,P <ARB
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M]Y;3SKC1]D69Q.1+8A Y?@<0PEXO!\C3CG*:9EG+94)!L= 6Y7"9%")E.7<
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M 4 H!0"@% * 4 H!0"@% * 4 H!0"@/&Y3$P\HD"4V^(S1!3Q4E!D4V"A0*
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<4QE"%5344**I3C8VN@T!ZD.@?-0$T H!0'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
